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Cellular DNA is susceptible to damage by chemical agents that causes modifications 
which includes interstrand cross-links (ICL). ICLs covalently attach the complementary 
DNA strands, and interfere with replication and transcription by preventing strand 
separation. The deliberate formation of ICL in DNA by bi-functional alkylating 
chemotherapeutic agents leads to the death of cancer cells. Development of tumors 
resistant to these agents is a factor in the lack of response in some patients, with removal 
of ICL believed to play a role in resistance. In mammalian cells, the precise role of 
excision repair in eliminating ICL is not completely understood. For better understanding 
of the repair pathways involved in removing ICL damage, ICL DNA duplexes containing 
well-defined modified moieties are required to mimic the lesions induced by 
chemotherapeutic agents. 
This thesis describes two major approaches that have been investigated to synthesize 
ICL DNA. The first describes a method to prepare DNA duplexes containing cross-linked 
N3-butylene-N3
 
thymidines that enables the preparation of asymmetric nucleotide 
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sequences around cross-linked sites. Protective groups for the 3’- and 5’-hydroxyl 
moieties were screened for compatibility of subsequent extensions from a cross-linked 
thymidine dimer incorporated in a support bound oligonucleotide by automated DNA 
synthesis. Two cross-linked dimer phosphoramidites were prepared, one with 
dimethoxytrityl (DMT) and allyloxycarbonyl (Alloc) protective groups at 5’-O positions 
and a 3’-O-t-butyldimethylsilyl (TBS) group which enabled the production of completely 
asymmetric ICL DNA duplexes in good yields. After coupling of the cross-linked 
phosphoramidite to a linear strand assembled on the solid support, the DMT group was 
cleaved on the synthesizer to allow for the synthesis of the second arm of the duplex. The 
Alloc group was then removed via an off-column strategy to expose the 5'-hydroxyl 
group to complete assembly of one strand of the duplex to form a "Y-shaped" 
intermediate. Final removal of a 3'-O-TBS group off column followed by coupling with 
deoxynucleoside 5'-phosphoramidites yielded ICL DNA duplexes containing completely 
asymmetric nucleotide composition around the cross-link site. The identity and 
composition of the ICL duplexes were confirmed by mass spectrometry (ESI-TOF) and 
enzymatic digestion. The synthesized ICL duplexes displayed characteristic features of a 
B-form duplex and had stabilities that were higher than those of the unmodified controls 
assessed by circular dichroism (CD) spectroscopy and UV thermal denaturation 
experiments. 
The second major project describes approaches to prepare a 7-deaza-2’-
deoxyguanosine cross-linked dimer where the C7 atoms are attached by an alkylene 
linker. The chemical instability of alkylated N7 2’-deoxyguanosine (dG) represents a 
major challenge for preparing ICL DNA containing an alkylene linkage between the N7 
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atoms. The incorporation of a C7-alkylene cross-linked dimer of 7-deaza-2’-
deoxyguanosine in DNA would allow for the preparation of a chemically stable ICL 
which mimic lesions formed by bifunctional alkylating agents (i.e. mechlorethamine and 
hepsulfam). Two synthetic methods were explored to prepare 7-deazaguanine (and other 
7-deazapurines). These involved two cyclization strategies to prepare these molecules 
starting from a pyrimidine or a pyrrole to produce the purine.  In both synthetic methods 
it was challenging to purify some of the intermediates. All intermediates in the synthetic 
method starting from the pyrimidine precursors to produce the 7-deazapurines were more 
stable while the production of the 7-deazapuines from the pyrroles resulted in higher 
yields.  
An attempt to produce a C7 cross-linked dimer of 7-deaza-2’-deoxyguanosine 
containing a heptamethylene linker is described.  Starting from 7-deazaguanine, 7-iodo-7-
deaza-2’-deoxyguanosine was prepared in good yield. This nucleoside was converted to 
5’-O-DMT-7-iodo-7-deaza-2’-deoxyguanosine and the Sonogashira reaction used with 
1,6-heptadiyne to introduce the heptamethylene linker. Unfortunately, multiple 
challenges were encountered with the dimerization and hydrogenation reactions which 
did not allow for the synthesis of the desired dimer for solid-phase synthesis of the ICL 
DNA. 
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Chapter 1. Introduction 
1.1 General introduction 
Nucleic acids are linear bioactive macromolecules with a number of important roles and 
functions including the storage of genetic information and serving as a template for the 
process of replication by which they can duplicate themselves with the aid of proteins. 
Together with proteins, nucleic acids are found in abundance in all living cells, where 
they function in encoding, transmitting and expressing genetic information.  
There are two classes of nucleic acids found in living cells. 2’-Deoxyribonucleic acid 
(DNA) is found mainly in the nucleus of the cell, while ribonucleic acid (RNA) is found 
mainly in the cytoplasm of the cell although it is usually synthesized in the nucleus. In 
cells, genetic information is encoded in the sequences of nucleic acids, and DNA serves 
as the instructor for the construction of an entire organism. DNA contains the genetic 
codes to make RNA and the RNA in turn then contains the codes for the primary 
sequence of amino acids to make proteins. This process is described as central dogma of 





Scheme 1-1. Central dogma of biology. 
 
For more than half a century the structures of DNA and RNA were recognized as 
polymers of four nucleotides, which afford a huge number of sequences. Each nucleotide 
consists of three components: A pentose sugar, phosphate group and heterocycle 
(nucleobase). The sugar and phosphate groups form the structural framework of nucleic 
acids, including DNA and RNA. This backbone is composed of alternating sugar and 
phosphate units, and defines the directionality of the molecule. 
Two types of pentose sugars are found in nucleic acids. The pentose sugar in DNA (2′-
deoxyribose) differs from the sugar in RNA (ribose) by the absence of a hydroxyl group 
(−OH) at the 2′ carbon of the sugar ring. Through a glycosidic bond, nucleobases are 
linked to the 1’-carbon of pentose sugar, which is referred as the anomeric position. 
Without an attached phosphate group, the moiety of a pentose sugar and a nucleobase is 
known as a nucleoside. The phosphate group connects successive sugar residues by 
bridging the 5′-hydroxyl group on one sugar to the 3′-hydroxyl group of the adjacent 
sugar along the chain. These nucleoside linkages are linked by phosphodiester groups in 
both RNA and DNA. 
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Nucleobases consist of two types of heterocycles: purines or pyrimidines. The purines are 
bicyclic with fused six and five membered rings whereas the pyrimidines have a single 
six member ring. There are two primary purines (adenine (A) and guanine (G)) and three 
primary pyrimidines (cytosine (C), uracil (U) and thymine (T)). Their structures are 
shown in Figure 1-1 and Figure 1-2. Among these five nucleobases, normally four kinds 
are found in either DNA or RNA. A, G and C are found in both DNA and RNA. A major 
difference between DNA and RNA is that DNA contains thymine, but not uracil, whereas 
RNA contains uracil but not thymine. 
 
 




Figure 1-2. Structure of nucleotide, nucleoside and nucleobases of RNA. 
 
The four nucleotides A, C, G, and T are the building units for DNA molecules, in which 
the nitrogen-containing nucleobases have potential to form hydrogen bonds between 
them. In Watson-Crick base pairing A always pairs with T through two hydrogen bonds, 
and G always pairs with C through three hydrogen bonds. The C1’-C1’ distance spans of 
A:T and G:C hydrogen-bonded pairs are nearly identical, allowing them to bridge the 
sugar-phosphate chains uniformly (see Figure 1-3). In a DNA molecule, the two strands 
coil around each other to form a double helix through an extensive network of hydrogen 
bonds. The three-dimensional structure for the DNA double helix was first proposed by 
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James D. Watson and Francis H. C. Crick in 1953.[1, 2] The two DNA strands run in 
opposite directions as determined by the orientation of the 5′ to 3′ phosphodiester bond. 
The sugar-phosphate backbone runs along the outside of the helix, and the nucleobases 
are embedded inside. Within DNA duplex the nucleobase pairs (A:T and G:C) on the two 
complementary strands interact through hydrogen bonds. 
 
 




DNA in the cell exists as a right handed double-stranded helix with what is known as a 
B-form DNA structure, which was first solved by Franklin and Gosling in 1953.[3, 4] In 
this structure, there are approximately 10 base pairs per turn (each turn at 3.4 nm), and 
the distance between two adjacent base pairs is 0.34 nm. The intertwined strands form a 
right-handed helix with two grooves of different widths, referred to as the major groove 
(2.2 nm wide) and the minor groove (1.2 nm wide).[5] The interactions between proteins 
and nucleic acids play a crucial role in central biological processes, ranging from the 
replication, transcription and recombination to enzymatic events utilizing nucleic acids as 
substrates.[6-8] Proteins can bind to the major groove of DNA where they can make 
sequence-specific contacts with the nucleobases.[9-12] In addition, some proteins have 
preference to interact with nucleic acids via the minor groove.[11-17] The B-form 





The major groove is depicted in orange, and the minor groove is depicted in yellow. The carbon 
atoms of the backbone are shown in white.[18] 
Figure 1-4. Structure of B-DNA showing the location of the major and minor grooves. 
 
In a solution with a high salt concentration, a different right-handed DNA structure may 
be formed known as A-form. Compared to B-DNA, the A-DNA duplex is a wider right-
handed helix, with a shallow, wide minor groove and a narrower, deeper major groove. 




Another DNA structure that is known is referred to as Z-form. Different from the two 
forms above, Z-form DNA is a left-handed helix. One turn spans 4.6 nm, comprising 12 
base pairs. DNA containing alternating G-C sequences in alcohol or high salt 
concentration can form such structures.[22-27] 
B-form DNA is commonly formed in cell, so the following contents mainly focus on this 
form without further description. 
 
1.2 DNA damage and Repair 
DNA is the repository of genetic information, thus its integrity and stability are essential 
to life. Although DNA is the carrier of genetic information, it has limited chemical 
stability, and subject to damage from both environmental factors and normal metabolic 
processes inside the cell. 
The degree and spectrum of DNA damage depends on the source and the type of 
environment to which it is exposed. Some types of damage are ubiquitous and potentially 
present in all extracted DNA, while other types of damage are caused by exposure to one 
or more specific sources. It has been estimated that DNA damage occurs at a rate of 
1,000 to 1,000,000 molecular lesions per cell per day.[28, 29] 
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DNA may be modified in a variety of ways, such as hydrolysis, oxidation and 
nonenzymatic methylation (some examples are shown in Table 1-1).[30] If left 
unrepaired, these DNA modifications in critical genes may impede a cell's ability to carry 
out its bioactive functions, and ultimately lead to mutations and genomic instability. 
Links between DNA damage and the increase of mutagenesis, ageing, carcinogenesis and 
some other diseases have been demonstrated.[31] For example, skin cancer may be 
caused by excessive exposure to UV radiation from sunlight. Another example is the 
damage caused by tobacco smoke, which can lead to mutations in lung cells and 
subsequent cancer of the lung. Besides the exposure to exogenous chemicals, DNA is 





Table 1-1. Common Types of Damaged Bases Found in DNA 
Normal base 
Examples of common base modifications 
































Table 1-1. Common Types of Damaged Bases Found in DNA (continued) 
Normal base 
Examples of common base modifications 

























   





Table 1-1. Common Types of Damaged Bases Found in DNA (continued) 
Normal base 
Examples of common base modifications 
Deamination Oxidation Alkylation UV 

























Adapted from reference [30] 
 
Some alkylating agents have been used for chemotherapy of diseases like cancer by 
modifying specific DNA site(s). However, cells have also developed repair functions for 
DNA damage, and reverse the cytotoxicity of many clinically used DNA-damaging 
13 
 
agents. Better understanding of the interaction between DNA damage and repair could 
lead to the improvement in the effectiveness of existing anticancer drugs, and the 
development of novel and effective molecules to treat various diseases.[32] 
 
1.2.1 Hydrolysis of DNA 
The process of hydrolysis of DNA involves either deamination or total removal of 
individual bases. The hydrolysis of the phosphodiester bonds is a thermodynamically 
favored process (ΔG°′ = −5.3 kcal/mol), but extremely slow in the DNA backbone.[33, 
34] Phosphodiester linkages that join the nucleotides of DNA are highly resistant to 
spontaneous hydrolysis, and studies with model compounds indicates that the half-life of 
phosphodiester hydrolysis is approximately 30 million years in the absence of 
nucleases.[34-37] This means that spontaneous hydrolysis of the phosphodiester linkages 
in DNA can be ignored under biological conditions. 
In contrast to RNA in which the phosphodiester bond in the backbone is the least stable 
under physiological conditions, the most labile bond in DNA is the N-glycosyl bond that 
attaches the base to the deoxyribose backbone. Loss of a DNA nucleobase will produce 
an apurinic or apyrimidinic (AP) site. The mechanisms and reactivities of purine and 
pyrimidine nucleosides to glycosidic bond hydrolysis depend on the relative acidities of 
various functional groups on the leaving group bases.[30]  Lindahl et al. compared the 
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 (t1/2 = 14,700 y) while the reaction is faster for the latter with 




 (t1/2 = 730 y).[38, 39] This accounts for why hydrolytic 
cleavage of the glycosidic bonds in DNA is often referred to as depurination. Kinetic 
studies indicate that hydrolysis of 2’-deoxypurines proceeds via an acid-catalyzed SN1 
reaction mechanism where equilibrium protonation increases the leaving group ability of 
the base and facilitates unimolecular, rate-limiting C-N bond cleavage that generates the 
free nucleobase and an oxocarbenium ion (shown in Scheme 1-2).[30, 40] The 
oxocarbenium ion undergoes subsequent hydration to yield an AP site. It is found that 
depurination occurs about four times faster in single-stranded DNA than it does in 
double-stranded DNA. Some damage caused by free radicals and alkylating agents lead 
to promotion of DNA hydrolysis of the bases as some damaged nucleobases generate 





Scheme 1-2. Depurination process [30, 40] 
 
Because the reactive species is H2O, AP sites may occur along all DNA strands. Under 
metabolically active conditions it is estimated that approximately 2,000-10,000 AP sites 
are generated in genomic DNA of mammalian tissues per cell per day, and steady state 
levels of 10,000–50,000 abasic sites have been detected in cells. [31, 39, 43, 44] Besides 
the biochemical reaction from various metabolites, hydrolytic damage may also result 
from the overabundance of reactive oxygen species. The presence of AP sites in a DNA 
16 
 
sample is problematic due to the fact that the AP site may lead to base-pairing failure 
during DNA replication. 
To counteract the deleterious action of AP sites, organisms have developed multiple and 
robust DNA repair mechanisms including base excision repair (BER), nucleotide 
excision repair (NER), recombination and translesion DNA synthesis (TLS).[30, 41, 45-
47] In eukaryotic cells, the deleterious action of AP sites is also prevented by the action 
of a multiplicity of DNA repair and tolerance pathways.[47] 
Another type of hydrolytic DNA damage that occurs under physiological conditions is 
the hydrolysis of cytosine to form uracil (shown in Scheme 1-3).[31, 48-51] Sequencing 
studies on DNA extracted from ancient samples have determined that this is the major 
damage complicating data analysis.[52, 53] Interestingly, cytosine is prone to 
deamination via attack of hydroxide on the neutral nucleobase or attack of water on the 
N3-protonated base, which results in the displacement of its exocyclic amino group to 
afford uracil. Uracil does not exist in DNA, and it can be effectively detected and 
removed by repair enzymes. However, if not detected and repaired, it can lead to base 
mispairing by interacting with adenine. In a subsequent round of replication, the adenine 
in turn would specify thymine, and as a result this process generates a mutated daughter 




Scheme 1-3. Deamination of 2’-deoxycytidine into 2’-deoxyuridine 
 
 




Cytosine deamination may be caused by hydrolysis. Unlike nucleobase loss in DNA 
strands, it has been established that cytosine deamination in single-stranded DNA occurs 
at a rate 140 times faster compared to double-stranded DNA and it is known that 
mispaired cytosines deaminate at a rate between these processes.[55-57] 
 
1.2.2 Oxidation of DNA 
Reactive oxygen species (ROS), which can be generated by both normal cellular 
metabolism (endogenous) and ionizing or ultraviolet radiation (exogenous), may lead to 
oxidative DNA damage.[58] These ROS include superoxide (O2
–·
), hydrogen peroxide 
(H2O2), hydroxyl radicals (OH
·
) and singlet oxygen (
1
O2) and they can oxidize DNA, 
which can lead to several types of DNA damage, including oxidized bases and single‐ 
and double‐strand breaks. DNA damage produced by ROS is the most frequently 
occurring damage.[28, 59-64] 
The highly reactive hydroxyl radical (•OH) reacts with DNA by addition to the double 
bonds of the DNA bases and by abstraction of an H atom from the methyl group of 
thymine and each of the C-H bonds of 2’-deoxyribose. Addition to the C5-C6 double 
bond of pyrimidines may lead to the formation of C5-OH and C6-OH radicals while H 
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atom abstraction from C5-methyl of thymine results in the allyl radical. Adduct radicals 
differ in terms of their redox properties, with C5-OH adduct radicals being reducing and 
C6-OH adduct radicals oxidizing.[65] Oxidation may also occur to purine and pentose 
sugar moieties. Numerous products are produced by a variety of mechanisms. [66-70] 
DNA base products of interaction with reactive oxygen species are shown in Figure 1-6. 
Among the library of adducts formed with reactive oxygen species, 8-oxo-2’-
deoxyguanosine (8-oxo-dG) and 8-hydroxy-2’-deoxyguanosine (8-OHdG) (molecular 
structures shown in Figure 1-7) are the most common marker for oxidative DNA damage 
and can be measured in virtually any species.[61, 71-74] It is formed and enhanced most 
often by chemical carcinogens. Similar oxidative damage occurring in RNA form 8-OHG 
(8-hydroxyguanosine) and has been implicated in various neurological disorders.[75-77] 
8-Oxo-dG is a mutagenic product that forms a base pair with adenine.[78-80] Such 
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Figure 1-6. DNA base products of interaction with reactive oxygen and free radical 








Figure 1-7. Equilibrium between two oxidized adducts, 8-oxo-2’-deoxyguanosine (8-




1.2.3 UV-induced damage 
Ultraviolet light and other types of radiation can do damage to DNA in organisms via 
photochemical reactions. Solar UV rays may lead to a variety of toxic DNA lesions along 
genomic DNA strands. When exposed to UV radiation, covalent cross-links may occur in 
adjacent cytosine and thymine residues to produce pyrimidine dimers. Among them 
cyclobutane pyrimidine dimers (CPD) and pyrimidine–pyrimidone-(6-4)-photoproducts 
(6-4PP) are found most commonly.[86-93] The formation of CPD and 6-4PP (as well as 
its Dewar valence isomers) are shown in Scheme 1-4.[92-96] CPD lesion 1 and 6-4PP 
lesion 4, caused by these reactions, and their secondary products the Dewar valence 
isomers (Dewar lesion) 5, are the most abundant UV lesions and are responsible for much 





1: CPD, 2: spore photoproduct, 4: 6-4PP photoproduct, 5: Dewar valence isomer of 4. 




Due to UV-B (315-280 nm) and UV-C (< 280 nm) irradiation dimerization may occur 
through electrocyclic ring formation between two adjacent pyrimidines along DNA 
strands in cells (Scheme 1-4). Triggered by exposure to UV light, the cis-syn cyclobutane 
pyrimidine dimer (CPD) is formed between two C5 C6 double bonds of two adjacent 
pyrimidine bases (usually a pair of thymines) by [2 + 2] cycloaddition, whereas a 
cycloaddition between the C5 C6 double bond of the 5′ nucleoside and the C4 carbonyl 
group of the 3′ nucleoside, named the Paternó–Büchi reaction, leads to 6-4PP lesions.[93] 
Even though UV-A (400-315 nm) does not directly affect the nucleobases, it may lead to 
the formation of CPD lesions by the excitation of photo sensitizers and triplet energy 
transfer.[93] 
Of the three categories of solar UV radiation, only UV-A and UV-B are able to penetrate 
Earth's atmosphere. Thus, these two types of UV radiation are of greatest concern to 
humans and other creatures, especially as continuing depletion of the ozone layer causes 
higher levels of this radiation to reach the planet's surface. The lesions formed by UV 
irradiation will lead to distortion of DNA's structure, introducing bends or kinks and 
thereby impeding transcription and replication. Relatively flexible areas of the DNA 




To counteract the DNA damage caused by UV, cells have developed a number of repair 
mechanisms. Cooperating with the enzyme photolyase, photoreactivation is found as an 
efficient repair pathway in bacteria and several other organisms.[98, 99] During 
photoreactivation, photolyase binds pyrimidine dimer lesions; in addition, a second 
molecule known as a chromophore converts light energy into the chemical energy 
required to directly revert the damaged site of DNA to its intact form. Photolyases are 
found in numerous organisms, including fungi, plants, invertebrates such as fruit flies, 
and vertebrates including frogs. However, there is no indication for their existence in 
human cells.[100] 
Excision repair including base excision repair (BER) and nucleotide excision repair 
(NER) plays an important role in DNA repair of these dimers in several organisms with 
the aid of glycosylases and polymerases. In contrast to photoreactivation, these pathways 
are much more complex and do not directly reverse DNA damage but instead replace the 
damaged DNA with new, undamaged nucleotides.[101-106] 
In addition, mutagenic repair or dimer bypass, recombinational repair, cell-cycle 
checkpoints, apoptosis and certain alternative repair pathways are found to be operative 




1.2.4 Alkylating agents 
Alkylation lesions can be formed along DNA and RNA strands when exposed to 
alkylating agents that result from endogenous compounds, [107, 108] environmental 
agents [109-111] and alkylating drugs. Alkylating agents are mutagenic and genotoxic. 
 DNA alkylating agents can be monofunctional or bifunctional. Bifunctional alkylating 
agents can introduce interstrand and intrastrand cross-links along DNA strands, and these 
cross-links are responsible for the inhibition of DNA synthesis and for cytotoxicity (more 
details in Sections 1.3 and 1.4). Cytotoxicity of monofunctional alkylating agents is 
related to single strand breaks in DNA or to damaged nucleobases. 
Depending on the source of the alkylating agents, they can be classified as endogenous 
and exogenous (including chemotherapy drugs). 
 
1.2.4.1 Endogenous alkylating agents 
There are many possible sources of endogenous alkylating agents and several compounds 
have been identified. 
S-Adenosyl methionine (SAM, molecular structure shown in Figure 1-8) is a weak 
chemical methylating agent involved in methyl group transfers in biochemical reactions. 
SAM was first discovered by Cantoni in 1952.[112] It is made from adenosine 
triphosphate (ATP) and methionine by methionine adenosyltransferase. The methyl group 
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bonded to the methionine sulfur atom in SAM is chemically reactive, and allows methyl 
donation to bioactive molecules in cells, such as nucleic acids, proteins, lipids and 
secondary metabolites. It is shown to induce mutations in DNA and mainly generates N7-






Quaternary ammonium compounds, such as betaine and choline (molecular structures 
shown in Figure 1-8) are alkylating agents. Betaine occurs in numerous vertebrate tissues 
as an osmolyte, ensuring osmoprotection. Although choline originates from exogenous 
sources such as diet, tobacco smoke or environmental contaminates, some may also be 
formed endogenously from cellular precursors.[116] These act as methyl group donors in 






S-Adenosyl methionine (SAM) Choline 




Another important class of alkylating agents are N‐nitroso compounds (NOCs), which 
originate from the diet in foods such as smoked meat, bacon and fish.  They can also be 
formed in vivo by acid-catalyzed and bacterial nitrosation in the stomach and via nitric 
oxide (NO) formation during inflammation.[117-126] Based on their chemical structures, 
NOC are divided into two major groups: N-nitrosamines and N-nitrosamides. Both are 
formed by the reaction of a nitrite compound with amines or amides. Under acidic 
conditions, nitrite forms intermediate nitrosating species such as nitrous anhydride and 
the nitrous acidium ion (N2O3, H2NO2
+
, respectively) (see Equation (1) in Scheme 1-5). 
[125, 127, 128] In vitro, the nitrosation of amines is accelerated by thiocyanates; the 
nitrosation of amides is catalyzed by citrate and other organic acids.[129, 130] Under 
neutral conditions, nitrosation occurs via bacteria catalyzed processes in the 
hypochlorhydric stomach in individuals with chronic gastritis.[125] The reaction between 
secondary amines and nitrite affords N-nitrosamines (Equation (2) in Scheme 1-5) while 
nitrosation of amides produces N-nitrosamides (Equation (3) in Scheme 1-5). These 
NOCs act as alkylating agents that react along nucleic acid strands. The alkylation 











(nitrous acidium ion) 
Equation 2: Formation of N-nitrosamines 
 
Equation 3: Formation of N-nitrosamides 
 
Scheme 1-5. Schematic diagram of NOC formation [125, 127] 
 
Employing the endogenous alkylating agents, the most frequent effect of DNA 
methylation is the generation of N7-meG and N3-meA. N7‐meG is relatively harmless, 
because this modification does not alter the coding specificity of the base. However, 
alkylation on N7 of 2’-deoxyguanosine will accelerate the hydrolysis leading to the 
generation of mutagenic apurinic (AP) sites and imidazole ring opening of N7‐meG, 
which results in the halting of DNA replication.[131, 132] N3‐meA is a cytotoxic DNA 
lesion that blocks replication. All living cells have an efficient DNA glycosylase that 
removes 3‐meA from DNA, generating an AP site. SAM also generates the minor 
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pyrimidine lesions N3‐methylthymine (N3-meT) and N3‐methylcytosine (N3-meC). 
N3‐meT blocks DNA replication in vivo while N3‐meC is a strong inhibitor of DNA 
synthesis and could lead to mutagenesis.[133-135] 




4‐methylthymine (O4‐meT) and O4‐ethylthymine (O4‐etT), which may lead to 
GC→AT and TA→CG transitions during DNA replication.[28, 136-138] 
 
1.2.4.2 Exogenous alkylating agents 
There are many different kinds of exogenous alkylating agents, most of which are 
electrophilic compounds. The simplest are halocarbons generated from industrial 
production, terrestrial (e.g. by plants and fungi) and marine environments.[110, 111] 
These compounds may lead to alkylated DNA lesions which are mutagenic and possibly 
carcinogenic.[139-141] However, no adequate evidence shows the link between 
carcinogenicity and exposure to halocarbons in animals and humans.[142, 143] 
N-nitroso compounds (NOC) may be generated from tobacco smoke and in the diet as 
well as other environmental sources.[125, 144-146] In animal dietary intake experiments 
N-nitroso compounds showed their potent carcigonenicity as the precursors of cancer 
development.[145, 147] Tobacco smoke contains both tobacco-specific N-nitroso 
compounds and several other nitroso compounds, e.g. N-nitrosodimethylamine. Tobacco-
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specific nitrosamines have shown carcinogenicity in laboratory animals, and some known 
molecules are identified with the molecular structures shown in Figure 1-9. Employing 
tobacco-specific nitrosamines will afford a series of alkylated adducts along DNA 
strands, and their formation is shown in Scheme 1-6.[148-151] In the diet, the key role of 
nitrite and nitrogen oxides in forming N-nitroso compounds by interaction with 
secondary and tertiary amino compounds (see Scheme 1-5) has led to the examination 
worldwide for the presence of N-nitroso compounds in food.[125, 145, 152-154] 
 
   
 
A B C D 
A) 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK); B) 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL); C) N-nitrosonornicotine (NNN); D) N-nitrosodimethylamine 
(NDMA) 





Scheme 1-6. Overview of metabolism and DNA adduct formation by the tobacco-




Mustard gas, alkyl sulfate-ester and sulfonic-esters can also act as alkylating agents. All 
these alkylating agents are electrophilic compounds, which can transfer active alkyl 
groups to nucleophilic positions of the DNA nucleobases. Those with two alkylating 
functional groups can react with two positions of DNA to form cross-links within a DNA 
strand (intrastrand), between the two DNA strands (interstrand) or between DNA and 
protein. The damaged DNA, especially interstrand cross-linked DNA, can be mutagenic 
and are potentially cytotoxic. Some alkylating agents have been used in chemotherapy. 
Alkylating drugs are mostly methylating agents (e.g. temozolomide and streptozotocin, 
an antibiotic) or chloroethylating agents (e.g. carmustine, lomustine and fotemustine). 
The effects of these drugs are strongly modulated by DNA repair processes. 
Understanding and controlling repair processes may therefore allow development of new 
therapies by protecting normal tissues or by potentiating effects in target tissues.[158-
161] More details related to bifunctional alkylating agents are discussed in Section 1.3. 
Ethylene oxide is classified as a known human carcinogen. The formation of alkylated 
DNA adducts, mainly N7-(2-hydroxyethyl)-2’deoxyguanosine (7-BEG) in DNA, is 
considered as an important early event in the carcinogenic process of ethylene 
oxide.[162-165] 
Some natural substances also exhibit potent antitumor properties, such as CC-1065, 
duocarmycin A, and duocarmycin SA (molecular structures shown in Figure 1-10). [166] 
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These substances alkylate mainly in the minor groove of DNA, with N3-alkyl 2’-
deoxyadenosine (N3-alkylA) as the main adduct (the example of duocarmycin SA action 
on DNA is shown in Scheme 1-7).[167] The binding affinity, selectivity and reaction 
mechanism involving DNA alkylation or cleavage, is currently being studied to explore 
analogs (i.e. adozelesin, bizelesin, and carzelesin) as agents for cancer chemotherapy. 
 
 
   
CC-1065 (+)-Duocarmycin A Duocarmycin SA 






Scheme 1-7. Binding pattern of Duocarmycin SA with DNA and thermally induced 
depurination. [167] 
 
Alkylating agents containing conjugates such as N-methylpyrrole (Py)-N-
methylimidazole (Im) polyamides and 1,2,9,9a-tetrahydrocyclopropa[1,2-c]benz[1,2-
e]indol-4-one (CBI) with a 5-amino-1H-indole-2-carbonyl linker have been synthesized 
and exhibited highly efficient sequence-specific DNA alkylation. These agents are under 
development towards application as antitumor agents.[168, 169] 
 
1.2.4.3 Alkylating sites 
There are a variety of nucleophilic sites along nucleic acid strands, as a result alkylated 
lesions may be introduced at almost all O- and N-atoms in the nucleobases, as well as at 
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O-atoms in phosphodiesters. The alkylation pattern depends on the number of reactive 
sites within the alkylating agent (monofunctional versus bifunctional), its particular 
chemical reactivity (SN1 versus SN2-type nucleophilic substitution), the type of alkyl 
group addition (methyl, chloroethyl, etc.) and the DNA substrate (double- or single-
stranded).[170] Alkylation damage in RNA generally follows the same pattern as for 
single-stranded DNA.[171] Exposure to methylating agents such as methyl 
methanesulfonate (MMS), N-methyl-N-nitrosurea (MNU), tobacco-specific nitrosamines 
(N-methyl-N’-nitro-N-nitrosoguanidine (MNNG)) and drugs like temozolomide (TMZ), 
streptozotocin (STZ) or dacarbazine (molecular structures shown in Figure 1-11), results 
in a broad spectrum of alkylated adducts. The alkylation pattern for DNA duplexes may 























Streptozotocin (STZ) dacarbazine diethylsulfate 
ethyldiazonium 
ion 





Figure 1-12. Position of the reactive sites of some DNA alkylators on G-C or A-T base 
pairs [172-175] 
  
The SN1 pathway is dependent on the stability of the formed carbocations, generated 
prior to their attack on DNA residues with low preference between nitrogen or oxygen. 
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Thus, alkylating agents of the SN1-type (e.g. MNU) alkylate both oxygens and nitrogens 
in nucleic acids. By contrast, both the properties of alkylating agents and nucleophilicity 
of targeted sites are important in the SN2 pathway. The main adducts with SN2 alkylating 
agents (e.g. MMS) occur on nitrogen due to the fact that nitrogen has higher 
nucleophilicity than oxygen.[176-180]  





-alkylT) are highly mutagenic and genotoxic, whereas 
N-alkylations (e.g. N3-alkylA and N1-alkyl adenine (N1-alkylA)) are cytotoxic, but 
relatively less mutagenic.[181-184] 
The preferred alkylation sites in duplex DNA depends on the nature of the alkylating 
agent(s). For example, employing diethylsulfate (structure shown in Figure 1-11) the 
preferred sites of reaction follow the order: N7G >> P-O > N3A >> N1A ~ N7A ~ N3G ~ 
N3C >> O
6
G. In contrast, the preferred sites for alkylation by ethyldiazonium ion 









T > N3G ~ N3T ~ N3C ~ N7A.[176-178] Two more examples of methylation 
patterns in single-stranded and double-stranded nucleic acids employing alkylating agents 
MMS and MNU are shown in Table 1-2. [148] Examples of alkylated DNA nucleobases 




Table 1-2. Methylation patterns of single-stranded vs. double-stranded nucleic acids 
upon reaction with MMS and MNU
a,b
 [148] 












N1- 18 11 3.8 2.8 2 1.3 
N3- 1.4 1.5 10.4 2.6 nd
e
 9 
N7- 3.8 nd 1.8 1.8 nd 1.7 
Guanine 
N3- ~1 nd 0.6 0.4 1 0.8 
O
6
- – 0.2 0.3 3 4 6.3 




- nd nd nd nd nd 0.11 
N3- nd 0.4 nd nd nd 0.3 
O
4




- nd Nd – nd nd 0.1 
N3- 10 7 <1 2.3 1.5 0.6 
Diester 2 Nd 0.8 ~10 nd 17 
a
 Adapted from refs.[171, 176] 
b




 The values are from data compilation by ref. [176], and originate from experiments with the ssDNA phage 
M13, and RNA from TMV, yeast, HeLa cells, animal ribosomes, and µ2 phage. 
d
 These data are from the original work of ref. [171] and indicate methylation pattern in RNA from 
bacteriophage R17. The values are percent of the total radioactivity analysed for methylation. 92% (MMS) 
and 89% (MNU) of the total radioactivity were recovered as identifiable and detectable residues (>0.5% of 
total radioactivity). 
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3MeG 7MeG 3MeC 3EtC 3MeT 8MeG 
 
     
eA EA 1,2-eG 2,3-eG eC 
Figure 1-13. Structures of DNA alkylation lesions. (Adapted from reference [185]) 
 
The data in Table 1-2 clearly shows the high nucleophilic reactivity of the N7-position of 
guanine in DNA, with the formation of N7-alkyl guanine (N7-alkylG) as the predominant 
alkylation adduct, which does not possess any mutagenic or cytotoxic properties in itself. 
However, it is subject to rapid spontaneous depurination and enzymatic removal, thus 
creating cytotoxic abasic sites.[148, 178, 186-188] 
Compared to other DNA adducts, N7-guanine adducts are less chemically stable. The 
instability of N7-guanine adducts is caused by an additional positive charge on the 
guanine ring system. In general, larger alkyl groups promote depurination in 
dsDNA.[177] This has been demonstrated under physiological conditions (pH 7.4, 
37°C).[189] In addition, N7-guanine adducts, which accumulate in DNA with continuous 
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exposure or treatment, usually reach a steady state of biological equilibrium after 7 to 10 




-meG are more 
persistent. Compared to intact 2’-deoxyguanosine, N7-meG depurinates 106 times faster 
under the conditions of pH7 at 37 °C.[193] Besides depurination, other reactions occur to 
N7-guanine adducts, for example ring opening to yield 5-N-alkyl-2,6-diamino-4-
hydroxyformamidopyrimidine (alkyl-FAPy), loss of the C-8 proton and rearrangement to 
C8 adducts. 
The presence of N7-meG and other N7-guanine adducts (which originate from 
endogenous and exogenous sources) has been demonstrated ubiquitously in DNA of 
human cells.[116, 194-201]  Despite the ubiquitous nature of N7-guanine adducts, their 
application as a biomarker of exposure in larger molecular epidemiology studies is not 
common practice due to the chemical instability. 
In addition to N7-alkylG, N3-alkylA is generated as another primary N-alkylation 
product.[148] In contrast to the relatively innocuous N7-alkyl G lesions, N3-alkyl A 
lesions are highly cytotoxic and the presence of this lesion in DNA is thought to halt 
DNA polymerase, which then initiates a cascade of events including cell death.[202-205] 
Alkylation (mainly methylation) at the guanine O
6
 position confers the greatest 
mutagenic and carcinogenic potential.[206-208] The formation of this damage may lead 
to a G:C–A:T mutation. This lesion can not only generate point mutations but can also 
initiate mismatch repair-mediated DNA recombination and cell death.[181, 209] The 
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relative preference for incorporation of T and C opposite an O
6
-meG lesion varies 
somewhat with polymerase and sequence context.[210] 





-meG·C base pairs indicates that O
6
-meG·C forms a wobble pair under neutral 
conditions (Figure 1-14 a) while this base pairing is weaker than canonical C·G pairings 
by 4–5 kcal/mol.[211, 212] O6-meG·T mispairs are relatively unstable, forming only one 
hydrogen bond, but adopt a shape similar to Watson–Crick pairs (Figure 1-14 b).[213, 
214] The Watson–Crick-like conformation of O6-meG·T mispairs has been postulated to 
allow preferential incorporation of T opposite O
6
-meG by high-fidelity polymerases but 
cannot account for the fact that the polymerase only weakly discriminates against O
6
-
meG·C.[215, 216] Repair pathways to revert this damage have been studied by a couple 
of research groups including ours.[217-221] 
In single-stranded DNA, the N1-position of adenine and the N3-position of cytosine are 
also subject to methylation by monofunctional methylating agents to generate the 
replication blocking and mispairing lesions, N1-methyladenine (N1-meA) and N3-
meC).[185] In double-stranded DNA, these sites are protected due to base pairing, but 





Figure 1-14. Structures of O
6
-meG·C (a) and O
6
-meG·T (b) pairs in DNA duplexes, 
unbound by protein. Hydrogen bonds are shown as dashed lines. The presence or absence 
of the H bond indicated by the “?” has been the subject of some controversy.[216] 
 
Numerous cellular pathways, including direct DNA damage reversal, base excision repair 
(BER), nucleotide excision repair (NER: long/short-patch, transcription coupled/global 
genome), mismatch repair (MMR), homologous recombination (HR) or nonhomologous 
end-joining (NHEJ), have evolved as DNA repair pathways to defend against alkylation-
induced cell death or mutation.[148, 222] 
Alkylating agents modify DNA in different patterns, which produce lethal and mutagenic 
lesions to both healthy and diseased cells without proper discrimination. Maintaining a 
proper balance of alkylating potentials and DNA repair pathways is one of the important 




1.3 Bifunctional alkylating agents and other cross-linking agents 
Alkylating drugs have been used as anticancer drugs for decades and continue to play an 
important role in the treatment of several types of cancers.[159, 223-227] Most alkylating 
drugs are monofunctional methylating agents (More details in Section 1.2) or 
bifunctional alkylating agents such as nitrogen mustards (e.g., chlorambucil and 
cyclophosphamide), or chloroethylating agents (e.g., nimustine [ACNU], carmustine 
[BCNU], lomustine [CCNU], and fotemustine). Employing bifunctional alkylating 
agents, interstrand cross-links (ICLs) may be generated between two complementary 
DNA strands (DNA-protein crosslinks may be formed as well). Formation of an ICL 
covalently linking the opposite strands of double helix results in severe disruptions of 
normal DNA functions, such as replication, transcription, and recombination. Compared 
to DNA damage with monoalkylating agents, ICLs are more highly cytotoxic and have 
more complicated effects on the biological process in damaged cells.[148, 222, 228-232] 
In the bacterial or mammalian genome 20 ICLs, if left unrepaired, will be lethal to cells. 
[233, 234] 
A description of several types of bifunctional alkylating agents, according to their source 




1.3.1 Nitrogen Mustards 
Nitrogen mustards are bifunctional alkylating agents containing N,N-bis-(2-
chloroethyl)amine functional groups. Mustards are extensively used in cancer 
chemotherapy while they are highly carcinogenic.[235, 236] Clinically important 
examples for this category include mechlorethamine, chlorambucil and phosphamide 










Figure 1-15. Molecular structures of clinical mustards 
 
Employing nitrogen mustards, a lesion will be formed via the aziridinium intermediate 
(see Scheme 1-8) to produce monofunctional guanine-N7 adducts and interstrand cross-
linked adducts involving two guanines in GNC· GNC (5′ → 3′ / 5′ ← 3′) sequences as the 
main adducts.[235-243] Computer-modelling to investigate the preference of the 1,3- 
versus 1,2-cross-linkage indicated that the former linkage was favored both 
thermodynamically and kinetically. Compared to the 1,2 linkage, the dG-to-dG N7-to-N7 
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1,3 linkage was much more flexible, which leads to a more entropic state for this 
linkage.[241] 
Due to the introduction of a five-atom linkage with these mustards, a distortion of the 
DNA helix is generated. Studies have shown that the linkage distance span (5.1 Å) is 
shorter than the minimal distance between the guanines (6.8 Å), which leads to static 
bend of 12.4-16.8
o
 per lesion in B-form DNA.[244-246] 
 
 





Nitrogen mustards are genotoxic, and produce a wide array of mutations, including base 
substitutions at both G·C and A·T base pairs, intragenic as well as multilocus deletions 
and chromosomal rearrangements.[237] 
Besides the main adduct involving N7-guanine, melphalan and chlorambucil also induce 
substantial alkylation at adenine N3 while cyclophosphamide forms phosphotriesters with 
relatively high frequency.[237] The modification of side chains of this category of 
alkylating agents may alter their binding patterns with both region- and sequence-
selectivity. For example, employing nitrogen mustards attached to a variety of carrier 
molecules (intercalators, polypyrroles, polyimidazoles, bis(benzimidazoles), 
anilinoquinolinium salts and polybenzamides) the generated adducts range from reaction 
primarily at most guanine N7 sites in the major groove (chlorambucil) to selected adenine 
N3 sites at the 3’-end of poly(A/T) sequences in the minor groove (tallimustine).[248] 
 
1.3.2 Chloroethylnitrosourea 
Among nitrosourea compounds used in chemotherapy, the 2-chloroethylnitrosoureas 
(CENUs) are employed as bifunctional alkylating agents which may generate cross-links 
within DNA strands.[249-251] 
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Numerous CENUs have been developed, including bis(chloroethyl) nitrosourea (BCNU, 
carmustine), 1-(2-chloroethyl)-3-cyclohexyl)-1-nitrosourea (CCNU, lomustine), 1-(2-
chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU, semustine) and 






Figure 1-16. Molecular structures of BCNU, CCNU, methyl-CCNU and chlorozotocin 
 
These bifunctional alkylating agents share the same core moieties, 
2-chloroethylnitrosourea, which may degrade to form the 2-chloroethyl carbonium 
ion.[252-254] This is a strong electrophile capable of alkylating guanine, cytidine, and 
adenine. The chloride atom at the terminal may be displaced to provide another lesion to 
form DNA cross-links (either intrastrand or interstrand).[249] Interstrand cross-links are 
considered to be associated with the cytotoxicity of nitrosoureas. Of these four 
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nitrosoureas, chlorozotocin has low carbamoylation activity.[255-257] Methyl-CCNU is 
known to be a human carcinogen and the other three are listed as reasonably anticipated 
human carcinogens. 
Chloroethylnitrosoureas (CENUs) are clinically important chemotherapeutic agents, 
forming an ethylene-bridge ICL lesion between N1-G and N3-C. CENUs may also 
generate alkylation at the N7- and O
6
- positions of guanine, with the latter lesion being 
the precursor to the interstrand cross-link.[258] 
 
1.3.3 Bifunctional alkylene sulfonates and sulfamates 
Busulfan and hepsulfam (structures shown in Figure 1-17) are major representatives of 
this family, and they have been investigated and used for treatment of some 
diseases.[259-265] Sulfonate is a good leaving group accounting for the electrophilicity 
of these agents. As a result, busulfan and hepsulfam have a higher reactivity than nitrogen 








Busulfan is the drug of preference in treatment of chronic myelogenous or granulocytic 
leukemia because its cytotoxic activity results in primary damage or destruction of 
hematopoietic cells.[266] The butylene lesion mainly occurs at the N7 of guanine. In 
1961 P. D. Lawley suggested the formation of N7-diguanyl cross-links with busulfan, and 
in 1980 was confirmed through a chromatographic study while no distinction has been 
made as to whether this bridge represents an inter- or intrastrand cross-link.[245, 267] 
Later study showed busulfan mainly leads to the formation of an intrastrand cross-link 
within DNA duplex, preferentially to generate double-base lesions at 5′-GA-3′ sites. To a 
lesser extent, cross-linking lesions between the N7 atoms of two guanines occurs at 5’-
GG-3’ sites. [268] 
Hepsulfam is a bisulfamic ester which is similar in structure to busulfan while more 
hydrophilic than busulfan.[265] It is employed as a bifunctional alkylator inducing both 
DNA-DNA and DNA-protein cross-links.[269] Compared to busulfan, hepsulfam 
generates ICL DNA mainly on N7 of two guanines, and as a result exhibits higher 
toxicity and cytotoxicity.[264] 
Sequence-specificity studies were performed with dimethylsulfonates of different carbon-
length to investigate cross-linking patterns. Intrastrand cross-linking was favored for 5- 
and 6-methylene linkage containing agents and the main adduct occurred at N7 of 
guanine in 5’-GNC sites. Random cross-linking is observed in 5’-GNC and 5’-GC with 
an 8-methylene linkage. This is not consistent with general patterns observered for other 
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cross-linking agents (i.e. nitrogen mustards).  It was proposed that the sequence 
specificity involved the local disruption of initial monofunctional cationic N7-
alkylguanine prior to closure of the interstrand linkage in the second covalent reaction. 
Based on molecular modeling calculations, a nitrogen mustard could involve a 
noncovalent association for this step. This difference may account for this 
inconsistency.[270] 
 
1.3.4 Nitrous Acid 
Nitrous acid mostly originates from nitrites which are common food additives, and under 
acidic conditions in the stomach produces this reactive intermediate.  Nitrous acid is a 
mutagenic agent that induce ICLs in the DNA duplex, preferentially at d(CpG) steps. The 
occurrence of nitrous acid leads to deamination and cross-linking in the cell, and these 
two kinds of damage proceed by diazotization of an exocyclic amino group.[271, 272] 
Displacement by water results in deamination while nucleophilic substitution from the 
amino group of another DNA residue generates a cross-link.  It has been estimated that 
for every four deaminations of 2’-deoxyguanosine, the most readily deaminated DNA 
component, one ICL is formed.[273, 274] 
Nitrous acid-induced DNA ICLs form preferentially between two 2’-deoxyguanosine 
(dG) residues in [5’-d(CG)]2 sequences, forming a cross-link lesion in which the guanines 
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share a common exocyclic amino group (Shown in Figure 1-18). It has been proposed 
that this sequence preference is due to the close proximity of an exocyclic amine of dG 






(A) Structure of the nitrous acid induced DNA interstrand cross-link. (B) Schematic 
representation of the cross-linked dodecamer duplex with the residue numbering scheme. Note in 
particular the cross-linked guanines (G7 and G7′), and the cytosines preceding the cross-link, C6 
and C6′, which would base pair with G7′ and G7, respectively, in normal B-DNA. 
Figure 1-18. ICL formation with nitrous acid.(Adapted from reference [277]) 
 
Molecular modeling studies suggest that the resulting cross-linked lesion can be 
accommodated with minimal structural reorganization in B-form DNA, despite a severe 
propeller twist of the cross-link lesion.[275] Structural studies of nitrous acid induced 
DNA interstrand cross-links indicated that the cross-linked guanines formed a nearly 
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planar, covalently linked ‘G:G base pair’, stacked on the 3’  side of guanines of the 
spatially adjacent G:C base pairs. The complementary partner cytidines, which normally 
form a base pair with the cross-linked guanines, are flipped out of the helix, adopting 
well defined extrahelical positions in the minor groove. The identity of the flanking base 
pairs significantly altered the stacking patterns and phosphate backbone 
conformations.[278] 
 
1.3.5 Mitomycin C 
Mitomycin C (MC, shown in Figure 1-19), discovered in the 1950s in fermentation 
cultures of the microorganism Streptomyces caespitosis, is a bifunctional alkylating agent 
used as an antitumor antibiotic.[279-281] A number of close structural variants of MC 
have since been synthesized and isolated, collectively called mitomycins.[282-286] In 
mammalian cells alkylation of DNA with MC will lead to selective inhibition of DNA 
synthesis and mutagenesis. It has therefore been widely used as a tool to study such 







Mitomycin C MC-mono-dG adduct 
Figure 1-19. Mitomycin C and MC-mono-dG adduct.[289] 
 
Employing MC, damage occurs with a guanine residue to form MC-mono-dG adduct 
(principally at N
2
 of guanine), a G-G interstrand cross-link at CpG sites, or a G-G 
intrastrand cross-link at GpG sites.[290] Different from other bifunctional alkylating 
agents such as the nitrogen mustards, MC reacts with guanine residues of 5′-CG-3′ 
sequences through the minor groove of DNA. MC itself is relatively inert to form 
covalent adducts with DNA, and requires sequential chemical or enzymatic reductions of 
its quinone ring to initiate alkylation. The adducts of MC alkylation of DNA molecules 





Activation of only one of the alkylating functions gives monoadduct 2 and 4, whereas activation 
of both alkylating functions can give products 3 and 5. 






Employing MC as an alkylating agent, a structural study found that the formation of the 
intrastrand cross-link led to a distortion of B-form DNA with a 14.6±2.0° bend per lesion 
(minimum value). The bend may be generated in a considerable deviation from parallel 
of the normals to the best planes of the intrastrand cross-linked guanines, due to the 
formation of the MC intrastrand lesion requiring a shorter distance between their N
2
 
atoms than normal. The observed bending may account for the increased flexibility of 
MC-modified DNA, localized to distinct regions, as observed in earlier work by 
hydrodynamic methods and electron microscopy. The MC adduct-caused DNA bend may 
serve as a recognition site for certain DNA-binding proteins. [289, 294, 295] 
 
1.3.6 Psoralen 
Psoralen and its derivatives (molecular structures shown in Figure 1-20) are planar, 
tricyclic, semiaromatic compounds. They are bifunctional photoreagents that efficiently 
intercalate in double stranded DNA. Psoralen preferentially forms ICL DNA at d(TpA) 
dinucleotides upon exposure to light. This agent initially intercalates noncovalently 
between base-pairs of the DNA duplex. Upon absorption of a single long wavelength 
photon (ultraviolet light of 320-410 nm), either the furan-side or pyrone-side of the drug 
reacts with a pyrimidine base to form a cyclobutanyl monoadduct. Furan-side 
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monoadducts can absorb a second photon to cross-link the thymine base on the 
complementary strand of the DNA duplex.[296-299] Psoralens have been investigated as 
photoactive probes of nucleic acid structure and function.[243, 244, 247-249] As 




psoralen 4’-hydroxymethyl-4,5’,8-trimethylpsoralen (HMT) 
Figure 1-20. Molecular structure of psoralen and 4’-hydroxymethyl-4,5’,8-
trimethylpsoralen (HMT). 
 
The formation of the ICL lesion with psoralen leads to a significant distortion of B-form 
DNA structure. One example of a structural study was conducted with 4’-hydroxymethyl-
4,5’,8-trimethylpsoralen (HMT) as the cross-linking agent.  The d(T·A) base-pair with 
the thymine on the DNA furan-side (the strand with the furano portion linked to DNA is 
designated as F-strand) showed the least distortion, and there existed strong π-stacking 
interactions between the adenine base and the HMT pyrone ring. By contrast, the most 
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dramatic distortion in the d(T·A) base-pair with the thymine on the pyrone-side (the 
strand with the pyrone portion linked to DNA is designated as P-strand) resulted from a 
steric repulsion between the O
4
 keto oxygen of the thymine base and the HMT pyrone 
ring. There was virtually no stacking interaction between the adenine of this base-pair 
and the HMT furan ring. The perturbations on P-strand also had effect on the direction of 
the phosphoribose backbone, and accounted for the destabilization of the DNA duplex at 
the P-strand in the HMT adduct as compared to the native B-form DNA.[298] 
 
1.3.7 Triazene 
The 1,3-dialkyl-3-acyltriazenes, including 1-(2-chloroethyl)-3-methyl-3-carbethoxy-
(CMC), 1-(2-chloroethyl)-3-methyl-3-acetyl-(CMA), 1-(2-hydroxyethyl)-3-methyl-3-
carbethoxy-(HMC), 1-(2-hydroxyethyl)-3-methyl-3-acetyl-(HMA) and 1,3-dimethyl-3-
acetyl-(DMA),  can undergo degradation to produce a bifunctional alkylating agent.[300-
302] 
Two degradative routes have been demonstrated for these compounds (shown in Scheme 
1-10). The process of deacylation and tautomerization will generate an active 
alkanediazonium intermediate. Generation of the diazonium followed by DNA alkylation 
or hydrolysis (also giving rise to dG adducts) ensues and completes the major pathway of 
triazene decomposition. In the case where the N1 alkyl group is chloroethyl, quenching of 
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the diazonium yields chloroethylation at N7 or O
6
 of guanine. As with the nitrosoureas, 
O
6
 chloroethylation ultimately leads to the dG-dC interstrand cross-link while N7 
chloroethylation at N7 may proceed to form a dG-dG intrastrand lesion. [300, 303] 
 
 
Scheme 1-10. Degradation of 1,3-dialkyl-3-acyltriazenes to afford DNA alkylation 
adducts. [244, 300] 
 
1.3.8 Platinum complexes 
Platinum complexes, such as cisplatin [cis-diamminedichloroplatinum(II)], carboplatin 
[(1,1-cyclobutanedicarboxylato)platinum(II)], oxaliplatin [(trans-L-
diaminocyclohexane)oxalatoplatinum(II)] and nedaplatin [cis-Diammine-glycoloato-
O,O’-platinum(II)] are used in chemotherapy for testicular and ovarian cancers, among 
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others.[304-306] The molecular structures of these agents are shown in Figure 1-21. 
These drugs enter the cell by diffusion or with the aid of a transporter, become activated 
by forming aqua complexes, and bind to nuclear DNA, which in eukaryotes is packaged 
in highly condensed chromatin structures comprising nucleosome building blocks. 
Cisplatin reacts well with both free and nucleosomal DNA, showing a slight preference 





cisplatin Carboplatin oxaliplatin nedaplatin 
Figure 1-21. Molecular structures of cisplatin, carboplatin and oxaliplatin 
 
In the reaction between cellular DNA and cisplatin, different bifunctional adducts are 
formed including intrastrand and interstrand cross-links (including ICL DNA and cross-
linked DNA-protein).[304, 308] The most prevalent adduct is the 1,2-intrastrand cross-
link to generate cis-[Pt(NH3)2]
2+
 1,2-d(GpG). In this adduct, the platinum is covalently 
bound to the N7 position of adjacent purine bases, preferentially to the N7 of guanine. 
Monofunctional adducts and 1,3-interstrand cross-link  (and even longer range)  adducts 
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are also found after the administration of platinum complex(es), each of which gives rise 
to a distinct structural element that interacts with DNA differently.[304] 
The ability of cisplatin to bind to DNA and distort its structure suggested that it would 
interfere with the normal functioning of this important cellular component. Among all the 
formed adducts, the bioactivity of cisplatin is generally attributed to the formation of ICL 
DNA by sequential platination of two nucleophilic sites within the DNA duplex. The 
formation of the 1,2-intrastrand cis-[Pt(NH3)2]
2+
  cross-link leads to structural distortion 
of B-form DNA, which is unwound and bent towards the major grove.[227, 304, 309-
313]  Compared to the main 1,2-intrastrand cross-linked adducts at 1,2-d(GpG) sites, the 
solution structure of a short ICL duplex at the GC:GC site indicated that the 2’-
deoxyguanosine-bridging cis-diammineplatinum(II) lies in the minor groove, and the 
complementary 2’-deoxycytidines are extrahelical. The double helix is locally reversed to 
a left-handed form, and the helix is unwound and bent toward the minor groove. The 
NMR structure differs markedly from previously proposed models but accounts for the 
chemical reactivity, the unwinding, and the bending of cisplatin interstrand cross-linked 
DNA and may be important in the formation and repair of these cross-links in 
chromatin.[314] Crystal structures of ICL adducts show the double-helix is bent and 
unwound but with significantly different angle values. The platinum coordination is 
nearly square and the platinum residue is embedded into a cage of nine water molecules 
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linked to the cross-linked guanines, the two ammine groups, and to the phosphodiester 
backbone through other water molecules.[315] 
Despite its use in the clinic, cisplatin has several disadvantages including severe toxicity 
(i.e. nephrotoxicity, neurotoxicity, and emetogensis) and limited solubility in aqueous 
solution (only allowing for administration intravenously). Furthermore, cisplatin is 
employed as a chemotherapy agent to a relatively narrow range of tumors. Some tumors 
have natural resistance to cisplatins, while others develop resistance after the initial 
treatment. Compared to cisplatin, carboplatin is less toxic and can be administered at a 
much higher dose. However, carboplatin is only active in the same range of tumors as 
cisplatin and is still administered intravenously. The same limitations also apply to 
oxaliplatin and nedaplatin. The exploration of less toxic, orally active compounds that are 
non-cross-resistant with cisplatin and carboplatin is needed.[305] 
 
1.4 Interstrand cross-links and DNA repair 
Alkylating agents, especially bifunctional alkylating agents, are widely used in 
chemotherapy regimens for cancer treatments. A variety of bifunctional alkylating agents, 
i.e. chlorambucil, cyclophosphamide, CCNU, melphalan, procarbazine, cisplatin, BCNU, 
busulfan and mitomycin C, are administrated for the treatment of patients with malignant 
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diseases. Bifunctional alkylating agents form monoadducts, intrastrand cross-links, and 
interstrand cross-links (ICLs) in DNA (and DNA-protein cross-links as well).[316] 
ICL lesions covalently connect the strands of DNA, and therefore disturb cell cycle 
progression interfering with replication, transcription, and any other processes requiring 
strand separation. Compared with other forms of DNA damage, the repair of ICLs is a 
laborious challenge. As a result, ICLs are extremely toxic, particularly to dividing cells, 




DNA replication and its transcription to RNA can be blocked by ICLs. ICLs may also cause the 
distortion of chromatin structure, which prevent the access of DNA-interacting proteins. The 
introduction of ICLs into tumor cells will lead to their death via mitotic catastrophe or p53-
ligand-dependent apoptosis. 




Although they might differ in their clinical activity, all alkylating agents share the same 
mechanism of action. These agents act directly on DNA, resulting in its cross-linking and 
causing DNA strand breaks, leading to abnormal base pairing and inhibiting cell division. 
When DNA is altered in this manner, desired cellular activities come to a halt and the cell 
cannot multiply. Alkylating anticancer drugs are effective during all phases of the cell 
cycle and are used to treat a wide variety of cancers.[320] 
Simple methylating agents form adducts at the N- and O-atoms in DNA bases. N-
methylation adducts comprise more than 80% of methylated bases. Since there are a 
variety of nucleophilic sites (N- and O-atoms) within DNA duplexes, the introduction of 
bifunctional alkylating agents usually generates a broad spectrum of ICL adducts while 
some containing intrastrand cross-links may also be formed.[321] It has been 
demonstrated that some cross-linking agents (i.e. nitrous acid, formaldehyde and 
mitomycin C) have preference to form 1,2 ICLs while some others (i.e. nitrogen mustards 
and hepsulfam) generate 1,3 ICL DNA moieties as major products.[238, 240, 246, 274, 
322-334] 





Table 1-3. Summation of DNA cross-linking agents and their interaction within DNA 
duplex. (Adapted from reference [244]) 
Agent or class thereof ICL specificity DNA groove occupancy 
N-mustard dG N7-dG N7 major 
chloroethylnitrosoureas (CNU) dC N3-dG N1 major 
1,3-dialkyl-3-acytriazene dC N3-dG N1 major 
Busulfan dG N7-dG N7 major 
Clomesone dC N3-dG N1 major 
Glycidaldehyde not known not known 
Diepoxybutane dG N7-dG N7 major 
carzinophilin/azinomycin B dG N7-dG N7 
dG N7-dA N7 
major 
Cisplatin dG N7-dG N7 major 
Isochrysohermidin not known not known 
cyclopropylpyrroloindole dimers dA N3- dA N3 minor 
Bizelesin dA N3- dA N3 minor 





dinuclear cis-DDP dimers dG N7- dG N7 major 
8-methoxypsoralen T C5,6- T C5,6 major 
4,5’,8-trimethylpsoralen T C5,6- T C5,6 major 
Cyclophosphamide dG N7- dG N7 major 
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Hexamethylmelamine not known minor 





RSU-1069 not known not known 
aza aromatic N-mustards dG N7- dG N7 major 
Nitromin dG N7- dG N7 major 
chlorambucil N-oxide dG N7- dG N7 major 
















AZQ/DZQ dG N7- dG N7 major 
















As shown in the table above, a majority of the lesions formed by the bifunctional 
alkylating agents to produce ICL DNA occur in major groove at the N7 of guanine, and 
the preference of these as the main adducts are consistent with the better accessibility and 
higher nucleophilicity at this site. It is of great interest to understand the relationships 
between N7-guanine adducts and exposure, mutagenesis, and other biological endpoints. 
ICL N7-guanine adducts do not affect Watson Crick base pairing and pose a challenge to 
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study as they are chemically unstable and may lead to the production of FAPY and 
depurination products, which are potentially toxic in biological process of the cell. N7-
guanine adducts have been shown to be excellent biomarkers for internal exposure to 
direct acting and metabolically activated carcinogens.[189] 
There are also some examples of ICL lesions that protrude in the minor groove. Agents 
that alkylate DNA in the minor groove are potent cytotoxins, and represent a class of 
cytotoxic antitumor agents whose DNA sequence specificity may lead to a high 
selectivity of action.[335] Together with their potential sequence selectivity of interaction 
with DNA, they are of great interest as potential anticancer drugs. 
These alkylated DNA adducts exhibit different stabilities. N7-alkylG adducts are 
chemically unstable caused by the formal placement of an additional positive charge on 
the guanine ring system.[336] In double-stranded DNA (dsDNA) the half lives range 
from as little as 2 to 150 h, and larger alkyl groups generally promote depurination in 




-alkylG), which accounts for a 
lower proportion of alkylated DNA adducts, are more stable and persist in the absence of 
the DNA repair protein O
6





-alkylT) are highly mutagenic and genotoxic, whereas 
N-alkylations (e.g., N3-alkylA and N1-alkylA) are cytotoxic, but less mutagenic.[222] 
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The cellular responses to ICLs, in particular DNA repair, are of importance not only for 
maintaining genome stability, but also for tumor resistance against chemotherapeutic 
agents. DNA repair is essential for maintaining the integrity of genomic DNA, and their 
loss is associated with cancer predisposition syndromes.[337] The current applications of 
ICL repair are mainly explored for the use of ICL-inducing chemicals in biochemical or 
genetic analysis of cells and cell lines as well as their anticancer chemotherapeutics.[316, 
338] This is an efficient strategy for the study of specific DNA damage induced by 
bifunctional alkylating agents. Several classes of bifunctional alkylating agents have been 
employed in cancer therapies, such as cisplatin (with intrastrand cross-links as main 
adduct around 5–8% ICL),[319, 339-341] bis(2-chloroethyl)methylamine and nitrogen 
mustards (1–5% ICLs),[246, 319, 342] bis(2-chloroethyl)nitrosurea (BCNU or 
carmustine, around 8% ICLs),[343] Mitomycin C (MMC, 5–14% ICLs),[344] and 
Pyrrolo[2,1-c][1,4]benzodiazepines (PBD, 440-fold higher ICL formation activity than 
the nitrogen mustards).[345, 346] 
ICL repair mechanisms are more complicated compared to those of mono-alkylated 
damage. An ICL represents a formidable block to the DNA replication machinery and 
requires a combination of Fanconi anemia (FA) repair, NER, translesion synthesis (TLS), 
and HR repair for efficient repair.[148, 319, 347] The repair of ICL remains an active 
field of study while genetic studies indicated that various classes of proteins are involved 
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in this biological process.[348-350] On the other hand, the study of DNA repair pathways 
may attribute to the therapeutic effects of alkylating agents (particularly bifunctional 
alkylating agents), therefore, characterization of the repair pathways is essential for 
developing new treatments.[222] 
 
1.5 Synthesis of ICL oligonucleotides for repair studies 
DNA, which carries genetic information, is subjected to various chemical reactions 
resulting in damage within the cell. The chemical reactions occurring to DNA may 
generate lesions within DNA duplexes, which interferes with the bioactivities of DNA 
and induces mutations in the DNA sequences. If left unrepaired and allowed to 
accumulate, these damages will lead to carcinogenesis and cell death. 
ICL lesions are toxic and result in havoc in the damaged cells as stated above. The repair 
of this category of lesions to restore genomic integrity is more complicated, and 
understanding the mechanism(s) involved continues to be challenging, particularly in 
mammalian cells. The processing of ICL, introduced by bifunctional alkylating drugs 
employed during chemotherapy against diseases such as cancers, can reduce the efficacy 
of this group of drugs. A better understanding of the relationship between ICL and DNA 
repair might enable the development of improved therapeutic agents. The pursuit of 
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understanding the repair of interstrand cross-links by repair systems has necessitated the 
synthesis of sufficient quantities of such damaged DNA.[351] 
Formerly, DNA from bacteria and bacteriophages and DNA fragments treated with 
bifunctional alkylating agents (i.e. to form ICLs) were used in biochemical studies. There 
are a variety of nucleophilic sites within DNA duplexes, which leads to a wide spectrum 
of alkylated adducts. Employing bifunctional alkylating agents, monoadducts, intrastrand 
and ICL adducts can usually be generated. For example, the approach to generate ICL 
DNA duplexes by treatment of DNA with nitrogen mustards, cisplatin, BCNU or 
mitomycin C, is very inefficient, yielding only about 1–5% of ICL adducts, with 
monoadducts and intrastrand cross-links making up the majority of products.[247, 352] 
Thus, it is very challenging to isolate the expected DNA sequences containing the desired 
ICL lesion(s).   
Another strategy for the preparation of ICL DNA involves the solution and solid-phase 
synthesis of modified oligonucleotides. Oligonucleotides containing modified moieties 
are commonly used for a wide range of biochemical and biophysical studies. Some 
modified oligonucleotides have been investigated as therapeutic and diagnostic agents, 
such as antisense oligonucleotides to block gene expression by binding with 
complementary sequences of target mRNA. They are also employed as molecular probes 
to better understand the interaction between proteins and nucleic acids at molecular level, 
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which in fact is responsible for all aspects of cellular or viral gene expression.[351, 353-
358] A combined approach (solution synthesis and solid-phase synthesis) enables the site 
specific incorporation of a modification at a defined position within any sequence 
context. 
This method for the preparation of modified DNA oligonucleotides normally consists of 
two synthetic parts. A phosphoramidite of a modified nucleoside is first prepared in 
solution followed by incorporation into an oligonucleotide by a solid-phase DNA 
synthesizer. 
Solid-phase synthesis (SPS), invented initially for peptide synthesis in the 1960s by 
Bruce Merrifield, is a method in which target compounds are synthesized step-by-step on 
a solid support in a reactant solution. This approach has also been applied for the 
preparation of other molecules including DNA and RNA.[359] SPS is carried out on a 
solid support held between filters, in columns that enable all reagents and solvents to pass 
through freely. Compared to solution synthesis, SPS has a number of advantages. 
a) Excess reagents are used to drive reactions quickly to completion. 
b) Impurities and excess reagents are easily washed away, and no purification is required 
after each step. 
c) The process can be operated automatically and is suitable for parallel synthesis. 
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Resins are widely employed as solid support. They are the insoluble particles, typically 
50-200 μm in diameter, to which the oligonucleotide is bound during synthesis. Many 
types of solid support have been used, but controlled pore glass (CPG) and polystyrene 
have proved to be the most useful. 
Opposite to the 5′- to 3′-direction of DNA biosynthesis during the process of DNA 
replication, the synthesis of oligonucleotides on the solid-phase synthesizer usually 
proceeds in the 3′- to 5′-direction. One nucleoside is added per SPS cycle while the 







Scheme 1-11. SPS cycle for oligonucleotides 
 
As shown above, the first 5’-O-DMT-nucleoside (4,4′-dimethoxytrityl) is attached to the 
solid-support through a linker. The DMT protective group is sensitive to acids, and can 
be cleaved from the 5’-OH to afford a new reaction site. This step is called detritylation, 






Figure 1-23. Mechanism of acid-catalyzed detritylation 
 
Following detritylation, the support-bound nucleoside is ready to react with a nucleoside 
phosphoramidite. The nucleoside phosphoramidite, which is activated with tetrazole, 
enters the reaction cycle. With the aid of the soft base diisopropylamine, the 
phosphoramidite is attacked by the 5′-hydroxyl group of the support-bound nucleoside to 





Figure 1-24. Mechanism of coupling reaction of nucleoside phosphoramidite 
 
It is inevitable that after each coupling step some unreacted 5′-hydroxyl groups remain on 
the resin-bound oligonucleotide as a result of failure of the phosphoramidite to couple. If 
these are present, their 5′-hydroxyl groups would compete in the next coupling step, 
reacting with the incoming phosphoramidite. One extra step is needed to block the 
unreacted 5′-hydroxyl groups with capping reagents. These capped oligomers will no 
longer react during subsequent coupling steps in the DNA synthesis cycle, resulting in 
truncated sequences. 
After the coupling step, the formed phosphite-triester is oxidized with iodine to generate 






Figure 1-25. Mechanism of oxidation 
 
The DMT protective group at the 5′-end of the resin-bound DNA chain is removed with 
acid to free a new primary hydroxyl group, which enters the next reaction cycle. 
The reaction cycle is repeated with the appropriate nucleoside phosphoramidites 
(including the modified nucleoside phosphoramidite) until the desired oligonucleotide is 
produced on the solid support. In contrast to the synthesis of oligonucleotides with 
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standard DNA nucleobases, oligonucleotide synthesis with specialized monomers often 
requires modified synthetic or deprotection conditions.[353] 
A cleavage procedure is performed to remove the synthesized oligonucleotide from the 
solid support as well as the protective groups on the nucleobases and 2-cyanoethyl group 





Figure 1-26. Cyanoethyl phosphodiester deprotection with ammonia 
 
Depending on the efficiency of synthesis and wash steps, the amount of failure sequences 
may vary, and as a result a mixture of oligonucleotides including the expected sequence 
and failure sequences are generated. Purification is required to separate the desired 
oligonucleotide from such failure sequences. The most common methods for purification 
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are high-performance liquid chromatography (HPLC) and polyacrylamide gel 
electrophoresis (PAGE). 
A combination of solution synthesis and solid-phase synthesis enables the introduction of 
modified residues into DNA and the preparation of ICL DNA duplexes. The synthesis of 
ICL DNA duplexes will be introduced with some examples in Chapter 2. 
ICL lesions can be introduced either in form of a cross-linked dimer or as ICL precursors 
that can undergo a specific coupling reaction after incorporation into complementary 
strands and annealing.[355, 362] 
 
1.6 Purification and characterization methods of oligonucleotides 
The lengths of oligonucleotides produced by automated solid-phase synthetic process 
typically range from 10 to 80 nucleotides, and the synthesis scales vary from nanograms 
to kilograms, depending on the application. Although the synthesis efficiencies are very 
high, the overall yields of the products decrease as the impurities accumulate with the 
increasing number of synthetic cycles. Truncated oligonucleotide sequences and other 
process-related modifications and impurities are often artifacts of synthesis. Coupling and 
capping failures may lead to a series of deletion sequences, which constitutes the major 
impurities in solid-phase synthesis. Additional impurities may result from incomplete 
detritylation and incomplete oxidation as well as from the starting materials and post-
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synthesis processing. It is important to analyze synthetic products to determine whether 
the purity is sufficient or if further purification is required. In addition, the analysis of 
intermediates and final products is also necessary for quality control and design study. To 
obtain final products of good quality, the impurities need to be removed to ensure that the 
purity of synthetic oligonucleotides meets the requirements for the experiments to be 
performed.  
Oligonucleotide purification is typically performed either by HPLC and PAGE. HPLC is 
an efficient method for the analysis and purification of synthetic oligonucleotides. It can 
be used for the separation of oligomers of similar size. The technique depends on the 
structure and length of the oligonucleotides, the presence or absence of the trityl group, 
and the nature of any modifications. The purification of synthetic oligonucleotides is 
usually challenging because the small differences in size, charge and hydrophobicity 
between the full-length product and impurities may lead to co-elution. HPLC systems 
typically consist of the following components: an injector, pumps for delivery of solvents 
through the column, an interchangeable HPLC column, a column oven, a solvent mixing 
system, and a detector (normally UV/visible). Reversed-phase (RP-HPLC) and strong 
anion-exchange (SAX-HPLC) are typically employed in this field. Following HPLC 




1.6.1 Reversed-phase HPLC 
Crude oligonucleotides containing the desired products, failure sequences and other 
impurities may vary in hydrophobicity. Reversed-phase HPLC separates oligonucleotides 
and contaminants on the basis of differences in hydrophobicity. The mixture of 
oligonucleotides is injected onto a column of hydrocarbon chains (normally C8 or C18) 
which are chemically bound to a silica support of defined pore size, typically about 300 
Å. Elution with a mobile phase such as aqueous ammonium acetate forces the 
oligonucleotide to interact strongly with the reversed-phase column. Further elution with 
a gradient of organic solvent such as acetonitrile in aqueous ammonium acetate causes 
the individual components in the mixture to enter the mobile phase, which becomes more 
hydrophobic as the percentage of acetonitrile increases. Molecules with a greater degree 
of hydrophobicity elute more slowly (for example if a DMT is retained on the desired 
oligonucleotide), and this leads to separation of the components in the mixture. 
Although reversed-phase HPLC is very powerful and routinely employed for the 
purification of oligonucleotides, there are certain limitations. It still remains challenging 
to separate long oligonucleotides from those failure sequences of a similar length. For 
those composed of stable secondary structures (e.g. hairpin loops), HPLC separation may 
lead to failure due to elution as a broad peak or even a series of peaks. Higher 
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temperature (60 °C) is needed to run HPLC separation by temporarily denaturing the 
secondary structures. 
 
1.6.2 Anion-exchange HPLC 
Anion-exchange HPLC separates oligonucleotides according to the charge differences. 
Each oligonucleotide is a polyanion and has a particular net negative charge based on the 
number of phosphodiester groups in the molecule. The anion-exchange purification 
method is performed with a salt-gradient elution on a quaternary ammonium stationary 
phase column or a similar structure (cationic). Separation of the crude mixture is 
accomplished by slowly increasing the ionic strength of the mobile phase to weaken the 
ionic interactions between the oligonucleotide (polyanion) and the stationary phase 
(cationic amine). The longer oligonucleotides with higher charge elute later than the 
shorter ones. This technique is effective in separating oligonucleotides of 5 to 50 bases in 
length from failure sequences at smaller quantities, and can be coupled with purification 
by RP-HPLC. 
Similar to RP-HPLC, anion-exchange HPLC is also limited by length (usually up to 
40mers). The separation of longer oligonucleotides usually results in lower resolution on 




1.6.3 Polyacrylamide gel electrophoresis (PAGE) 
Polyacrylamide gel electrophoresis (PAGE) is a technique that separate molecules based on 
their electrical charge and hydrodynamic properties, which are a function of chain length 
for DNA and RNA. PAGE purification can be used for oligonucleotides, up to nucleotide 
lengths of 100 and longer. Visualization using UV detection or intercalating staining 
techniques (STAINS-ALL™) can be used on oligonucleotides to enable a more sensitive 
level of detection with an increasing length of the oligonucleotide. Preparative PAGE is 
an alternative to HPLC separation however it is not commonly used due to lower 
recovery, lower mass loading as well as being more time-consuming and labor intensive. 
As with preparative HPLC, resolution decreases when performing preparative PAGE 
highlighting the need for verification of the purity prior to further steps. 
 
1.7 Biophysical Analysis of Oligonucleotides 
1.7.1 Mass Spectrometry 
Mass spectrometry (MS) is employed for the measurement of the mass-to-charge ratio of 
molecules. Molecules must be ionized before their introduction into the vacuum system 
of the mass spectrometer. A number of ionization methods (i.e. electron impact 
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ionization, chemical impact ionization, fast atom bombardment and atmospheric pressure 
chemical ionization) have been explored and used for MS analysis. Compared with 
gaseous or volatile samples, thermally labile analytes require so-called soft ionization 
methods such as field desorption and electrospray ionization for the production of ionized 
particles with little or no fragment-ion content.[363-365]  
Among the existing soft ionization methods, electrospray ionization (ESI) is widely 
performed for accurate mass measurement, particularly for thermally labile, high 
molecular mass substances (ie. proteins, oligonucleotides, synthetic polymers, etc.).[366-
371] In this ionization method, a solution is nebulized under atmospheric pressure and 
exposed to a high electrical field which creates a charge on the surface of the droplet. 
Droplets rapidly become much smaller through vaporization of solvent when moving 
towards an analyzer.[371-377] 
1.7.2 Enzymatic Digests 
Exonucleases are a category of enzymes that degrade DNA or RNA to generate 
distinct cleavage products useful for the study of oligonucleotide sequences.[378] 
There are two classes of exonucleolytic enzymes, one specifically attacking at 3’-
hydroxyl terminus (3’→5’, 3’-exonuclease) and another at the 5’-phosphoryl terminus 
(5’→3’, 5’-exonuclease).[379] 
Snake venom phosphodiesterase, also called snake venom exonuclease, is a 3’- 
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exonuclease and attacks both DNA and RNA to produce 5’ monophosphate 
esters.[380, 381] Calf intestinal phosphatase is a type of alkaline phosphatase that 
catalyzes the hydrolysis of 5´-phosphate groups from DNA, RNA, and ribo- and 
deoxyribonucleoside triphosphates.[382-385] The combination of snake venom 
phosphodiesterase and calf intestinal phosphatase results in digestion of an 
oligonucleotide to the nucleosides. This combination of enzymes is useful in 
determining the nucleoside composition of synthesized ICL DNA duplexes as the 
percentage of four native nucleosides (2’-deoxycytidine, 2’-deoxyadenosine, 2’-
deoxyguanosine and thymidine) and cross-linked nucleoside when analyzed by RP 
HPLC.  
 
1.7.3 UV Thermal Denaturation Studies 
The stability of DNA duplexes depends on a number of factors such as hydrogen 
bonding and base stacking. The process to separate double-stranded helical DNA 
duplexes into single strand is referred to as denaturation. The denaturation process is 
generally reversible (the reverse process is known as renaturation), and is commonly 
caused by heating while some other factors, i.e. pH change, lowering ionic strength 
by decreasing the dielectric constant of the aqueous medium (with alcohol, ketones, 
amides, urea et al.) can also lead to denaturation of DNA duplexes.[386-390] 
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UV thermal denaturation is normally employed for this analysis. It was found that the 
absorption spectrum of native DNA was much lower than that of calculated 
constituent nucleotides at the characteristic ultraviolet wavelength near 260 nm. 
Heating double-strand nucleic acids may lead to the formation of single-stranded 
oligonucleotides by breaking hydrogen bonds and disrupting the ordered base 
stacking. Thermal denaturation of double-stranded duplexes usually occurs following 
a sigmoidal curve, monitoring absorbance at 260 nm with a relatively smooth increase 
in UV absorbance as the double strands unwind to single strands (hyperchromic 
effect).[391-393] The mid-point of this transition is measured as melting temperature 
(Tm) at which 50% of DNA is denatured into random-coil state. The Tm is dependent 
on a number of factors, i.e. the length and sequence of the DNA molecule and 
others.[394-401] 
 
1.7.4 Circular Dichroism (CD) Spectroscopy 
Circular dichroism (CD) has been employed for structural study of optically active 
molecules, with numerous examples in the literature.[402-408] CD spectroscopy has 
applications for the study of structure and interaction of biomacromolecules such as 
proteins and nucleic acids.[409-422] 
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Compared to nuclear magnetic resonance (NMR) and X-ray crystallography which may 
genenerate structural information of more direct and detailed residue-specificity, CD 
spectroscopy provides alternative measurements which can be performed with small 
amount of substrates in physiological buffers while monitoring structural changes 
adapting to environmental conditions (i.e. pH, temperature, ionic strength and interaction 
of other molecules).[423] CD spectroscopy is now widely used to provide structural 
information of nucleic acids, particually for the study of secondary structure of nucleic 
acids ranging from single‐stranded to triplex and quadruplex forms.[418, 424] 
In this thesis, CD spectroscopy is conducted with the modified DNA duplexes. This can 
provide the conformational information for the structural intergrity due to the formation 




Chapter 2. Project Outline 
2.1 Background and Significance of ICL Oligonucleotide Synthesis 
2.1.1 Current State of Knowledge 
There are a number of bifunctional alkylating agents which react with DNA including 
dialdehydes that are produced in the cell and compounds that have both been employed 
as therapeutics (i.e., BCNU and mechlorethamine) or studied in clinical trials (i.e. 
hepsulfam) (structure shown in Figure 2-1).[161, 189, 235, 317, 333, 425] Treatment of 
DNA duplexes with these bifunctional alkylating agents often results in a broad spectrum 
of alkylated DNA products, with only a small percentage of ICL duplex produced. Of all 
the nucleophilic sites in DNA, the N7-position of guanine is the most reactive with 
electrophiles.[144, 189, 426-430] Hundreds of DNA adducts have been identified 
addressing a number of issues such as the relationships between DNA adducts produced 
by exposure to chemical agents with mutagenesis and other biological endpoints. The 
covalent binding to DNA and the ability to form N7-guanine adducts has been considered 











Figure 2-1. The molecular structures of BCNU (1a), mechlorethamine (1b) and 
hepsulfam (1c) 
 
To counteract the damage of ICLs, cells have developed mechanisms to repair these 
lesions, and recover the integrity of their intact sequences. The failure to repair such 
lesions may cause inherited disorders. In contrast, the repair of ICLs in tumor cells leads 
to resistance against anti-tumor agents, which are introduced in cells to generate ICL 
lesions during chemotherapy. Therefore better understanding of the relationship between 
ICL damage and cell repair should not only significantly contribute to our understanding 
of the molecular basis of human disease but also to the mechanisms of resistance of 
tumor cells to chemotherapeutic agents. This knowledge will facilitate the development 
of new targets for tumor chemotherapy. 
Although significant progress has been made in studying various DNA repair pathways, 
the mechanisms underlying the repair of ICLs remain poorly understood, particularly in 
mammalian cells. As stated above, employing bifunctional alkylating agents adducts 
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containing alkylation at the N7 of guanine are usually generated as the major products. 
The investigation of the role these adducts plays is important in investigating DNA 
repair. The main obstacle in studying the mutagenic potency of N7-guanine adducts is 
their chemical instability which has prevented systematic investigation of the lesions in 
site-directed mutagenesis studies. The instability of N7-guanine adducts is created by the 
formal placement of an additional positive charge on the guanine ring system. The 
alkylated guanines undergo a further reaction resulting in cleavage of the N-glycosyl 
bond (Figure 2-2). This depurination creates an abasic site in the DNA and in the case of 
bifunctional alkylating agents, effectively removes the ICL formed. Alternatively, the 
imidazole ring of the alkylated guanine can undergo hydrolysis to produce a FAPY 
derivative, which is relatively resistant to further chemical reaction (Figure 2-2).[132, 
185, 189, 193, 235, 322, 336, 431-435] 
 
Figure 2-2. Potential products formed by alkylation of the N7 atom of 2’-




2.1.2 Examples of synthesized alkylene linked ICL oligonucleotides 
Understanding how ICL are repaired has been and continues to be a challenge. A better 
understanding of the mechanism(s) involved is not only of academic interest but may be 
relevant to cancer chemotherapy as well. Oligonucleotides functionalized by conjugation 
with a variety of molecules have been employed as substrates for various studies for a 
few decades with aliphatic linkers frequently used for tethering these modifications. The 
introduction of aliphatic linkers to synthesize ICL oligonucleotides via chemical 














 ICL (Wilds, Figure 2-3c),[443-
445] N3-T-alkylene-T-N3 (Miller and Wilds, Figure 2-3d),[446] N1-dG-ethylene-dC-N3 
(mimic BCNU lesion, Luedtke, Figure 2-3e),[447] and N1-dI-ethylene-T-N3 (mimic 1,3-






a b c 
 
  
e e f 





Recently, Yasuo Komatsu et al. applied amino linkers containing a carbamate structure 
for the preparation of covalent cross-linking of apurinic/apyrimidinic sites (AP pair) on 
opposite positions of complementary strands (Figure 2-4). Two aldehyde groups of the 




 representing aliphatic or aromatic linkers 
Figure 2-4. ICL reaction of an AP pair 
 
The development of chemically stable substrates that mimic the lesions formed by 




2.2 Statement of the Problem 
Cellular DNA is susceptible to damage by endogenous and environmental agents that 
may cause modifications such as cross-links. This can either occur on the same strand 
(intrastrand cross-link) or on the opposite strands of DNA (interstrand cross-link). 
Interstrand cross-links (ICL) in DNA exert significant biological effects by preventing 
replication and transcription, which cause cell death if the cross-link is not repaired.[235, 
317, 350, 425, 450, 451] 
ICL can also be introduced in DNA as a consequence of the action of cancer 
chemotherapeutic agents that kill cancer cells. Alkylating drugs such as 1,3-bis(2-
chloroethyl)-1-nitrosourea (BCNU or carmustine in Figure 2-1a) and mechlorethamine 
(Figure 2-1b) react to form ICL at different positions in DNA duplexes (Figure 2-3 and 
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Figure 2-5. Examples of ICL linkages introduced by alkylating drugs and major 
sequence motifs (a/b): N1-dG-alkylene-N3-dC; (c/d): N7-dG-alkylene-N7-dG). 
 
Development of tumors, resistant to these agents is a factor in the lack of response in 
some patients, with removal of ICL believed to play a role in resistance. These lesions are 
eliminated from DNA by a mechanism involving excision repair and recombination (for 
example in E. coli and in yeast).[450, 451] In eukaryotic cells, the precise role of excision 
repair in eliminating cross-links is not yet clearly understood.[235, 317] 
The investigation of ICL removal by repair enzymes requires access to substrates 
containing this damage. One way in which ICL containing DNA can be prepared 
involves direct treatment of DNA with bi-functional alkylating agents. However, this 
approach is not optimal for practical reasons. Alkylating agents lack target specificity and 
can react with numerous nucleophilic sites within DNA. As a result, a huge variety of 
alkylated adducts will be formed during this process.[235] As stated in Chapter 1, the 
preference of alkylating sites depends on several factors when they are employed for the 
introduction ICL along DNA complementary strands. Among all the discovered and 
developed bifunctional alkylating agents, the modified adducts containing N7-alkylated 
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guanine are predominant due to the higher nucleophilic reactivity at this site.[116, 194-
201] Even though less mutagenic or cytotoxic, the main ICL adducts containing N7-
alkylated guanine exhibit important biological properties (i.e. hepsulfam, NSC 3296801 
shown in Figure 2-6).[333] Due to the chemical instability some studies of N7-guanine 
adducts are challenging, in particular structural and DNA repair experiments. 
 
 
Figure 2-6. Structure of N7-dG-alkylene-dG-N7 ICL (n= 2~5) 
 
Another approach to investigate ICL repair involves the use of chemically synthesized 
substrates of well defined structure. Such substrates are challenging to prepare in 
quantities sufficient for biochemical and structural studies. Employing a combination of 
solution and solid-phase synthesis, ICL DNA that are mimics of clinically relevant 
lesions formed during chemotherapy can be produced. 
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Given the chemical instability of the N7-adducts of 2’-deoxyguanosine, we have had 
interest in the preparation of ICL containing the heterocycle 7-deazaguanine, whose C7 
atoms in complementary DNA strands are attached by an alkylene linker. One major goal 
of this thesis is the development of procedures to prepare 7-deazaguanine and ICL 
linking the C7 atoms to address some problems outlined above. 7-Deazaguanine (with the 
major tautomer shown in Figure 2-7), is an ideal analog of guanine. In comparison to 
guanine, 7-deazaguanine lacks the N7 atom, and thus loses a hydrogen-bond acceptor. As 
such, a Watson-Crick base pair may be formed between 7-deazaguanine and cytosine 
similar to guanine and cytosine (see Figure 2-8) while there is no Hoogsteen base pair 
(see Figure 2-9).[452] 
 
 












Figure 2-9. Hoogsteen base pair in G:C (top) while no such base pair is possible in 
deazaG:C (bottom) 
 
The five-member heterocyclic pyrroles consist of six π electrons which can delocalize 
over the five ring atoms, and the delocalization of p-orbital electrons of nitrogen affords 
an electron-rich system. By comparison, the six-member heterocyclic pyrimidine is 
electron-poor (deficient) due to the two nitrogens which act as electon-withdrawing 
groups. According to the structure of bicyclic 7-deazaguanine, a pyrimidine nucleus is 
fused to a pyrrole as an electron- dragging-pushing aromatic system. The fused structure 
shows the typical reactivity with reduced electron density in the five- member ring and 
increased electron density in the six-membered ring. A large range of pharmacological 




We proposed to prepare via organic synthesis a chemically stable ICL that mimics the 
alkylene lesions formed in duplex DNA as a result of treatment with alkylating drugs 
such as mechlorethamine and hepsulfam.[333, 425] These structural analogs would link 
the C7 atoms of two 7-deaza-2’-deoxyguanosine (C7-dG) nucleosides with an alkylene 
linker and will be incorporated into DNA by solid-phase synthesis (Figure 2-10). 
 
 
Figure 2-10. The C7-dG-alkylene-dG-C7 ICL oligonucleotides (n= 2~5) 
 
The similarity between guanine and 7-deazaguanine made the attempt to syntheize this 
ICL of interest (see Figure 2-6 and Figure 2-10). Compared with previously synthesized 
ICL duplexes by our group, these proposed substrates containing cross-linked 7-
deazaguanosine would have the following merits. 




2) The use of 7-deazaguanine should stabilize the introduction of alkylene linkers at 
this site in DNA. 
3) ICL oligonucleotides containing alkylene-linked 7-deazagaunine should not affect 
Watson-Crick base pairs between the two complementary strands, similar to the 











An additional goal of this thesis is to explore the use of various protective groups around 
the cross-linked nucleoside dimers (which are converted to phosphoramidites and then 
used in solid-phase synthesis) to enable the preparation of oligonucleotides containing 
different nucleotide compositions around the cross-linked site. This has been a limitation 
in our lab in preparing various ICL containing oligonucleotides. To date, due to the 
protective groups that have been explored, nucleotide sequences around the cross-linked 












Xs are the cross-linked nucleosides. PG1, PG2 and PG3 represent different protective groups. 
Figure 2-12. Synthetic strategies for preparation of symmetrical (a), partially 
asymmetrical (b) and completely asymmetrical sequences (c). 
 
For the preparation of ICL via strategy (c), four compatible protective groups are needed 
to prepare a cross-linked tripartite phosphoramidite, which enables ICL oligonucleotides 
to be prepared on a solid-phase synthesizer (see Figure 2-12c).    The three protective 
groups will be removed individually, followed by chain elongation by phosphoramidite 
coupling, from the support bound oligonucleotide until ICL synthesis is complete. 
Ultimately, these strategies will employed to produce ICL DNA substrates that will be 
used in biophysical, structural and biochemical studies in order to examine their 
interaction with DNA repair enzymes. These results will provide us with insights as to 
whether these lesions are recognized and repaired, thus establishing a relationship 
between DNA repair with chemotherapeutic resistance to these drugs which could aid in 
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the development of more effective alkylating therapeutics that could induce lesions that 
may resist repair. 
 
2.3 Specific Aims 
The overall goals of this thesis are:  
a) Optimize protective group and deprotection strategies to prepare ICL containing 
completely asymmetrical nucleotide sequences around the cross-linked site.  These 
studies are performed using a system containing a N3-thymidine-butylene-N3-thymidine 
interstrand cross-linked DNA, given the challenges that were forseen in preparing 
alkylene linked 7-deaza-2’-deoxyguanosine ICL (Chapter 3).  
b) To optimize methods to prepare the heterocycle 7-deazaguanine (Chapter 4).  
c) To prepare dimers of 7-deaza-2’-deoxyguanosine linked by a C7-alkylene linker 
employing the Sonogashira reaction and Pd-catalyzed hydrogenation to prepare ICL 





Chapter 3. Preparation of N3-thymidine-butylene-N3-
thymidine interstrand cross-linked DNA via an orthogonal 
deprotection strategy 
3.1 Introduction 
Cellular DNA, on exposure to various environmental and chemotherapeutic agents, can 
undergo damage with numerous modifications identified including interstrand cross-links 
(ICLs).  ICLs threaten genomic and cellular integrity because they present formidable 
blocks to essential metabolic processes that require obligate strand separation (replication 
and transcription).  Even though cells must efficiently detect and remove damage for 
survival, ICL-inducing agents continue to be employed as chemotherapeutic treatments 
for many cancers.[247, 459] However, resistance to ICL-inducing agents due in part to 
efficient DNA repair, can result in recurrent malignancies which are unresponsive to 
treatment,[460, 461] in addition to possibly increasing the risk of secondary cancers 
likely due to their mutagenic processing in normal cells.[462]  Despite the substantial 
progress in the fields of ICL repair in bacteria and yeast which occur primarily via a 
combination of processes including nucleotide excision repair (NER), homologous 
recombination (HR), and translesion synthesis (TLS),[348, 463-465] a complete 
understanding of such repair in mammalian systems is still unclear.[350, 352, 466-471] 
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In mammalian cells, ICL repair is thought to proceed by the coordination of proteins 
from several pathways, including NER,[472, 473] base excision repair (BER),[474] 
mismatch repair (MMR),[475, 476] HR,[477, 478] TLS,[479] and proteins involved in 
Fanconi anemia (FA).[480] Therefore, efforts to better understand the cellular responses 
to and repair of ICL-inducing lesions in mammalian cells offers the potential to improve 
the efficacy of these drugs in cancer therapy. 
One continuing approach to investigate the role that repair pathways play in removing 
ICL is to use chemically synthesized oligonucleotides which contain adducts that 
represent the lesions introduced by ICL-inducing agents.  Differing strategies have been 
developed to obtain ICL-containing DNA. One avenue to ICL synthesis involves the 
incorporation of stable ICL forming precursors into single stranded DNA using standard 
DNA synthesis after which hybridization triggers ICL formation.[447, 481]
 
 We and 
others have established an approach (mono and bidirectional) to synthesize cross-linked 
nucleosides to directly introduce the ICL, which enables exact placement of the desired 
ICL, using a combination of solution and solid-phase synthesis.[272, 329, 351, 443, 445, 
446, 482-485] However, several of these model ICL systems to date have contained 




We have previously reported the synthesis of N3-thymidine-butylene-N3-thymidine 
(N3T-butylene-N3T) ICL duplexes with either partial or complete symmetry around the 
site of the cross-link using nucleoside dimers containing DMT and TBS protecting 
groups on the 5’ and 3’-O functionalities using mono- and bis-phosphoramidite 
approaches.[446, 483] 
 
In order to accomplish the synthesis of asymmetric sequences it is 
imperative to design the dimer phosphoramidite to contain three different protective 
groups around the 5’- and 3’-O functionalities that are compatible with each other for 
selective removal without compromising the ICL lesion to introduce the cross-link into 
the desired ICL duplexes (shown in Figure 3-1).[486] 
 
 
Figure 3-1. Chemical structure of the N3T-butylene-N3T ICL. 
  
In order to construct completely asymmetrical nucleotide sequences around the ICL site, 
it was necessary to design the dimer phosphoramidites with protective groups that were 
compatible with each other (introduction as well as their removal) and more importantly 
their compatibility with solid-phase synthesis when being assembled within the desired 
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ICL duplexes.[486] The five functional groups that were investigated in the synthesis of 
the dimers and consequently the ICL duplexes were the DMT, TBS, Pac, Alloc and Lev 
groups.  The cleavage conditions that allow for their selective removal are shown in 
Table 3-1.[443, 482, 487-496] 
 
Table 3-1. Protective groups investigated for asymmetrical ICL synthesis 





























Preliminary study for the compatibility between Pac and Lev protecting groups was 
performed with synthesized 3’-O-phenoxyacetyl-5’-O-levulinoyl-thymidine (compound 
3-2), and the result indicated these two groups were not suitable as protecting groups 
together in the synthesis of the cross-linked dimers. Considering the higher lability of Pac 
under basic conditions, four functional groups, DMT, TBS, Alloc and Lev were 
investigated in the synthesis of the dimers, which were employed in the preparation of the 
cross-linked dimer phosphoramidites (compounds 3-11 and 3-16) to generate ICL DNA 
duplexes containing completely asymmetrical sequences. 
 
3.2 Experimental Procedures 
The syntheses and characterization of dimers 3-11 and 3-16 and precursors are described 
in Chapter 6.1. 
 
3.2.1 Solid-phase assembly of cross-linked DNA duplexes, purification and 
characterization 
The cross-linked duplexes CJW201, CJW202, CJW216 and CJW217, whose sequences 
are shown in Figure 3-2, were assembled using an Applied Biosystems Model 3400 
synthesizer on a 1 µmole scale employing standard β-cyanoethylphosphoramidite cycles 
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supplied by the manufacturer with slight modifications to coupling times described 
below. CJW201 and 202 were prepared for ligation into larger DNA for single molecule 
biophysical studies.  The other two ICL DNA duplexes were employed as substrates 








Figure 3-2. The sequences of ICL duplexes containing N3T-butylene-N3T  
 
Solutions of the nucleoside phosphoramidites containing standard protecting groups 
were prepared in anhydrous acetonitrile at a concentration of 0.1 M for the 3’-O-2’-
deoxyphosphoramidites, 0.15 M for the cross-linked phosphoramidites (3-11 and 3-
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16) and 0.2 M for the 5’-O-2’-deoxyphosphoramidites.  Assembly of sequences first 
involved detritylation (3% trichloroacetic acid [TCA] in CH2Cl2), followed by 
nucleoside phosphoramidite coupling with commercially available 3’-O-2’-
deoxyphosphoramidites (2 min), 5’-O-2’-deoxyphosphoramidites (3 min) or cross-
linked phosphoramidites 3-11 or 3-16 (10 min); Subsequent capping with acetic 
anhydride/pyridine/tetrahydrofuran (1:1:8, v/v/v; solution A, and N-methyl-
imidazole/tetrahydrofuran 16:84 w/v; solution B) and oxidation (0.02 M iodine in 
tetrahydrofuran/water/pyridine 2.5:2:1) followed every coupling phosphoramidite.  To 
form the Y intermediate first the cyanoethyl groups were removed from the 
polystyrene-linked oligomers by treating the support with 1 mL of anhydrous 
triethylamine (TEA) for at least 12 h.  The support was then washed with 30 mL of 
anhydrous acetonitrile (ACN) followed by anhydrous THF. The 5’-O-alloc group was 
removed from the partial duplex by treating the support with Pd(PPh3)4  and PPh3  (10 
: 20 eq. to the support bound oligonucleotide) in a buffer solution of butylamine-
formic acid  (1:1, 100 eq. the support bound oligonucleotide) for 3 h at 35
o
C.  The 
support was then washed with 30 mL each of anhydrous THF and ACN followed by 
drying via high vacuum (30 min).  The support was then subjected to a Pd scavenger 
treatment using a solution of ACN saturated with sodium N,N-diethydithiocarbamate 
solution (3 mL x 2) for a total of 1 h at RT.[497-499] This was followed by washing 
with 30 mL each of DCM and ACN followed by drying via high vacuum (30 min).  
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Chain assembly was continued using 3’-O-2’-deoxyphosphoramidites followed by 
detrilylation and an additional capping step for the 5’-OH group. Then, the tert-
butyldimethylsilyl (TBS) group was removed from the partial duplex by treating the 
support with 2 x 1 mL triethylamine trihydrofluoride (TEA•3HF) for a total of 1 h.  
The support was then washed with 30 mL each of anhydrous THF and ACN followed 
by drying via high vacuum (20 min). The final extension of the cross-linked duplex 
was then achieved using 5’-O-2’-deoxyphosphoramidites with a total detritylation 
exposure of 130 seconds and removal of the 3’-terminal trityl group on the 
synthesizer to yield duplexes CJW201, CJW202, CJW216 and CJW217 on the solid 
support.[446]  
The oligomer-derivatized polystyrene beads were transferred from the reaction 
column to screw cap microfuge tubes fitted with teflon lined caps and the oligomer 
released from the support and protecting groups removed by treatment with a mixture 
of concentrated ammonium hydroxide/ethanol (0.3 mL:0.1 mL) for 4 h at 55ºC. The 
cross-linked final products were separated from pre-terminated products by strong 
anion exchange (IEX) HPLC using a Dionex DNAPAC PA-100 column (0.4 cm x 25 
cm) purchased from Dionex Corp, (Sunnyvale, CA) with a linear gradient of 20–55% 
buffer B over 30 min (buffer A: 100 mM Tris HCl, pH 7.5, 10% acetonitrile and 
buffer B: 100 mM Tris HCl, pH 7.5, 10% acetonitrile, 1 M NaCl) at 40°C. The 
columns were monitored at 260 nm for analytical runs or 280 nm for preparative runs.  
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The purified oligomers were desalted using C-18 SEP PAK cartridges (Waters Inc.) 
as previously described.[445, 500]  
 
3.2.2 Enzymatic digests 
The cross-linked oligomers (0.1 A260 units) were characterized by enzymatic digestion 
(snake venom phosphodiesterase: 0.28 units and calf intestinal phosphatase: 5 units, in 10 
mM Tris, pH 8.1 and 2 mM magnesium chloride) for a minimum of 36 h at 37°C as 
previously described.[447] The resulting mixture of nucleosides was analyzed by 
reversed phase HPLC carried out using a Symmetry® C-18 5μm column (0.46 x 15 cm) 
purchased from Waters Inc, Milford, MA. The C-18 column was eluted with a linear 
gradient of 0-60% buffer B over 30 min (buffer A, 50 mM sodium phosphate, pH 5.8, 2% 
acetonitrile and buffer B, 50 mM sodium phosphate, pH 5.8, 50% acetonitrile). The 
resulting peaks were identified by co-injection with the corresponding standards and 
eluted at the following times: dC (4.6 min), dG (6.8 min), dT (7.4 min), dA (7.9 min), 
and cross-linked dimer (14.2 min) and the ratio of nucleosides was determined. The 
molar extinction coefficient of N3-thymidine-butylene-N3-thymidine was estimated to be 




3.2.3 Mass Spectrometry 
ESI mass spectra for small molecules were recorded at the McGill University Department 
of Chemistry Mass Spectrometry Facility with a Finnigan LCQ DUO mass spectrometer 
in MeOH or acetone. ESI mass spectra for oligonucleotides were obtained at the 
Concordia University Centre for Biological Applications of Mass Spectrometry 
(CBAMS) using a Micromass Qtof2 mass spectrometer (Waters) equipped with a 
nanospray ion source. The mass spectrometer was operated in full scan, negative ion 
detection mode. 
 
3.2.4 UV thermal denaturation 
Molar extinction coefficients for the oligonucleotides were calculated from those of 
the mononucleotides and dinucleotides according to nearest neighbor 
approximations.[501] Non-cross-linked duplexes were prepared by mixing equimolar 
amounts of the interacting strands and lyophilizing the mixture to dryness. The 
resulting pellet (both controls and cross-linked duplexes) were then re-dissolved in 90 
mM sodium chloride, 10 mM sodium phosphate, 1 mM EDTA buffer (pH 7.0) to give 
a final concentration of 2.8 μM for control and cross-linked duplexes.  The solutions 
were then heated to 90 
o
C for 10 min, cooled slowly to RT, and stored at 4 ºC 
overnight before measurements. Prior to the thermal run, samples were degassed by 
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placing them in a speed-vac concentrator for 2 min. Denaturation curves were 
acquired at 260 nm at a rate of heating of 0.5 
o
C/min, using a Varian CARY Model 
3E spectrophotometer fitted with a 6-sample thermostated cell block and a 
temperature controller. The data were analyzed in accordance with the convention of 
Puglisi and Tinoco[272]
 
 and transferred to Microsoft Excel™. 
 
3.2.5 Circular Dichroism (CD) spectroscopy 
Circular dichroism spectra were obtained on a Jasco J-815 spectropolarimeter equipped 
with a Julaba F25 circulating bath. Samples were allowed to equilibrate for 5-10 min at 
10ºC in 90 mM sodium chloride, 10 mM sodium phosphate, 1 mM EDTA (pH 7.0), at a 
final concentration of 2.8 μM for the cross-linked duplexes and ca. 2.8 μM for control 
duplexes. Each spectrum was an average of 5 scans. Spectra were collected at a rate of 
100 nm/min, with a bandwidth of 1 nm and sampling wavelength of 0.2 nm using fused 
quartz cells (Starna 29-Q-10). The CD spectra were recorded from 350 to 200 nm at 
10ºC. The molar ellipticity was calculated from the equation [] = ε/Cl, where ε is the 
relative ellipticity (mdeg), C is the molar concentration of oligonucleotides (moles/L), 
and l is the path length of the cell (cm). The data were processed on a PC computer using 
Windows™ based software supplied by the manufacturer (JASCO, Inc.) and transferred 




3.3 Results and discussion 
3.3.1 Synthesis of cross-linked dimer phosphoramidites 
In the process of screening out four compatible protective groups for this strategy, 
preliminary attempts to use the Lev and Pac groups as in the precursor 3’-O-
phenoxyacetyl-5’-O-levulinoyl-thymidine (3-2), which was prepared through the 
synthesis route in Scheme 3-1, were investigated but ultimately shown to be 
incompatible.[502, 503] Treatment of precursor 3-2 with 0.01 mol/L Na2CO3 or 0.001 
mol/L Na2CO3 in CH3OH/DCM [504, 505] and analysis by TLC revealed that both the 
Pac and Lev groups were removed under these conditions making them unsuitable as 
protecting groups together in the synthesis of the cross-linked dimers.  The four 
functional groups that were investigated in the synthesis of the dimers and consequently 
the ICL duplexes were the DMT, TBS, Alloc and Lev groups. 
The linker 4-iodobutyl 2-phenoxyacetate (3-3) was prepared as shown in Scheme 3-2 by 





a) 1.0 eq. 5’-O-DMT-thymidine, 1.5 eq. phenylacetyl chloride, 1.6 eq. triethylamine in anhydrous 
THF at RT overnight, 96%; b) 2.2 eq. p-TsOH, in DCM/CH3OH (9/1) at RT for 30 min. 76%. c) 
2.0 eq. Levulinic acid, 2.0 eq. EDC, in pyridine at RT for 18 h. 95%. 




a) 1.0 eq. phenoxyacetyl chloride, 2.5 eq. KI, in anhydrous THF at RT for 24 h., 95%. b) 1.0 eq. 
5’-O-DMT-thymidine, 2.2 eq. TBSCl, 4.4 eq. imidazole, in anhydrous DMF overnight, 99%. c) 
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2.0 eq. 4-iodobutyl-1-phenoxyacetate (3-3), 2.5 eq. DBU, in in CH3CN at RT for 24 h. 83%. d) 3 
mL propylamine in 10 mL DCM/1 mL CH3OH at RT for 6 h., 75%. e) 6.0 eq. imidazole, 3.0 eq. 
PPh3, 3.0 eq. iodine in anhydrous THF at RT for 6 h. 95%. 
Scheme 3-2. Synthesis route of N3-(4-Iodobutyl)-5’-O-dimethoxytrityl-3’-O-(tert-
butyldimethylsilyl)-thymidine (3-6) 
 
Starting from commercially available 5’-O-dimethoxytrityl-thymidine the free 3’-alcohol 
was protected as a TBS group using TBSCl to produce 5’-O-dimethoxytrityl-3’-O-(tert-
butyldimethylsilyl)-thymidine (3-4) in quantitative yields.  Linker (3-3) was then coupled 
at the N3 of thymidine in the presence of 1,8-diazabicyclo-(5.4.0)-undec-7-ene (DBU), a 
strong hindered base, to form the monoadduct N3-(4-(2-phenoxyacetate)butyl)-5’-O-
dimethoxytrityl-3’-O-(tert-butyldimethylsilyl)-thymidine (3-5) in 87% yield.  Removal of 
the Pac group on the linker moiety using propanamine at RT for at least 6 h (75%) 
followed by its conversion to N3-(4-iodobutyl)-5’-O-dimethoxytrityl-3’-O-(tert-
butyldimethylsilyl)-thymidine (3-6) with elemental iodine and Ph3P (95% yield) (Scheme 
3-2) set the stage for the critical dimerization reaction with 5’-O-levulinoyl-3’-O-
allyloxycarbonyl-thymidine (3-8). 
Two asymmetric phosphoramidites of the N3T-butylene-N3T dimer were synthesized, 
numbered as 3-11 and 3-16. Schemes 3-3 and 3-4 illustrate the synthesis of these two 
120 
 
nucleoside dimers, which allow for an orthogonal deprotection to assemble ICL DNA 




a) 1.0 eq. 1-hydroxybenzotriazole hydrate, 1.04 eq. allyl chloroformate and 1.12 eq. DIPEA in 
anhydrous THF at RT for 30 min. 79%.  b) 1.33 eq. Alloc-OBt (3-7), 0.2 eq. DMAP, in 
pyridine/THF (9/1) at RT for 24 h. 66%. c) 1.0 eq N3-(4-iodobutyl)-5’-O-dimethoxytrityl-3’-O-
(tert-butyldimethylsilyl)-thymidine (3-6), 2.0 eq. DBU, in in CH3CN at RT for 24 h. 68%. d) 0.1 
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eq. Pd(PPh3)4, 0.2 eq. PPh3, in 1-butanamine/formic acid (50/50) at RT for 2.5 h. 100%. e) 1.2 eq. 
ClP(OCE)(NiPr2), 1.5 eq. DIPEA, in THF at RT for 0.5 h. 71%. 




a) 2.0 eq. Levulinic acid, 2.0 eq. EDC, 0.01 eq. DMAP, in 1,4-dioxane at RT for 12 h. 
Quantitative yield. b) 2.2 eq. p-TsOH, in DCM/CH3OH (4/1) at RT for 0.5 hour. 69%. c) 1.33 eq. 
Alloc-OBt (3-7), 0.2 eq. DMAP, in THF/pyridine (9/1) at RT for 24 h. 85%. d) 1.0 eq. N3-(4-
iodobutyl)-5’-O-dimethoxytrityl-3’-O-(tert-butyldimethylsilyl)-thymidine (3-6), 2.0 eq. DBU, in 
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CH3CN at RT for 48 h. 55%. e) 0.5M hydrazine hydrate, in pyridine/acetic acid (9/1) at RT for 10 
min. 96%. f) 1.2 eq. ClP(OCE)(NiPr2), 1.5 eq. DIPEA, in THF at RT for 1 h. 71%. 
Scheme 3-4. Synthesis route of phosphoramidite 3-16. 
 
Two asymmetric phosphoramidites of the N3T-butylene-N3T dimer were synthesized, 
numbered as 3-11 and 3-16. Schemes 3-3 and 3-4 illustrate the synthesis of these two 
nucleoside dimers, which allow for an orthogonal deprotection to assemble ICL DNA 
containing sequences of asymmetric nucleotide composition around the cross-linked site. 
The precursors 3-10 and 3-15 of phosphoramidites 3-11 and 3-16 differ with respect to 
the placement of the Alloc and Lev protective groups at either the 5’ or 3’ position of one 
thymidine in the dimer. 
Compound 3-8 is itself synthesized from commercially available 5’-O-levulinoyl-
thymidine which is reacted with Alloc-OBt (3-7) in pyridine at RT overnight (78% yield). 
The dimerization reaction between compound 3-6 and 3-8 (which is in slight excess) is 
accomplished with DBU overnight to produce the dimer 3-9 in 68% yield. The Alloc 
group of dimer 3-9 was removed with Pd(PPh3)4 in a butylamine-formic acid buffer 
solution to give the free 3’-hydroxyl in 3-10 (100%), which was then converted to the 
cross-linked phosphoramidite 3-11 using a slight excess of N,N-diisopropylamino 
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cyanoethyl phosphonamidic chloride in the presence of Hunigs base.  This 
phosphoramidite was isolated by hexane precipitation in 71% yield. 
The synthetic route involving amidite 3-16 varied as follows.  The Lev group was 
introduced at the 3’-OH of 5’-O-dimethoxytrityl-thymidine with levulinic acid, in the 
presence of EDC and DMAP in dioxane at RT in quantitative yield to produce compound 
3-12.  This step required longer reaction times as it was sluggish in general.  The 5’-O-
DMT group was removed with p-TsOH to release a free 5’-OH (77%) followed by the 
introduction of the Alloc group as described above, producing compound 3-13 (85%).  A 
similar coupling reaction of compound 3-13 with 3-6 in the presence of DBU yielded the 
second precursor 3-14 in 55% yield.  The Lev protective group was removed by 
treatment with 0.5M hydrazine in a pyridine: acetic acid buffer (v/v 9/1) for 10 min at RT 
to yield the precursor 3-15 (96%). This was then phosphitylated as described above on 
the newly released free 3’-OH to produce the cross-linked phosphoramidite 3-16 in 71% 
yield. 
The isolated phosphoramidites 3-11 and 3-16 were analyzed by mass spectrometry and 
were found to have the expected molecular masses (1275.5786 and 1261.5638).  
31
P 
NMR analysis of these phosphoramidites revealed the presence of two signals for 3-11 





3.3.2 Design, purification and characterization of interstrand cross-linked DNA 
duplexes 
The ICL duplexes containing these dimers were synthesized on an ABI 3400 solid-phase 
DNA synthesizer using polystyrene (PS) rather than controlled-pore glass (CPG) solid-
support due to the incompatibility of triethylamine-trihydrofluoride (TEA•3HF) with the 
latter. As an added precaution, the cyanoethyl protecting groups were removed using 
triethylamine (TEA) as it has been observed that prolonged fluoride treatment using 
tetrabutylammonium fluoride (TBAF) could lead to chain cleavage.[471]  The assembly 
of ICL containing duplex CJW201 utilizing phosphoramidite 3-11 is illustrated in 
Scheme 3-5 (left).  The U shaped intermediate CJW201-U was assembled on solid 
support in one step by coupling 0.15M of 3-11 directly to a short linear segment of DNA 
for 10 min, followed by removal of the DMT group from the ICL dimer 3-11, followed 
by chain elongation.  Chain assembly in the 3’ to 5’ direction proceeded smoothly using 
3’-O-2’-deoxyphosphoramidites (0.1M). A higher concentration and longer coupling time 
was necessary for 3-11 to ensure a high coupling efficiency due to its larger size 
compared to the standard 3’-O-2’-deoxyphosphoramidites.  This step was followed by 
capping on the synthesizer to prevent undesired chain growth in subsequent steps.  At 
each stage of this assembly 1-2 mg of solid support was deprotected with ethanolic 
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ammonia (1:3 v/v, 0.5mL) at 55C for 4 h.  The success of either coupling or removal of 
a specific protecting group at each stage was then monitored using Ion exchange (IEX) 
HPLC.  From Figure 3-3, it is clear that coupling of the dimer phosphoramidite 3-11 was 
highly satisfactory where the major species at ca.18 min was that of the desired U 
intermediate.  After subjecting the oligo-bound support to TEA treatment as described 
above the Lev protective group was removed using hydrazine in an acetic acid: pyridine 
mixture (1:1), for 30 min at RT.  Unfortunately, the extent of removal of the Lev group 
cannot be monitored by direct deprotection and IEX HPLC analysis as above.  Extension 
from the free OH group serves as an indirect indicator for cleavage success.  This is 
because the Lev group is cleaved by the strong base NH4OH itself.  Scheme 3-5 (left) 
illustrates the removal of the Lev protective group followed by chain extension producing 
oligonucleotide CJW201-Y.  It is clear that there are a number of failure products 
suggesting that the deprotection conditions with hydrazine were not optimal for ICL 
synthesis while being retained on solid support.[500]  Although it has been reported that 
the Lev protecting groups are compatible with solid-phase synthesis and are removed 
completely using hydrazine treatment, these earlier studies involved only 
oligothymidylates. These findings were confirmed with a test oligothymidylate bearing 
5’-O-Lev-thymidine group, which on removal of the Lev group and subsequent extension 
proved successful for linear T rich sequences (Data not shown).  One possible reason for 
unsuccessful extension of the ICL could be due to steric hindrance at the cross-link site 
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making removal of the Lev group incomplete and /or oligonucleotide extension more 
difficult.  It was assumed that alternatively mixed base oligomers that contain benzoyl 
protected cytidine residues could undergo transamination at the N
4
 site in the presence of 
hydrazine or could be removed and this can cause undesired growth to form several 
failure products.[506-509] The 3’-O-TBS group was then removed from CJW201-Y by 
treating the support with anhydrous triethylamine overnight followed by TEA•3HF twice 
for 30 min at RT. C-18 reversed-phase HPLC analysis of the deprotected intermediate 
revealed complete removal of the silyl group with the shift of the major peak from 13.0 to 
9.5 min in the case of the cross-link. Continued synthesis with repetitive coupling of 5’-
O-2’-deoxyphosphoramidites at the 3’-end of intermediate CJW201-Y gave the full 
length CJW201-H.  Because of the challenges faced with the Lev group this route to 
synthesize ICL duplexes was not pursued, and instead amidite 3-16 was used as the 
second pathway in our attempts to synthesize asymmetric ICL duplexes. 
The assembly of ICL utilizing phosphoramidite 3-16 is illustrated in Scheme 3-5 (right). 
The U shaped intermediate CJW201-U was assembled on polystyrene solid support in 
one step by coupling 3-16 directly to a short linear segment of DNA followed by capping 
on the synthesizer as described above.  Analysis by IEX HPLC revealed that coupling of 
the dimer phosphoramidite was highly satisfactory (Figure 3-4).  After subjecting the 
oligo-bound support to TEA treatment overnight as described above the Alloc protective 
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group was removed with Pd(PPh3)4 in a butylamine-formic acid buffer solution for 3 h at 
35C to free the 3’-hydroxyl (Scheme 3-5 right and Figure 3-5).[489, 499, 510]  As in 
the case of the Lev group the successful removal of the Alloc groups has to be 
determined indirectly through subsequent extension of the Y oligo from the free OH 
group.  It is extremely essential that all traces of remnant Pd be removed using a Pd 
scavenger namely sodium N, N-diethyldithiocarbamate to enable the successful synthesis 
of the Y intermediate of CJW201.[497-499] Failure to perform this Pd scavenger step 
leads to oligonucleotide degradation as illustrated by IEX HPLC analysis of 
oligonucleotide CJW201-U with and without scavenger-washing (Figure 3-5). 
After capping the CJW 201-Y, the TBS group was removed as described above, starting 
with overnight treatment of the support with TEA followed by TEA•3HF. Formation of 
the complete 201-H duplex was accomplished with 5’ reverse phosphoramidites as 




















(i) Growth of the linear segment with 3’-O-2’-deoxyphosphoramidites; (ii) coupling of 
phosphoramidites 3-11/3-16 followed by extension with 3’-O-2’-deoxyphosphoramidites (to 
afford CJW201-U); (iii) removal of the Lev protective group;[511] in a or in a removal of the 
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Alloc protective group;[497-499, 512] in b (iv) extension with 3’-O-2’-deoxyphosphoramidites 
(to give CJW201-Y); (v) removal of the TBS protective group; (vi) extension with 5’-O-2’-
deoxyphosphoramidites followed by cleavage from the solid support and deprotection of the 
CJW201-H with NH4OH/C2H5OH. 
Scheme 3-5. Solid-phase synthesis procedure of oligonucleotide CJW201 involving 
N3T-butylene-N3T phosphoramidite 3-11 (left) and 3-16 (right). 
 
 
Figure 3-3. IEX analysis of CJW201-U (top) and CJW201-Y (bottom) prepared with 
phosphoramidite 3-11 (the column was monitored at 260 nm, and eluted at RT with a 
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gradient of 0 to 70% buffer B in 30 min. Buffer A: 10% acetonitrile, 100mM Tris-HCl 




Figure 3-4. IEX HPLC chromatogram of oligonucleotide CJW201-U using 







Figure 3-5. The effect of using a Pd scavenger in the synthesis of oligonucleotide 
CJW201-U with phosphoramidite 3-16 (CJW201-U (prepared with phosphoramidite 3-
16) was treated with Pd(PPh3)4 at 35 C for 3.5 h, and deprotected from solid support 
with ammonia/ethanol (3/1)  at 55
 C overnight. HPLC conditions are as described in the 





Figure 3-6. IEX HPLC chromatograph of CJW201-Y and CJW201-H prepared with 
phosphoramidite 3-16 (HPLC conditions are as described in the Figure 3-3 legend except 
a gradient of buffer B from 0.2 to 0.55 M over 30 min at 40 C was used for 201H). 
 
It is clear that the assembly of ICL using phosphoramidite 3-16 was superior to that of 3-
11.  Thus this route was chosen for solid-phase assembly of all subsequent cross-linked 
duplexes reported here. These include the three additional ICL sequences, CJW202, 
CJW216 and CJW217. The coupling of this dimer and removal of the protecting groups 
to form the various intermediates were all found to be similar to those of CJW 201. The 
full-length cross-linked H-oligomers were cleaved from the solid support and deprotected 
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by treating the support with a mixture of concentrated ammonium hydroxide/ethanol 
0.5mL, (3:1) at 55 C, overnight as previously reported.[513]  The crude oligomers were 
purified by IEX HPLC, using a gradient buffer of 20% to 55% B in 30 min, followed by 
desalting to afford the pure cross-linked duplexes CJW201/202/216/217 in yields of 11-
25 %.  These ICL duplexes were digested to the constituent nucleosides with a 
combination of snake venom phosphodiesterase and calf intestinal phosphatase in a 
buffer containing 10 mM Tris (pH 8.1) and 2 mM magnesium chloride at 37 
o
C for 16 h 
and analyzed by C-18 reversed phase HPLC. The extinction coefficient of N3T-butylene-
N3T was assumed to be 13156 liter/(mol.cm), as described earlier.  In addition to the four 
standard 2’-deoxynucleosides, one additional peak was observed with a retention time of 
14 min for the dimer (shown in Figures S48-51 in Supporting Information). This 
additional peak had a retention time identical to the completely deprotected dimer of 3-11 
and 3-16. As shown in Table 3-2, the ratios of the component 2’-deoxynucleosides and 
cross-linked nucleosides were consistent with the theoretical composition of ICL 
duplexes CJW201/202/216/217.  The molecular weight of the cross-linked duplexes as 
determined by mass spectrometry (ESI-TOF) were in close agreement with the expected 


















dC 1.00 1.00 
10663.2 10663.0 
dG 1.00 1.06 
dT 3.80 3.71 
dA 0.80 0.83 
dT-dT
 d




dC 1.00 1.00 
10661.2 10661.1 
dG 1.00 1.06 
dT 7.00 7.47 
dA 2.00 2.06 
dT-dT
 d




dC 1.00 1.00 
6716.7 6716.4 
dG 1.00 1.00 
dT 1.50 1.42 
dA 1.50 1.48 
dT-dT
 d






dC 1.00 1.00 
6110.1 6110.0 
dG 1.00 1.05 
dT 0.33 0.34 
dA 0.67 0.67 
dT-dT
 d
 0.17 0.17 
a) Retention time of the ICL oligonucleotide CJW201-H with IEX. HPLC conditions are as 
described in the Figure 3-6 legend. b) Retention time of the ICL oligonucleotide CJW201-H 
with IEX. HPLC conditions are as described in the Figure 3-3 legend except a gradient of buffer 
B from 0.2 to 0.55 M over 30 min was used. c) Nucleoside ratio analysis was run with 0 to 60% 
of mobile buffer B in 30 min on RPLC. Buffer A: 2% acetonitrile, 50 mM sodium phosphate, pH 
5.8; Buffer B: 50% acetonitrile, 50 mM sodium phosphate, pH 5.8. d) The extinction coefficient 
for dT-dT was assumed to be 13156 liter/(mol.cm). 
 
3.3.3 UV thermal denaturation and Circular Dichroism spectra (CD) of ICL 
duplexes 
The stability of the cross-linked duplexes (both symmetrical and asymmetrical) was 
assessed by the ultraviolet thermal denaturation experiments, as illustrated in Figure 3-7 
to 3-9 and reported in Table 3-3.  The profiles for duplexes CJW216 and CJW 217 were 
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sigmoidal indicating cooperativity with values of approximately 73 and 65C, 
respectively. The control duplexes for CJW216 and CJW217 (sequences shown in 
Figure 3-10) were prepared by solid-phase synthesis for this study. Single-strand DNA 
oligonucleotides were prepared, and the complementary oligonucleotides were 
hybridized for Tm studies. The biophysical study of ICL DNA duplexes CJW217 was 
perfomed and compared to its control duplex CJW215.[483]  
 
 
Solutions contained a duplex concentration of 2.8 μM in 90 mM sodium chloride, 10 mM sodium 
phosphate and 1 mM EDTA buffer, pH 7.0. The rate of data acquisition was 0.5 oC/min. 
Figure 3-7. Absorbance (A260) versus temperature profiles of CJW215 (control) and 














Conditions are as described in the legend for Figure 3-7.  
Figure 3-8. Absorbance (A260) versus temperature profiles of cross-linked duplex 








































Solutions contained a duplex concentration of 1.7 μM in 90 mM sodium chloride, 10 mM sodium 
phosphate and 1 mM EDTA buffer, pH 7.0. The rate of data acquisition was 0.5 oC/min. 
Figure 3-9. Absorbance (A260) versus temperature profiles of cross-linked duplexes 
CJW201 and CJW202. 
 
  
Control duplex for CJW216 CJW215 (Control duplex for CJW217) 
























    
CJW216 43.5 73.5 30 
CJW217 53.5 65.5 12 




mm TTT  .  
 
In contrast the profiles for CJW201 and CJW202 were broad which were not 
unexpected due to the smaller amount of complementary segments only on one side of 
the cross-linked dimer (shown in Figure 3-9). 
The CD spectra of cross-linked duplexes as well as the non-cross-linked control were 
recorded at 10ºC (spectra are shown Figure 3-11). In all cases, the CD spectra of the 
duplexes exhibited signatures characteristic of B-form DNA with a positive maximum 
peak centered around 275 nm, a negative peak at approximately 250 nm and a cross over 
around 260 nm.[514] The CD spectra of non-cross-linked controls revealed some minor 
differences, particularly a reduction of the signal at 275 nm as shown in Figure 3-11. In 
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the case of cross-linked duplex CJW217, the CD spectra suggested that when the cross-





Figure 3-11. Circular dichroism spectra of cross-linked duplexes CJW201, CJW202, 
CJW216 and CJW217 (The analysis was conducted in 90 mM sodium chloride, 10 mM 
sodium phosphate and 1 mM EDTA (pH 7.0) with 0.5 OD of oligonucleotides. The CD 


































Previously, Webba da Silva et al. have shown that CJW 216 displays dramatic widening 
of the major groove of the B-DNA stem without disruption of Watson-Crick base pairing 
due to the dominant contribution of cooperative and cumulative base stacking to the 
stability of the ApT compared to the TpT step suggesting that the latter is more 
deformable within a DNA stem. The configurational constraints of the butylene tether 
perturb the structure, resulting in accommodation in a region between major and minor 
grooves that is in a staggered fashion and that deviates from being perpendicular to the 




In this chapter, the compatibility of protective groups for solution and solid-phase 
synthesis to produce ICL oligonucleotide duplexes was studied. Five kinds of protective 
groups, dimethoxytrityl (DMT), tert-butyldimethylsilyl (TBS), levulinoyl (Lev), 
phenoxyacetyl (Pac) and allyloxycarbonyl (alloc) were evaluated for the masking of the 
3’- and 5’- hydroxyls of thymidine. Incompatibility of Pac and Lev protective groups was 
observed by the preliminary studies with 5’-O-levulinoyl-3’-O-phenoxyacetyl-thymidine. 
DMT, TBS, Lev and Alloc protective groups were employed in this study. Two novel 
cross-linked dimer phosphoramidites 3-11 and 3-16 were prepared by multistep synthesis 
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in solution, and the assembly of ICL duplexes by solid-phase synthesis were studied for 
each extension to form the final products. By comparison, phosphoramidite 3-16 (with 
DMT and Alloc protective groups for the two 5’-O positions and one TBS for the 3’-O 
position) afforded better conversion of key extension steps (from U-shaped to Y-shaped 
oligonucleotide intermediates). 
Two partially asymmetrical and two completely asymmetrical ICL duplexes containing 
N3T-butylene-N3T have been successfully synthesized using phosphoramidite 3-16. The 
duplexes display characteristics typical of B-form as observed by circular dichroism 
spectroscopy. The formation of expected ICL duplexes was further confirmed with 
enzymatic digestion and MS analysis. Ultimately, this protective group combination may 






Chapter 4. Development of two cyclization strategies to 












Figure 4-1. Structures of guanine, adenine and their 7-deaza analogos 
 
Derivatives of 7-Deazapurine (pyrrolo[2,3-d]-pyrimidine, structures shown in Figure 4-
1), which can be converted to nucleosides and nucleotides, have been investigated as 
probes for various physical and biochemical studies in the field of nucleic acids.[452] 
The imine nitrogen at the 7 position of purine nucleosides (in guanine and adenine) is 
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located in the major groove of B-form DNA and can act as a hydrogen bond acceptor by 
Hoogsteen base pairing. 7-Deazapurine nucleobases such as 7-deaza-guanine and 7-
deaza-adenine are able to form Watson-Crick base pairs, maintaining pairing specificity 
of the respective natural nucleobases. The absence of the N7 atom of these 7-
deazapurines disrupts the formation of Hoogsteen hydrogen bonding. The modification at 
the 7-position alters the electronic properties of the heterocycle and eliminates a major 
groove cation-binding site that could affect the organization of salts and water in the 
major groove. These analogs can easily be incorporated in oligonucleotides, either by 
enzymatic means or by automated solid-phase synthesis.[517-519] When the nucleotides 
containing 7-deazapurines replace their natural counterparts in PCR reactions, the 
modified DNA displays improved properties, such as lower melting temperature of the 
duplex. They can be employed in DNA sequencing reactions, for PCR of GC-rich 
templates and to improve the DNA bands in polyacrylamide gel electrophoresis. 
Increased stability of nucleic acids containing the 7-deazapurines (7-deaza-adenosine and 
7-deaza-guanosine) over their 7-aza analogs has been shown by precluding protonation at 
the 7-position.[520] It was reported that oligonucleotides possessing at least one 
substituted 7-deazapurine nucleobase would hybridize to form duplexes with 
significantly more stability than unmodified oligonucleotides.[521] Further studies have 
been undertaken to evaluate the influence of alkyl, alkynyl as well as halogeno 
substituents at the 7 position of oligonucleotides containing 7-deazaadenine and 7-
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deazaguanine. The modified DNA duplexes were observed for alternating, consecutive, 
or randomly distributed 7-substituted 7-deazaadenine residues to produce the same 
increase in stability. The increased stability of the duplex structures can be explained by 
hydrophobization of the modified DNA, stronger H-bonding, and/or more favorable 
stacking interactions.[522, 523] 
Absence of the nitrogen atom at the 7-position in deazapurines is also utilized for the 
syntheses of sequence-specific DNA in the study of chemotherapy and cell repair.[524-
532] 7-Deaza-adenosine is a potent and selective inhibitor of hepatitis C virus.[533, 534] 
7-deaza-2’-deoxyguanosine exhibits extraordinarily chemical, physical and biological 
properties compared with its corresponding 7-aza analog. The incorporation of 7-
deazaguanine modifications into DNA is frequently used to probe protein recognition of 
H-bonding information in the major groove of DNA. [526, 527, 535, 536]  
Several naturally occurring 7-deazapurine ribonucleosides, such as tubercidin, 
toyocamycin and sangivamycin, exhibit a broad spectrum of biological activity 
(structures shown in Figure 4-2). The frequent natural occurrences and the biological 
properties of this class of compounds have promoted ample studies toward the synthesis, 
biological activity, and incorporation in oligonucleotides as well as the chemically 
designed analogues. The 7-position of 7-deazapurine is an ideal site for modifications 






Tubercidin Toyocamycin Sangivamycin 
Figure 4-2. Structures of tubercidin, toyocamycin and sangivamycin 
 
Though the 7-deazapurine analogs are of great interest, their efficient syntheses are still 
challenging. For example, the preparation of 7-deazaguanine was reported following the 
synthetic route shown in Scheme 4-1.  
 
 
a) Sodium methoxide (2.0 eq.) in MeOH refluxed for 4 h or overnight; b). Sodium acetate 
trihydrate (2.0 eq.), in water (or DMF) at RT to 80 
o
C for 2 h to 2 days. (20% to 86%). 




In this approach, the pyrimidine ring is prepared first in moderate yield followed by 
another cyclization to produce the purine with yields that vary significantly (ranging from 
20% to 86%). Attempts to synthesize this compound by our lab resulted in yields ranging 
between 20 to 40%).[526, 527, 543, 546-551]  
Thus, it is worthwhile to develop methods for the chemical syntheses of the 7-
deazapurines. To this end, we have explored two synthetic routes to afford a series of 7-
deazapurines, which are shown to first form the pyrimidine followed by conversion to 
purine (shown in Scheme 4-2) and from the formation of a pyrrole followed by 
transformation to purine (shown in Scheme 4-3). In the design of the two synthetic 
methods, synthesis begins with commercially available reagents containing a methylene 
group adjacent to two electron-withdrawing groups (carboxylate and/or nitrile). In 
Scheme 4-2 a reaction between dimethylchloroacetal and ethyl 2-cyanoacetate or 
malononitrile would afford precursors to enable formation of the pyrimidine ring. 
Subsequent cyclization would produce 7-deazapurine analogs containing electron-
withdrawing groups found in the starting reagents. For the second synthetic method 
(Scheme 4-3) the condensation intermediates from chloroacetaldehyde and ethyl 2-
cyanoacetate or malononitrile would undergo cyclization to generate 2-aminopyrroles, 





EW = CO2Et or CN; X = O or NH; Y = OH, NH2 or SH 
Scheme  4-2. Approach A for preparation of 7-deazapurines 
 
 
EW = CO2Et or CN; EW' = CONH2 or CNHNH2; X = O or NH; Y = OH, NH2 or SH 
Scheme  4-3. Approach B for preparation of 7-deazapurines 
 
4.2 Experimental 
Details of the synthesis and characterization of all compounds in this chapter are 




4.3 Results and Discussion 
4.3.1 Pyrimidine Approach for 7-Deazapurine Analogs (Method A) 
The precursors, ethyl 2-cyano-4,4-dimethoxybutanoate (4-1) and 2-(2,2-
dimethoxyethyl)malononitrile (4-2) were prepared with modifications to reported 
procedures (Figure 4-3).[534, 536, 552-554] A mixture of ethyl 2-cyanoacetate or 
malononitrile with sodium methoxide was stirred vigorously at RT for 4 h. The solvent 
was removed, and the powder was dried in high vacuum. A solution of 
dimethylchloroacetal in anhydrous THF was added to the solution and refluxed for 
another 20 hours. The compounds were obtained (EW: 55% for CO2Et; 61% for CN as 













EW = CO2Et or CN 
a) 1.10 eq. sodium hydride in anhydrous DMF at RT for 1 to 4 h; b) 1.10 eq. dimethylchloroacetal 
in anhydrous DMF, reflux for 20 h. 
Figure 4-3. Synthesis of ethyl 2-cyano-4,4-dimethoxybutanoate (4-1, EW = CO2Et) and 




The formation of pyrimidine precursors was conducted employing ethyl 2-cyano-4, 4-
dimethoxybutanoate or 2-(2,2-dimethoxyethyl)malononitrile with 1.0 eq. of guanidine, 
urea or thiourea and 1.0 eq. of sodium methoxide (2.0 eq. of sodium methoxide for 
guanidine hydrochloride) in anhydrous MeOH. The solution was refluxed overnight to 
generate the pyrimidine intermediates.[552] After cooling down to RT, the intermediates 
were filtered through a short silica gel column to remove the inorganic salts, and then 
hydrochloric acid (2 N) was added to the solution. The reaction was continued under 
acidic conditions under reflux for another 24 hours. After cooling down to RT, the brown 
solution was run through a short silica gel column to yield the various 7-deazapurines. 
The structures and yields after the two cyclization steps are shown in Table 4-1. 
 























































































4.3.2 Pyrrole Approach for 7-Deazapurine Analogs (Method B)  
An alternative approach was explored to prepare 7-deazapurines involving the 
preparation of pyrrole heterocycles that would undergo further conversion into the 
bicyclic products. Condensation between chloroacetaldehyde and ethyl 2-cyanoacetate or 
malononitrile was conducted with the catalyst piperidine and acetic acid at RT to reflux 
for 16 h.[555-566] The product was extracted with EtOAc from aqueous solution, and 
then concentrated under high vacuum. The reaction of the condensation intermediates in 
saturated ammonia solution resulted in unsuccessful synthesis of ethyl 2-amino-1H-
pyrrole-3-carboxylate and 2-amino-1H-pyrrole-3-carbonitrile (structures shown in Figure 
4-4). We also employed different concentrations of aqueous ammonia in MeOH for 
pyrrole cyclization, however, the desired products were not formed. When these 
syntheses were attempted in a saturated solution of ammonia in anhydrous MeOH at RT 
for 16 h following with reflux for another 24 h the desired intermediates were obtained as 
brown powders in good yields (EW: 67% for CO2Et; 59% for CN). NMR analysis of the 
products revealed that the electron-withdrawing groups at C3 of pyrrole underwent 
ammonolysis to afford the amide precursor (structures shown in Figure 4-5). Even 
though the synthesized precursor was different from the expected product (ethyl 2-amino-





EW = CO2Et or CN; EW’ = CONH2 or CN 
a) 0.1 eq. piperidine, 0.1 eq. acetic acid in anhydrous DCM at RT to reflux for 12 h; b) saturated NH3 (gas) 
in MeOH, RT 16 hours then reflux for 24 h. 











Figure 4-5. Structures of ethyl 2-amino-1H-pyrrole-3-carboxylate, 2-amino-1H-pyrrole-




The two intermediates, 2-amino-1H-pyrrole-3-carboxamide (4-5) and 2-amino-1H-
pyrrole-3-carbonitrile (4-6) were then used in reaction with guanidine, urea or thiourea 
(1.0 eq.) in anhydrous MeOH under reflux for 24 h to generate desired 7-deazapurines. 
The formed products as well as corresponding isolated yields are shown in Table 4-2. 
 
Table 4-2. Formation of 7-deazapurines 2-amino-1H-pyrrole-3-carboxamide and 2-
amino-1H-pyrrole-3-carboximidamide 
 



















































































4.3.3 Comparison of Pyrimidine (Method A) versus Pyrrole (Method B) Approach 
for 7-Deazapurine Analogs 
Overall, the yields of the products for Method A (from pyrimidine to purine in Scheme 4-
2) were lower compared to the yields obtained for the procedure for the purine 
cyclization step from the pyrrole precursors (Method B shown in Scheme 4-3). 
In Method A, anhydrous solvents such as DMF and MeOH were required for most steps. 
The final cyclization of the pyrimidines to form the purines required aqueous acid. By 
156 
 
comparison, all the synthetic steps in Method B occurred in anhydrous MeOH. Some of 
the reaction conditions in Method A require a higher degree of caution, particularly the 
step involving sodium hydride (which can ignite in air) which is required for the 
preparation of intermediates 4-1 or 4-2 whereas the reagents involved in Method B were 
milder. 
Throughout the course of this study, the intermediates involved in Method A were found 
to be more stable compared with those in Method B. For example, ethyl 4-chloro-2-
cyanobut-2-enoate (4-3) and 2-(2-chloroethylidene)malononitrile (4-4) were prone to 
polymerization. Decomposition of the two substituted pyrroles, 2-amino-1H-pyrrole-3-
carboxamide (4-5) and 2-amino-1H-pyrrole-3-carbonitrile (4-6) were observed during 
storage (occurring over a few weeks). These intermediates had to be prepared and used 
relatively quickly. 
Base and acid are employed in both approaches A and B for the two cyclization steps. In 
approach A the first cyclization to form intermediates 4-1 or 4-2 was conducted under 
basic conditions to afford the pyrimidines. The formation of the purines from the 
pyrimidines employed acid. The conditions are reversed in approach B. Cyclization from 
intermediate 4-5 or 4-6 was conducted under acidic conditions first, followed by 




Some of the intermediates and products in both methods were challenging to purify. In 
approach A the purification to obtain the non-cyclic intermediates 4-1 or 4-2 by column 
chromatography required a gradient of mixtures of solvents as eluent since TLC analysis 
revealed similar Rf values of substituted intermediates and unreacted starting reagents. In 
particular, the purification of purines 4-7 to 4-12 was difficult as the Rf values were 
similar to the unreacted pyrrole starting materials in approach B. 
 
4.4 Summary 
In summary, two efficient and convergent synthetic routes for the preparation of a series 
of 7-deazapurines were explored. These molecules were synthesized based on two 
cyclization strategies, either from pyrimidine to purine or from pyrrole to purine to enable 
the preparation of a wide range of 7-deazapurine analogs. 
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Chapter 5. Synthesis of cross-linked nucleosides containing 7-
deaza-2’-deoxyguanosine 
5.1 Introduction 
Cellular DNA is susceptible to damage by endogenous and environmental agents that 
may cause modifications such as interstrand cross-links. This can either occur on the 
same strand (intrastrand cross-link) or on the opposite strands of DNA (interstrand cross-
link). Interstrand cross-links (ICL) in DNA exert significant biological effects by 
preventing replication and transcription, which cause cell death if the cross-link is not 
repaired.[235, 316, 317, 319, 350, 425, 450, 451, 567-571]  
ICL can also be introduced in DNA as a consequence of the action of cancer 
chemotherapeutic agents that kill cancer cells. There are a number of bifunctional 
alkylating agents which react with DNA including dialdehydes that are produced in the 
cell and chemotherapeutics, i.e., 1,3-bis(2-chloroethyl)-1-nitrosourea (also known as 
BCNU or carmustine in Figure 5-1a), mechlorethamine (Figure 5-1b) and hepsulfam. 
Treatment of DNA duplexes with these bifunctional alkylating agents often results in a 
broad spectrum of alkylated DNA products, with only a small percentage of ICL duplex 
produced. These alkylating agents react to form ICL at different positions in DNA 
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Figure 5-1. The molecular structures of BCNU (1a), mechlorethamine (1b) and the 
relevant ICL oligonucleotides ((1c/1e): N1-dG-alkylene-N3-dC; (1d/1f): N7-dG-alkylene-
N7-dG). 
 
Development of tumors, resistant to these agents is a factor in the lack of response in 
some patients, with removal of ICL believed to play a role in resistance. These lesions are 
eliminated from DNA by a mechanism involving excision repair and recombination (for 
example in E. coli and in yeast).[450, 451] In eukaryotic cells, the precise role of excision 
repair in eliminating cross-links is not yet clearly understood.[235, 317, 471, 568-571] 
While alkylating agents react at numerous positions in DNA, to our knowledge, the N7-
position of guanine is the most reactive of all the nucleophilic sites in DNA.[144, 189, 
238, 240, 241, 246, 270, 322, 426-430, 530] Hundreds of DNA adducts have been 
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identified addressing a number of issues such as the relationships between DNA adducts 
produced by exposure to chemical agents with mutagenesis and other biological 
phenomena. The covalent binding to DNA and the ability to form N7-guanine adducts 
has been considered as evidence of genotoxicity for several drugs and chemicals. 
The main obstacle in studying the mutagenic potency of N7-guanine adducts is their 
chemical instability which has prevented systematic investigation of the lesions in site-
directed mutagenesis studies. The instability of N7-guanine adducts is created by the 
formal placement of an additional positive charge on the guanine ring system. The 
alkylated guanines undergo a further reaction resulting in cleavage of the N-glycosyl 
bond (Figure 5-2). This depurination creates an abasic site in the DNA and in the case of 
bifunctional alkylating agents and effectively cleaves the ICL formed. Alternatively, the 
imidazole ring of the alkylated guanine can undergo hydrolysis to produce a FAPY 
derivative, which is relatively resistant to further chemical reaction (Figure 5-2).[189, 


































Figure 5-2. Consequences of N7-2’-deoxyguanosine alkylation:  Depurination (left) and 




The investigation of ICL removal by repair enzymes requires access to substrates 
containing this damage. One way in which ICL containing DNA can be prepared 
involves direct treatment of DNA with bi-functional alkylating agents. However, this 
approach is not optimal as: (1) Some DNA adducts formed are difficult to isolate and are 
chemically unstable, making repair and structural studies challenging.  (2)  Some 
alkylating agents lack target specificity and can react with numerous nucleophilic sites 
within DNA [235]. 
Another approach to investigate ICL repair involves the use of chemically synthesized 
substrates of well defined structure. Such substrates are challenging to prepare in 
quantities sufficient for biochemical and structural studies. Employing a combination of 
solution and solid-phase synthesis, ICL DNA that are mimics of clinically relevant 
lesions formed during chemotherapy can be produced. 
To overcome the instability of main adduct with the treatment of alkylating agents, we 
have attempted to produce subtle changes via a synthesis technique combining solution 
and solid-phase synthesis by introducing a 7-deaza-2’-deoxyguanosine residue. The 
removal of the nitrogen lone pair electrons should reduce the electrostatic charge in the 
vicinity of a major groove site with high cation occupancy.[452, 572] Besides, the 
introduction of alkylene linkers to C7 sites of 7-deaza-2’-deoxyguanosines enables the 
prepared ICL duplexes containing a chemically stable moiety to mimic the alkylene 
lesions formed in duplex DNA as a result of treatment with alkylating drugs such as 
mechlorethamine and hepsulfam [333, 425]. These structural analogs will link the C7 
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atoms of two 7-deaza-2’-deoxyguanosine (C7-dG) nucleosides with an alkylene linker 





















Figure 5-3. The C7-dG-alkylene-dG-C7 ICL oligonucleotides (n= 2~5). 
 
For the preparation of the cross-linked dimer containing 7-deazaguanine moieties, the 
precursor 5’-O-dimethoxytrityl-7-iodo-7-deazaguanosine needs to be synthesized in 
adequate quantities. The synthesis started from 7-deazaguanine, and followed Scheme 5-
1 to afford two expected precursors 5’-O-dimethoxytrityl(DMT)-7-iodo-7-deaza-2’-
deoxyguanosine and 5’-O-dimethoxytrityl(DMT)-3’-O-tert-butyldimethylsilyl(TBS)-7-
iodo-7-deaza-2’-deoxyguanosine. The classic approach for preparation of 7-iodo-7-
deaza-2’-deoxyguanosine was to convert the 7-deaza-2’-deoxyguanosine to the 6-chloro 
compound, which was suitable for the better selectivity on C7 than C8 of 7-deaza-2’-
deoxyguanosine. The 6-chloro nucleoside was then converted back to the keto derivative 
by hydrolysis.[573-579] In addition to the extra synthetic steps, the 6-chloro derivatives 
163 
 
had very poor solubility characteristics, which confounded their functionalization.[575, 
579-581] 
According to Scheme 5-1, 7-iodo-7-deazaguanine was prepared by protecting the 6-oxo 
group with trimethylsilyl chloride and treatment with phenoxyacetyl chloride. After the 
glycosylation, introduction of protective groups was performed to produce 5’-O-
dimethoxytrityl-7-iodo-7-deaza-2’-deoxyguanosine and 5’-O-dimethoxytrityl-3’-O-tert-
butyldimethylsilyl-7-iodo-7-deaza-2’-deoxyguanosine. 
The alkylene linker to be placed between the two 7-deazaguanines was introduced by the 
palladium-catalyzed Sonogashira reaction followed with hydrogenation to convert the 
linker from an alkynylene into alkylene functionality. In order to perform the 
Sonogashira reaction at the C7 of 7-deaza-2’-deoxyguanosine, the C7 site was first 
activated with an iodo group. To enhance the reactivity and selectivity (competitive with 
C8) of iodinated substitution at the C7 position of the 7-deazaguanine heterocyclic 
moiety, the 6-oxo group has to be masked.[523, 582] At this position the labile protective 
group TMS was introduced while the 2-amine was protected with a phenoxyacetyl (Pac). 
After the substitution of the iodo atom at the C7 site, the workup procedure to remove the 
high boiling-point solvent (DMF) resulted in the cleavage of TMS at the 6-oxo position. 
In order to synthesize the Sonogashira substrate 5’-O-DMT-7-iodo-7-deaza-2’-
deoxyguanosine, the modified Robins N-glycosylation method was employed. 
Glycolysation of 7-iodo-7-deazaguanine (NPac) with 1-chloro-2-deoxy-3,5-di-O-p-
toluoyl-β-D-erythro-pentofuranosyl was performed via a one-pot reaction in anhydrous 
acetonitrile to afford the β anomer nucleoside at the C1’ atom of the 
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deoxyribofuranose only. Afterwards, the protective toluoyl group was removed with a 
saturated solution of ammonia in anhydrous MeOH while also removing the Pac group 
from the amine at the 2-position. Before the attachment of DMT to the 5’-O of 7-deaza-
2’-deoxyguanosine, the isobutyryl (iBu) protective group was added to the exocyclic 
amine. A portion of 5’-O-DMT-7-iodo-7-deaza-2’-deoxyguanosine was set aside for the 
synthesis of 5’-O-DMT-3’-O-TBS-7-iodo-7-deaza-2’-deoxyguanosine. 
The introduction of the linker to the C7 site of 7-deaza-2’-deoxyguanosine was 
performed with the Sonogashira reaction (shown in Scheme 5-2). This reaction was 
conducted with palladium and copper catalyst under mild basic condition to enable the 
formation of a new sp
2
-sp carbon-carbon bond.[535, 583-586] A concern was that the 
DMT may be removed at higher temperature, so the coupling reaction was carried out at 
40 
o
C under argon atmosphere. However, it was observed the TBS protective group was 
removed under the conditions of the Sonogashira reaction. The two precursors 5’-O-
DMT-7-iodo-7-deaza-2’deoxyguanosine and 5’-O-DMT-3’-O-TBS-7-iodo-7-deaza-2’-
deoxyguanosine produced the same monomer product 5’-O-DMT-7-alkynylene-7-deaza-
2’deoxyguanosine. This monomer was then reacted with 5’-O-DMT-7-iodo-7-deaza-2’-
deoxyguanosine via a second Sonogashira reaction, and alkynylene linker was 
established between the two 7-deaza-2’-deoxyguanosines. Hydrogenation to reduce the 
triple-bond linker to corresponding alkylene was attempted with catalyst Pd/C under 





a) 3.0 eq. TMSCl, in anhydrous pyridine at RT for 1.5 h, then 1.5 eq. PacCl was added and the reaction 
proceeded overnight at RT; b) 1.3 eq. iodine in DMF at RT for overnight, 71% for steps a and b; c) NaH 
(2.5 eq.), anhydrous acetonitrile at RT for 12 h, 66%; d) NH3/CH3OH at RT overnight; e) 6.0 eq. TMSCl, 
anhydrous pyridine at RT for  2 h, then 1.5 eq. iBuCl overnight at RT; f) NH3/CH3OH (sat.) ice-bath for 30 
min. or TBAF/THF (cat.), 10 eq. KF in MeOH for 5 hours; g) 1.2 eq. DMTCl, in anhydrous pyridine at RT 
overnight, 42% for steps d to g; h) 2.0 eq. TBSCl, 4.0 eq. imidazole, in anhydrous DMF at RT for 
overnight, 91%.  





a) 4.0 eq. 1,6-heptadiyne, 0.02 eq. PdCl2(PPh3)2, 0.1 eq. CuI, 0.1 eq. PPh3 in Et3N/DMF at 40 
o
C for 60 h, 
86%; b) 0.02 eq. PdCl2(PPh3)2, 0.1 eq. CuI , 0.1 eq. PPh3 in Et3N/DMF at 40 
o
C for 60 h; c) 60 psi H2, 100 
mg Pd/C (10%) in 30 mL MeOH at RT for 60 h. 
Scheme 5-2. Synthesis of C7 cross-linked dimer containing 5’-O-DMT-7-deaza-2’-
deoxyguanosine. 
 
5.2 Experimental Procedures 
Details of the synthesis and characterization of all compounds in this chapter are 
described in Chapter 6.3. 
 
5.3 Results and discussion 
In this chapter a synthetic strategy to prepare a cross-linked dimer containing two 7-
deaza-2’-deoxyguanosines was explored. A key intermediate connects the C7 atoms of 7-
deaza-2’-deoxyguanosines with sp2-sp3 bonds to an alkylene chain. This adduct would 
enable further synthesis of a cross-linked dimer phosphoramidite which would be 
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incorporated into DNA to produce interstrand cross-linked oligonucleotides by solid-
phase synthesis to mimic the lesions formed in DNA by some chemotherapeutic agents. 
Starting from 7-deazaguanine prepared in Chapter 4, a phenoxyacetyl group was 
attached to the 2-amino group while the 6-oxo position was protected with TMS before 
iodination of the C7 site. The lability of TMS on the 6-oxo group resulted in N-(5-iodo-4-
oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-2-phenoxyacetamide as the product 
obtained after workup. This substrate was coupled with 1-chloro-3,5-di-O-toluoyl-2-
deoxy--D-ribofuranose at C1’ in anhydrous acetonitrile which produced the β anomer 
only.  Toluolyl protective groups on both 3’-O and 5’-O atoms were removed with a 
saturated solution of ammonia in anhydrous MeOH, and three more synthetic steps were 
conducted before the attachment of the DMT protective group at the 5’-O position. 
Overall, the multi-step procedure to produce protected nucleoside (5’-O-DMT-7-iodo-7-
deaza-2’-deoxyguanosine) gave the expected products at each step in moderate yields. To 
our knowledge, the Sonogashira reaction is more sensitive requiring inert atmosphere 
compared to the Heck, Stille, Suzuki and Hiyama coupling reactions. The reaction system 
was purged with argon three times to remove the trace oxygen/air to avoid side reactions. 
Normally the coupling reactions are performed at higher temperature for better 
conversions, however, thermal instability of the DMT group was a concern when the 
linker was introduced at the C7 of 7-iodo-7-deaza-2’-deoxyguanosine. The yields to 
attach the alkylene linker to 7-iodo-7-deaza-2’-deoxyguanosine by Sonogashira coupling 
were lower compared with other synthetic strategies (such as nucleophilic substitution 
reaction, Mitsunobu reaction explored by our group and others) to introduce ICL. 
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Two substrates 7-iodo-7-deaza-5’-O-DMT-2’-deoxyguanosine (NiBu) and 7-iodo-7-
deaza-5’-O-DMT-3’-O-TBS-2’-deoxyguanosine (NiBu), were employed for the 
Sonogashira coupling reaction. In Chapter 3 we studied the synthetic strategy to produce 
ICL duplexes containing assymetric nucleotide composition around a cross-linked site 
with the selective removal of compatible protective groups (DMT, TBS and Alloc) and 
sequential nucleotide extensions. 5’-O-DMT-3’-O-TBS-7-iodo-7-deaza-2’-
deoxyguanosine (NiBu) was first explored for the coupling with the diyne linker.  A 
cross-linked dimer with different compatible protective groups on the 3’-O and 5’-O 
groups would enable the preparation of ICL duplexes containing partially or completely 
asymmetric sequences around cross-linked sites. In this chapter, we planned to synthesize 
a cross-linked dimer containing two different protective groups on 5’-O and 3’-O (two 
DMT on 5’-O and one TBS on 3’-O). It has been reported that silyl protective groups can 
be cleaved under the conditions of Pd-catalyzed hydrogenation.[587-590] We observed 
that the TBS protective group was unstable under the Sonogashira reaction conditions. 
The Sonogashira coupling reaction was first conducted with the catalyst system of 
bis(triphenylphosphine)palladium(II) dichloride, copper (I) iodide under the conditions of 
Et3N/DMF (v/v, 0.5:2). NMR characterization of the product isolated using 5’-O-DMT-
3’-O-TBS-7-iodo-7-deaza-2’-deoxyguanosine (NiBu) as starting material indicated that 
the TBS group was cleaved. The attempt to reduce the alkalinity of the reaction system 
(the ratio of Et3N to DMF was 0.1:2) still resulted in the removal of TBS. The same 
product was obtained from both 5’-O-DMT-3’-O-TBS-7-iodo-7-deaza-2’-
deoxyguanosine (NiBu) and 5’-O-DMT-2’-7-iodo-7-deaza-2’-deoxyguanosine (NiBu). 
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The attempt to form the cross-linked dimer by a second Sonogashira coupling reaction 
was not successful. The conversion of the Sonogashira coupling performed between the 
two monomers 5’-O-DMT-7-iodo-7-deaza-2’deoxyguanosine (NiBu) (5-6) and 5’-O-
DMT-2’-deoxy-7-(1,6-heptadiynyl)-7-deazaguanosine (5-7) did not proceed in high yield 
for the formation of the dimer. One possible reason is the steric hindrance of the moieties 
(both containing DMT protective groups) which may have resulted in lower accessibility 
of palladium catalyst to the C7 sites. To form the linkage by the Sonogashira coupling 
reaction, the palladium (0) core would be centered between four bulky groups, two 
triphenylphosphine and two 5’-O-DMT-7-deaza-2’deoxyguanosines in the transition 
state. NMR analysis of what was isolated from the reaction indicated that monomer(s) 
and dimer co-existed in the final product. 
We attempted to proceed with the synthesis of phosphoramidite(s) with the hydrogenated 
compound(s), however 
31
P NMR data also showed the mixture of one monomer and 
dimer from 5 peaks around 148 ppm. 
 
5.4 Summary 
In this chapter, 7-iodo-7-deazaguanine was coupled with 1-chloro-3,5-di-O-toluoyl-2-
deoxy--D-ribofuranose. After the removal of the toluoyl protective groups, the 
precursor 5’-O-DMT-7-iodo-7-deaza-2’-deoxyguanosine was produced in moderate 
yield. The Sonogashira coupling reaction was performed on 7-iodo-7-deazaguanosine to 
introduce the C7-alkynyl linker to form the monomer. Attempts to form a cross-linked 7-
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deazaguanosine dimer containing a heptamethylene linker via a second Sonogashira 







Chapter 6. Experimental Procedures 
6.1 Experimental procedure for preparation of the N3-thymidine-
butylene-N3-thymidine dimer 
6.1.1 Materials and General Methods 
5’-O-Levulinoyl-thymidine, 5’-O-dimethoxytrityl-thymidine, 3’-O-dimethoxytrityl-
2’-deoxyribonucleoside-5’-O-(β-cyanoethyl-N,N’-diisopropyl) phosphoramidites and 
N,N-diisopropylamino cyanoethyl phosphonamidic chloride were purchased from 
ChemGenes Inc. (Wilmington, MA). 5’-O-Dimethoxytrityl-2’-deoxyribonucleoside-
3’-O-(β-cyanoethyl-N,N’-diisopropyl)phosphoramidites, protected 2’-
deoxyribonucleoside-polystyrene supports and ancillary reagents for solid-phase 
synthesis were purchased from Glen Research (Sterling, Virginia). Allyl 
chloroformate, n-butylamine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), formic acid, 
1-hydroxybenzotriazole hydrate, hydrazine hydrate, levulinic acid, phenoxyacetyl 
chloride, tert-butyldimethylsilyl chloride (TBS-Cl),  p-toluene sulfonic acid (p-
TsOH), diisopropylethylamine (DIPEA), 4-dimethylaminopyridine (DMAP), 
triphenylphosphine, sodium N,N-diethydithiocarmbamate, tetrakis(triphenyl 
phosphine)palladium(0) and all other chemicals and solvents for synthesis were 





butyldimethylsilyl)-thymidine were all prepared with minor modifications to published 
procedures.[425]
 
Flash column chromatography was performed using silica gel 60 (230–400 mesh) 
obtained from Silicycle (Quebec City, QC). Thin layer chromatography (TLC) was 
performed using precoated TLC plates (Merck, Kieselgel 60 F254, 0.25 mm) purchased 
from EMD Chemicals Inc. from (Gibbstown, NJ). All solvents for column 




C NMR spectra were recorded on a Varian 500 MHz NMR spectrometer at RT at 




C, respectively. Chemical shifts were 
reported in parts per million downfield from tetramethylsilane. 
31
P NMR spectra (
1
H 
decoupled) were recorded at a frequency of 202.4 MHz with H3PO4 used as an external 
standard.  
 
6.1.2 Synthesis of Cross-Linked Phosphoramidites 
Compound 3-1. 5’-O-Dimethoxytrityl-3’-O-phenoxyacetyl-thymidine 
 
The title compound was prepared as previously described with the yield 96%.[425] 




H NMR (CDCl3, ppm): δ 1.31 (s, 3H, C5-CH3), 2.36-2.40 (ddd, J = 14.5, 8.0, 5.5 Hz, 
1H, 2’-H), 2.39-2.44 (ddd, J = 14.5, 6.0, 5.5 Hz, 1H, 2”-H), 3.37-3.41 (dd, J = 10.5, 8.0 
Hz, 1H, 5’-H), 3.41-3.44 (dd, J = 10.5, 2.5 Hz, 1H, 5”-H), 3.72 (s, 6H, -OCH3 of DMT), 
4.04-4.07 (ddd, J = 5.5, 5.5, 5.5 Hz, 1H, 3’-H), 4.59 (s, 2H, CH2 of Pac), 5.48-5.49 (ddd, 
8.0, 5.5, 2.5, 1H, 4’-H), 6.33-6.35 (dd, J =8.0, 6.0 Hz, 1H, 1’-H), 6.76-6.94 (m, 7H, Phs 
of DMT and Pac), 7.17-7.31 (m, 11H, Phs of DMT and Pac), 7.53 (s, 1H, H6). 
13
C NMR (CDCl3, ppm): δ 11.65, 37.82, 55.27, 63.58, 65.18, 76.41, 83.94, 84.27, 87.28, 
111.80, 113.35, 114.63, 122.03, 127.27, 128.07, 128.11, 129.68, 130.06, 130.11, 135.10, 
135.15, 135.25, 144.16, 150.45, 157.54, 158.80, 150.82, 163.58, 168.54. 
ESI-MS (M+Na
+
): consistent with the reported value. [425] 
 
Compound 3-2. 5’-O-Levulinoyl-3’-O-phenoxyacetyl-thymidine 
 
5’-O-Dimethoxytrityl-3’-O-phenoxyacetyl-thymidine (1.738 g, 2.560 mmol, 1.0 eq.) was 
dissolved in a mixture of DCM/CH3OH (4:1, 50 mL). Then, p-TsOH (1.071 g, 5.632 
mmol, 2.2 eq.) was added at RT. After 30 min, the reaction was diluted with DCM (200 
mL) and then washed with aqueous NaHCO3 (5%, 100 mL). The organic layer was 
washed with distilled water (100 mL), and dried over sodium sulfate and concentrated to 
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give a colorless gum. The gum was then dissolved in pyridine (16 mL). EDC (0.697 g, 
3.648 mmol, 2.0 eq.) and levulinic acid (0.424 g, 3.648 mmol, 2.0 eq.) were added at RT. 
After 18 h, the solvent was removed in vacuo, the crude product was taken up in DCM 
(50 mL) and the solution was washed with aqueous NaHCO3 (3%, 50 mL). The organic 
layer was dried over sodium sulfate and concentrated to give a yellowish gum. The crude 
product was purified by silica gel column chromatography using hexane/EtOAc (49:1) as 
eluent to afford 0.822 g (95%) of product as a colorless foam.  
Rf (SiO2 TLC): 0.28 in hexane/EtOAc (1:1).  
1
H NMR (CDCl3, ppm): δ 1.87 (s, 3H, C5-CH3), 2.12 (s, 3H, CH3 of Lev), 2.17-2.22 
(ddd, J = 14.5, 5.5, 1.5 Hz, 1H, H2’), 2.39-2.44 (ddd, J = 14.5, 8.0, 6.5 Hz, 1H, H2”), 
2.50-2.53 (t, J = 6.5 Hz, 2H, CH2 of Lev), 2.72-2.75 (t, J = 6.5 Hz, 2H, CH2 of Lev), 
4.16-4.18 (dd, J = 12.0, 3.0 Hz, 1H, H5’), 4.24-4.27 (ddd, J = 9.0, 3.5, 3.0 Hz, 1H, H4’), 
4.38-4.42 (dd, J = 12.0, 3.5 Hz, 1H, H5”), 4.62 (s, 2H, CH2 of Pac), 5.27-5.30 (ddd, J = 
9.0, 6.5, 1.5 Hz, 1H, H3’), 6.20-6.23 (dd, J = 8.0, 5.5 Hz, 1H, H1’), 6.84-6.96 (m, 3H, Ph 
of Pac), 7.20-7.25 (m, 2H, Ph of Pac), 7.28 (s, 1H, H6).  
13
C NMR (CDCl3, ppm): 12.60, 27.81, 29.72, 37.21, 37.83, 63.71, 65.12, 75.20, 82.12, 




): 497.1540 (calcd. 497.1541). 
 




Phenoxyacetyl chloride (3.412 g, 20 mmol, 1.0 eq.) and potassium iodide (8.300 g, 50 
mmol, 2.5 eq.) were dissolved in THF (50 mL) at RT. After 24 h, NaHCO3 (1.681g, 20 
mmol, 1.0 eq.) was added slowly to the solution. The solvent was removed in vacuo, the 
crude product was taken up with DCM (100 mL) and the reaction quenched with aqueous 
NaHCO3 (5%, 100 mL). The organic layer was washed with distilled water (100 mL × 2), 
dried over sodium sulfate and concentrated to give a viscous liquid. The crude product 
was purified by silica gel column chromatography using hexane/EtOAc (1:1) as eluent to 
afford 4.26 g (95%) of product.  
Rf (SiO2 TLC): 0.76 in hexane/EtOAc (1:1).  
1
H NMR (CDCl3, ppm): δ 1.63-1.71 (tt, J = 8.0, 6.5 Hz, 2H, CH2), 1.72-1.79 (tt, J = 8.0, 
6.5 Hz, 2H, CH2), 3.08-3.10 (t, J = 6.5 Hz, 2H, CH2), 4.15-4.17 (t, J = 6.5 Hz, 2H, CH2), 
4.56 (s, 2H, OCH2 of Pac), 6.83-6.85 (dd, J = 8.5, 0.5 Hz, 2H, Ph of Pac), 6.93-6.94 (dd, J 
= 7.0, 0.5 Hz, 1H, Ph of Pac), 7.19-7.23 (dd, J = 8.5, 7.0 Hz, 2H, Ph of Pac).  
13




): 372.9655 (calcd. 372.9703). 
 




The title compound was prepared as previously described in quantitative yield. [425] 
Rf  (SiO2 TLC): 0.44 in hexane/EtOAc (1:1). 
1
H NMR (CDCl3, ppm): δ 0.00, 0.05 (2s, 6H, SiCH3), 0.86 (s, 9H, SiC(CH3)3), 1.53 (s, 
3H, C5-CH3), 2.24-2.28 (ddd, J = 13.0, 6.5, 6.5 Hz, 1H, 2’-H), 2.34-2.36 (ddd, J = 13.0, 
6.5, 3.0 Hz, 1H, 2”-H), 3.29-3.31 (dd, J = 10.5, 3.0 Hz, 1H, 5’-H), 3.49-3.52 (dd, J = 
10.5, 3.0 Hz, 1H, 5”-H), 3.82 (s, 6H, OCH3 of DMT), 4.00-4.01 (ddd, J = 6.5, 6.5, 3.0 
Hz, 1H, 3’-H), 4.55-4.56 (ddd, J = 6.5, 3.0, 3.0 Hz, 1H, 4’-H), 6.38-6.40 (dd, J = 6.5, 6.5 
Hz, 1H, 1’-H), 6.86-6.88 (m, 4H, Ph of DMT), 7.13-7.45 (m, 9H, Ph of DMT), 7.69 (s, 
1H, H6). 
13
C NMR (CDCl3, ppm): -4.87, -4.67, 11.89, 17.94, 25.72, 41.56, 55.25, 62.94, 72.10, 
84.90, 86.80, 86.84, 111.01, 113.29, 127.96, 128.14, 130.05, 130.07, 135.46, 135.50, 
135.63, 144.35, 150.31, 158.76, 163.84. 








The title compound was prepared as previously described with a yield of 84%.[425] 
Rf  (SiO2 TLC): 0.63 in hexane/EtOAc (1:1). 
1
H NMR (CDCl3, ppm): δ 0.00, 0.06 (2s, 6H, SiCH3), 0.86 (s, 9H, SiC(CH3)3), 1.21-1.24 
(m, 2H, CH2 of butyl), 1.56 (s, 3H, C5-CH3), 1.71-1.74 (m, 2H, CH2 of butyl), 2.22-2.28 
(ddd, J = 14.5, 6.5, 6.5 Hz, 1H, 2’-H), 2.33-2.38 (ddd, J = 14.5, 3.0, 3.0 Hz, 1H, 2”-H), 
3.29-3.32 (dd, J = 10.5, 2.5 Hz, 1H, 5’-H), 3.47-3.50 (ddd, J = 6.5, 3.0, 3.0 Hz, 1H, 3’-
H), 3.49-3.51 (t, J = 7.5 Hz, 2H, CH2 of butyl), 3.80 (s, 6H, OCH3 of DMT), 3.98-4.01 (t, 
J = 7.5 Hz, 2H, CH2 of butyl), 4.24-4.27 (dd, J = 10.5, 5.5 Hz, 1H, 5”-H), 4.54-4.56 (ddd, 
J = 5.5, 3.0, 2.5 Hz, 1H, 4’-H), 4.64 (s, 2H, OCH2 of Pac), 6.33-6.45 (dd, J = 6.5, 3.0 Hz, 
1H, 1’-H). 6.85-6.94 (m, 4H, Ph of DMT), 6.97-7.00 (m, 3H, Ph of Pac), 7.26-7.33 (m, 
9H, Phs of DMT and Pac), 7.34-7.46 (m, 2H, Ph of DMT), 7.69 (s, 1H, H6). 
13
C NMR (CDCl3, ppm): -4.87, -4.65, 12.69, 15.30, 17.93, 24.20, 25.72, 40.72, 41.62, 
55.23, 62.90, 64.89, 65.27, 72.07, 85.48, 86.71, 86.82, 110.20, 113.25, 113.27, 114.58, 
114.66, 121.64, 127.12, 127.98, 128.13, 129.54, 129.59, 130.05, 130.08, 133.64, 135.43, 
135.48, 144.37, 150.82, 157.83, 158.72, 163.42, 168.98. 
ESI-MS (M+Na
+





Compound 3-6. N3-(4-Iodobutyl)-5’-O-dimethoxytrityl-3’-O-(tert-butyldimethylsilyl)- 
thymidine 
 
The title compound was prepared as previously described with a yield of 71%.[425] 
Rf  (SiO2 TLC): 0.71 in hexane/EtOAc (1:1). 
1
H NMR (CDCl3, ppm): δ 0.00, 0.06 (2s, 6H, SiCH3), 0.87 (s, 9H, SiC(CH3)3), 1.60 (s, 
3H, C5-CH3), 1.78-1.82 (m, 2H, CH2 of butyl), 1.89-1.93 (m, 2H, CH2 of butyl), 2.22-
2.26 (ddd, J = 13.0, 6.5, 6.5 Hz, 1H, 2’-H), 2.36-2.39 (ddd, J = 13.0, 7.0, 6.5 Hz, 1H, 2”-
H), 3.24-3.27 (t, J = 7.0 Hz, 2H, CH2 of butyl), 3.28-3.31 (dd, J = 11.0, 3.0 Hz, 1H, 5’-
H), 3.48-3.51 (dd, J = 11.0, 3.0 Hz, 1H, 5”-H), 3.83 (s, 6H, OCH3 of DMT), 3.98-4.02 
(ddd, J = 6.5, 6.5, 6.5,Hz, 1H, 3’-H), 4.00-4.03 (t, J = 7.0, 2H, CH2 of butyl), 4.53-4.55 
(ddd, J = 6.5, 3.0, 3.0 Hz, 1H, 4’-H), 6.40-6.42 (dd, J = 7.0, 6.5 Hz, 1H, 1’-H), 6.86-6.88 
(m, 4H, Ph of DMT), 7.26-7.35 (m, 7H, Ph of DMT), 7.44-7.45 (m, 2H, Ph of DMT), 




C NMR (CDCl3, ppm): -4.87, -4.66, 5.96, 12.69, 17.93, 25.71, 28.72, 30.90, 40.08, 
41.62, 55.26, 62.90, 72.05, 85.50, 86.72, 86.80, 110.21, 113.24, 113.26, 127.11, 127.97, 
128.12, 130.04, 130.07, 133.62, 135.43, 135.48, 144.34, 150.82, 158.70, 163.45. 
ESI-MS (M+Na
+
): consistent with previously reported value. [425] 
 
Compound 3-7. Allyl 1-hydroxybenzotriazole carbonate 
 
1-Hydroxybenzotriazole hydrate (6.06 g, 39.6 mmol, 1 eq.) was dissolved in THF (10 
mL) followed by the removal of the solvent in vacuo. The same operation was repeated 
twice. The white powder was dissolved in THF (30 mL). DIPEA (5.76 g, 44.6 mmol, 
1.12 eq.) was added, followed by the addition of allyl chloroformate (5.12 g, 41.2 mmol, 
1.04 eq.). After 30 min, the white precipitate was filtered off and washed with THF (20 
mL×2). The combined organic layer was collected and concentrated in vacuo.[2] The 
crude product was purified by silica gel column chromatography using hexane/EtOAc 
(1:1) as eluent to give 6.85 g (79%) of product. 
Rf (SiO2 TLC): 0.40 in hexane/EtOAc (1:1). 
1
H NMR (CDCl3, ppm): δ 5.03-5.04 (d, J = 6.0 Hz, 2H, OCH2 of Allyl), 5.42-5.44 (dd, J 
= 11.0, 0.5 Hz, 1H, CH of Allyl), 5.54-5.57, (dd, J = 16.0, 0.5 Hz, 1H, CH of Allyl), 
6.05-6.13 (ddt, J = 16.0, 11.0, 6.0 Hz, 1H, CH of Allyl), 7.55-7.58 (m, 1H, Ph), 7.78-7.80 








): consistent with the commercial reagent’s data. 
 
Compound 3-8. 5’-O-Levulinoyl-3’-O-allyloxycarbonyl-thymidine 
 
5’-O-Levulinoyl-thymidine (1.000 g, 2.938 mmol, 1 eq.), allyl 1-hydroxy benzotriazole 
carbonate (0.858 g, 3.908 mmol, 1.33 eq.) and DMAP (0.072 g, 0.588 mmol, 0.2 eq.) 
were dissolved in THF/pyridine (9:1, 100 mL) at RT. After 24 h, the solvent was 
removed in vacuo and the crude was taken up in DCM (50 mL). The organic layer was 
washed with aqueous NaHCO3 (5%, 50 mL) and dried over sodium sulfate. After being 
concentrated in vacuo, the crude product was purified by silica gel column 
chromatography using hexane/EtOAc (3:7) as eluent to afford 0.824 g (66 %) of product.  
Rf  (SiO2 TLC): 0.47 in hexane/EtOAc (3:7). 
1
H NMR (CDCl3, ppm): δ 1.86 (s, 3H, C5-CH3), 2.12 (s, 3H, CH3 of Lev), 2.17-2.22 
(ddd, J = 14.5, 8.5, 6.5 Hz, 1H, H2’), 2.47-2.51 (ddd, J = 14.5, 5.5, 1.5 Hz, 1H, H2”), 
2.51-2.53 (t, J = 6.0 Hz, 2H, CH2 of Lev), 2.73-2.75 (t, J = 6.0 Hz, 2H, CH2 of Lev), 
4.25-4.27 (ddd, J = 3.5, 3.0, 3.0 Hz, 1H, H4’), 4.26-4.29 (dd, J = 12.0, 3.5 Hz, 1H, H5’), 
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4.38-4.41 (dd, J = 12.0, 3.0 Hz, 1H, H5”), 4.57-4.58 (d, J = 5.5 Hz, 2H, CH2 of Alloc), 
5.09-5.11 (ddd, J = 6.5, 3.0, 1.5 Hz, 1H, H3”), 5.22-5.25 (dd, J = 10.5, 1.0 Hz, 1H, CH of 
Alloc), 5.30-5.33 (dd. J = 17.0, 1.0 Hz, 1H, CH of Alloc), 5.82-5.90 (ddt, J = 17.0, 10.5, 
5.5 Hz, 1H, CH of Alloc), 6.25-6.27 (dd, J = 8.5, 5.5 Hz, 1H, H1’), 7.29 (s, 1H, H6).  
13
C NMR (CDCl3, ppm): 12.58, 27.80, 29.71, 37.36, 37.80, 63.91, 68.98, 77.63, 82.01, 
84.79, 111.50, 119.53, 131.00, 134.86, 150.40, 154.17, 163.90, 172.26, 206.40. 
ESI-MS (M+Na
+





Compound 3-6 (0.841 g, 1.000 mmol, 1 eq.) and compound 3-8 (0.468 g, 1.100 mmol, 
1.1 eq.) were dissolved in acetonitrile (30 mL) at RT. Then DBU (0.305 g, 2.000 mmol, 
2.0 eq.) was added dropwise. After 24 h, the solvent was removed in vacuo, the crude 
product was taken up in DCM (100 mL) and the solution was washed with three portions 
of aqueous NaHCO3 (5%, 100mL). The organic layer was dried over sodium sulfate, and 
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the crude product was purified by silica gel column chromatography using hexane/EtOAc 
(1:1 to 3:7) as eluent to afford 0.773 g (68%) of product.  
Rf  (SiO2 TLC): 0.69 in hexane/EtOAc (3:7).  
1
H NMR (CDCl3, ppm): δ 0.00 (s, 3H, SiCH3), 0.06 (s, 3H, SiCH3), 0.86 (s, 9H, 
SiC(CH3)3), 1.53 (s, 3H, C5-CH3), 1.72-1.74 (m, 4H, CH2 of butyl), 1.98 (s, 3H, C5-
CH3), 2.23 (s, 3H, CH3 of Lev), 2.23-2.25 (m, 2H, 2 x H2’), 2.26-2.29 (m, 2H, 2 x H2”), 
2.62-2.66 (t, J = 6.0 Hz, 2H, CH2 of Lev), 2.82-2.85 (t, J = 6.0 Hz, 2H, CH2 of Lev), 
3.28-3.30 (dd, J = 14.0, 2.5 Hz, 1H, H5’), 3.50-3.52 (dd, 14.0, 2.5 Hz, 1H, H5”), 3.82 (s, 
6H, OCH3 of DMT), 3.97-3.99 (m, 1H, H4’), 3.98-4.01 (t, J = 7.0 Hz, 4H, CH2 of butyl), 
4.35-4.39 (m, 2H, H4’ and H5’), 4.53-4.57 (m, 2H, H3’ and H5”), 4.67-4.69 (d, J = 5.5 
Hz, 2H, OCH2 of Alloc), 5.18-5.21 (m, 1H, H3’), 5.32-5.35 (dd, J = 10.5, 0.5 Hz, 1H, CH 
of Alloc), 5.40-5.44 (dd, J = 17.0, 0.5 Hz, 1H, CH of Alloc), 5.97-6.01 (ddt, J = 17.0, 
10.5, 5.5, Hz, 1H, CH of Alloc). 6.38-6.41 (m, 2H, 2 x H1’), 6.86-6.89 (m, 4H, Ph of 
DMT), 7.27-7.44 (m, 9H, Ph of DMT), 7.46 (s, 1H, H6), 7.69 (s, 1H, H6). 
13
C NMR (CDCl3, ppm): -4.90, -4.65, 12.67, 13.37, 17.92, 25.30, 25.71, 27.82, 29.73, 
37.52, 37.81, 41.01, 41.15, 41.64, 55.25, 62.83, 63.92, 68.96, 71.94, 77.68, 81.89, 85.39, 
85.41, 86.60, 86.76, 110.18, 110.64, 113.23, 113.26, 119.53, 127.08, 127.97, 128.14, 
130.03, 130.07, 131.02, 132.70, 133.51, 135.45, 135.52, 144.34, 150.74, 150.83, 154.19, 
158.68, 163.23, 163.47, 172.23, 206.22. 
ESI-MS (M+Na
+







Compound 3-9 (0.436 g, 0.384 mmol, 1.0 eq.), triphenylphosphine (0.020 g, 0.077 mmol, 
0.20 eq.) and tetrakis(triphenylphosphine)palladium(0) (0.044 g, 0.038 mmol, 0.10 eq.) 
were dissolved in THF (10 mL) at RT, followed by the addition of buffer composed of n-
butylamine (50 eq.) and formic acid (50 eq.). After 2.5 h, the solvent was removed in 
vacuo, the crude residue was taken up in DCM (100 mL) and the solution was washed 
with aqueous NaCl (sat., 100 mL). The organic layer was dried over sodium sulfate and 
concentrated for silica gel column chromatography using hexane/EtOAc (3:7 to 1:9) as 
eluent. The product was obtained as colorless foam in a yield of 0.400 g (100%). 
Rf  (SiO2 TLC): 0.32 in hexane/EtOAc (2:8).  
1
H NMR (CDCl3, ppm): δ 0.00 (s, 3H, SiCH3), 0.06 (s, 3H, SiCH3), 0.86 (s, 9H, 
SiC(CH3)3), 1.22-1.25 (m, 2H, CH2 of butylene), 1.53 (s, 3H, C5-CH3), 1.71-1.73 (m, 4H, 
CH2 of butylene), 1.96 (s, 3H, C5-CH3), 2.15-2.21 (m, 1H, H2’), 2.22 (s, 3H, CH3 of 
Lev), 2.23-2.28 (m, 1H, H2”), 2.35-2.38 (m, 1H, H2’), 2.44-2.47 (m, 1H, H2”), 2.60-2.63 
(t, J = 6.5 Hz, 2H, CH2 of Lev), 2.81-2.84 (t, J = 6.5 Hz, 2H, CH2 of Lev), 3.28-3.31 (dd, 
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J = 14.0, 3.0, 1H, H5’), 3.50-3.53 (dd, J = 14.0, 7.0, 1H, H5”), 3.82 (s, 6H, OCH3 of 
DMT), 3.96-3.98 (m, 1H, H4’), 3.97-4.01 (2 t, J = 7.0 Hz, 4H, CH2 of butyl), 4.12-4.14 
(m, 1H, H4’), 4.29-4.32 (m, 2H, H5’ and H5”), 4.39-4.45 (m, 1H, H3’), 4.54-4.57 (m, 
1H, H3’), 6.36-6.41 (m, 2H, 2 x H1’), 6.86-6.88 (m, 4H, Ph of DMT), 7.32-7.59 (m, 9H, 
Ph of DMT), 7.69 (s, 1H, H6), 7.71 (s, 1H, H6).  
13
C NMR (CDCl3, ppm): -4.9, -4.7, 12.7, 13., 17.9, 25.3, 25.4, 25.7, 27.9, 29.8, 37.9, 
40.3, 41.0, 41.6, 55.3, 62.8, 63.8, 70.9, 71.9, 84.0, 85.3, 85.4, 86.6, 86.8, 110.2, 112.9, 
113.2, 127.1, 127.6, 127.8, 128.0, 128.1, 128.3, 128.5, 128.6, 129.7, 130.0, 130.1, 131.7, 













Compound 3-10 (0.291 g, 0.276 mmol, 1.0 eq.) was dissolved in THF (1.25 mL) 
followed with the dropwise addition of DIPEA (0.054 g, 0.414 mmol, 1.5 eq.) and N,N-
diisopropylamino cyanoethyl phosphonamidic chloride (0.078 g, 0.331 mmol, 1.2 eq.) at 
RT. After 30 min, the reaction was diluted with EtOAc (50 mL). The organic layer was 
washed twice with aqueous NaHCO3 (3%, 100 mL) followed by aqueous NaCl (sat., 100 
mL), then dried over sodium sulfate. After concentration in vacuo, the gum was 
precipitated from hexane to yield 0.246 g (71%) of product.  
Rf (SiO2 TLC): 0.82 in hexane/EtOAc (2:8).  
31
P NMR (Acetone-d6, ppm): 148.39, 148.61.  
ESI-MS (M+Na
+




Compound 3-12. 5’-O-Dimethoxytrityl-3’-O-levulinoyl-thymidine 
 
5’-O-Dimethoxytrityl-thymidine (5.446 g, 10.00 mmol, 1.0 eq.), EDC (3.820 g, 20.00 
mmol, 2.0 eq.), DMAP (0.012 g, 0.10 mmol, 0.01 eq.) and levulinic acid (2.322 g, 20.00 
mmol, 2.0 eq.) were dissolved in 1,4-dioxane (60 mL) at RT. After 12 h the solvent was 
removed in vacuo, the residue was taken up in DCM (100 mL) and the solution was 
washed with aqueous NaHCO3 (5%, 100 mL). The organic layer was dried over sodium 
sulfate, and concentrated for purification by silica gel column chromatography. The 
product was isolated as a colorless foam in a yield of 6.42 g (99%).  
Rf  (SiO2 TLC): 0.40 in hexane/EtOAc (1: 9).  
1
H NMR (CDCl3, ppm): δ 1.29 (s, 3H, C5-CH3), 2.12 (s, 3H, CH3 of Lev), 2.32-2.38 
(ddd, J = 13.5, 7.0, 6.0 Hz, 1H, H2’), 2.58-2.62 (ddd, J = 13.5, 5.5, 4.5 Hz, 1H, H2”), 
2.63-2.66 (t, J = 6.5 Hz, 2H, CH2 of Lev), 2.67-2.70 (J = 6.5 Hz, 2H, CH2 of Lev), 3.35-
3.38 (dd, J = 13.0, 2.5 Hz, 1H, H5’), 3.39-3.42 (dd, J = 13.0, 2.5 Hz, 1H, H5”), 3.72 (s, 
6H, OCH3 of DMT), 4.06 (ddd, J = 5.0, 2.5, 2.5, Hz, 1H, H4’), 5.38-5.40 (ddd, J = 6.0, 
5.0, 4.5 Hz, 1H, H3’), 6.36-6.38 (dd, J = 7.0, 5.5 Hz, 1H, H1’), 6.75-6.77 (m, 4H, Ph of 




C NMR (CDCl3, ppm): 11.58, 27.96, 29.79, 37.79, 37.86, 55.26, 63.73, 75.67, 83.98, 
84.32, 87.19, 111.62, 113.32, 127.22, 128.03, 128.13, 130.08, 130.12, 135.15, 135.24, 
135.46, 144.21, 150.40, 158.76, 158.77, 163.60, 172.24, 206.30.  
ESI-MS (M+Na
+
): 665.2483 (calcd. 665.2475). 
 
Compound 3-13. 5’-O-Allyloxycarbonyl-3’-O-levulinoyl-thymidine 
 
Compound 3-12 (2.310 g, 3.594 mmol, 1.0 eq.) was dissolved in a mixture of 
DCM/CH3OH (4:1, 75 mL). Then, p-TsOH (1.505 g, 7.910 mmol, 2.2 eq.) was added at 
RT. After 30 min, the solution was diluted with DCM (300 mL) and then washed with 
aqueous NaHCO3 (5%, 150 mL). The organic layer was washed with distilled water (150 
mL), and dried over sodium sulfate and concentrated to give a colorless gum. The residue 
was purified by silica gel column chromatography using CH3OH/DCM (1:9) as eluent to 
afford the pure intermediate. This intermediate (0.620 g, 1.822 mmol, 1.0 eq.) was then 
dissolved in a mixture of pyridine/THF (9:1, 70 ml) to which was added allyl 1-
hydroxybenzotriazole carbonate 3-7 (0.531 g, 2.423 mmol, 1.33 eq.) and DMAP (0.045 
g, 0.364 mmol, 0.2 eq.) at RT. After 24 h, the solvent was removed in vacuo, the residue 
was taken up in DCM (100 mL) and the solution was washed with aqueous NaHCO3 
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(5%, 100 mL). The organic layer then was dried over sodium sulfate. The concentrated 
residue was purified by silica gel column chromatography using hexane/EtOAc (7:3) as 
eluent. The isolated product was obtained with a yield of 1.295 g (85%). 
Rf  (SiO2 TLC): 0.72 in hexane/EtOAc (7:3) 
1
H NMR (CDCl3, ppm): δ 1.93 (s, 3H, CH3-C5), 2.21 (s, 3H, CH3 of Lev), 2.22-2.27 
(ddd, J = 14.0, 8.5, 6.5 Hz, 1H, H2’), 2.41-2.45 (ddd, J = 14.0, 5.5, 1.5 Hz, 1H, H2”), 
2.58-2.61 (t, J = 6.5Hz, 2H, CH2 of Lev), 2.77-2.80 (t, J = 6.5Hz, 2H, CH2 of Lev), 3.76-
3.81 (dd, J = 11.5, 2.5 Hz, 1H, H5’), 4.24-4.26 (ddd, J = 5.0, 2.5, 2.5 Hz, 1H, H4’), 4.41-
4.44 (dd, J = 11.5, 2.5 Hz, 1H, H5”), 4.66-4.68 (d, J = 6.0 Hz, 2H, CH2 of Alloc), 5.26-
5.30 (ddd, J = 6.5, 5.0, 1.5 Hz, 1H, H3’), 5.30-5.33 (dd, J = 10.5, 1.0 Hz, 1H, CH of 
Alloc), 5.37-5.40 (dd, J = 17.0, 1.0 Hz, 1H, CH of Alloc), 5.90-5.96 (ddt, J = 17.0, 10.5, 
6.0 Hz, 1H, CH of Alloc), 6.40-6.43 (dd, J = 8.5, 5.5 Hz, 1H, H1’), 7.42 (s, 1H, H6).  
13
C NMR (CDCl3, ppm): 12.55, 27.86, 29.74, 37.15, 37.77, 67.34, 69.04, 74.74, 82.08, 
84.48, 111.74, 119.73, 131.04, 134.98, 150.62, 154.39, 163.82, 172.40, 206.40. 
ESI-MS (M+Na
+







Compound 3-6 (0.452 g, 0.537 mmol, 1.0 eq.) and compound 3-13 (0.251 g, 0.592 mmol, 
1.1 eq.) were dissolved in acetonitrile (20 mL) and DBU (0.164 g, 1.074 mmol, 2.0 eq.) 
added at RT. After 48 h, the solvent was removed in vacuo, the residue was taken up with 
DCM (100 mL) and the solution was washed with aqueous NaHCO3 (5%, 100 mL). The 
organic layer was dried over sodium sulfate and concentrated, then purified by silica gel 
column chromatography with a gradient of hexane/EtOAc (5:5 to 1:9) as eluent. The 
product was obtained with a yield of 0.336 g (55 %).  
Rf (SiO2 TLC): 0.76 in hexane/EtOAc (1:9). 
1
H NMR (CDCl3, ppm): δ 0.00 (s, 3H, SiCH3), 0.06 (s, 3H, SiCH3), 0.86 (s, 9H, 
SiC(CH3)3), 1.53 (s, 3H, C5-CH3), 1.71-1.74 (m, 4H, CH2 of butyl), 1.95 (s, 3H, C5-
CH3), 2.24 (s, 3H, CH3 of Lev), 2.23-2.25 (m, 1H, H2’), 2.23-2.27 (m, 1H, H2”), 2.36-
2.39 (m, 1H, H2’), 2.46-2.50 (m, 1H, H2”), 2.62-2.64 (t, J = 6 Hz, 2H, CH2 of Lev), 
2.80-2.83 (t, J = 6 Hz, 2H, CH2 of Lev), 3.28-3.30 (dd, J = 10.5, 1.5 Hz, 1H, H5’), 3.50-
3.52 (dd, J = 10.5, 1.5 Hz, 1H, H5’’), 3.83 (s, 6H, OCH3 of DMT), 3.99-4.02 (m, 1H, 
H4’), 3.99-4.02 (t, J = 5.5 Hz, 4H, CH2 of butyl), 4.21-4.24 (m, 1H, H4’), 4.43-4.48 (m, 
2H, H5’ and H5”), 4.54-4.57 (m, 1H, H3’), 4.70-4.72 (d, J = 6.0 Hz, 2H, OCH2 of Alloc), 
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5.31-5.34 (m, 1H, H3’), 5.33-5.36 (dd, J = 10.5, 1.0 Hz, 1H, CH of Alloc), 5.40-5.44 (dd, 
J = 17.0, 1.0 Hz, 1H, CH of Alloc), 5.95-6.02 (ddt, J = 17.0, 10.5, 6.0 Hz, 1H, CH of 
Alloc), 6.38-6.42 (m, 2H, 2 x H1’), 6.87-6.89 (m, 4H, Ph of DMT), 7.28-7.44 (m, 9H, Ph 
of DMT), 7.46 (s, 1H, H6), 7.67 (s, 1H, H6).  
13
C NMR (CDCl3, ppm): -4.89, -4.66, 12.67. 13.27, 17.92, 25.31, 25.71, 27.90, 29.73, 
37.24, 37.79, 41.02, 41.17, 41.64, 55.26, 62.90, 67.30, 69.00, 72.01, 74.76, 82.01, 85.15, 
85.45, 86.63, 86.79, 110.18, 110.84, 113.26, 113.29, 119.63, 127.08, 127.96, 128.17, 
130.05, 130.08, 131.12, 132.87, 133.48, 135.52, 135.58, 144.38, 150.85, 150.95, 154.46, 
158.73, 163.22, 163.46, 172.31, 206.08.  
ESI-MS (M+Na
+








Compound 3-14 (0.441 g, 0.388 mmol, 1.0 eq.) was treated with 10 mL HPAA (0.5 M 
hydrazine in a buffer composed of 9 mL pyridine and 1 mL glacial acetic acid) at RT. 
After 10 min, the solution was diluted with DCM (100 mL) and washed with aqueous 
NaHCO3 (5%, 100 mL). The water phase was extracted twice with DCM (100 mL). The 
combined organic layer was dried over sodium sulfate and concentrated, then purified by 
silica gel column chromatography with a solvent system of hexane/EtOAc (1:9). The 
product was obtained with a yield of 0.387 g (96%). 
Rf  (SiO2 TLC): 0.56 in hexane/EtOAc (1:9).  
1
H NMR (CDCl3, ppm): δ 0.00 (s, 3H, SiCH3),  0.06 (s, 3H, SiCH3), 0.86 (s, 9H, 
SiC(CH3)3), 1.53 (s, 3H, C5-CH3), 1.71-1.73 (m, 4H, CH2 of butyl), 1.95 (s, 3H, C5-
CH3), 2.23-2.29 (m, 2H, H2’ and H2”), 2.35-2.38 (m, 1H, H2’), 2.41-2.45 (m, 1H, H2”), 
3.27-3.31 (dd, J = 14.0, 3.0 Hz, 1H, H5’), 3.50-3.54 (dd, J = 14.0, 3.5 Hz, 1H, H5’’), 3.83 
(s, 6H, OCH3 of DMT), 3.97-4.00 (m, 1H, H4’), 3.98-4.00 (t, J = 6.0 Hz, 4H, CH2 of 
butyl), 4.15-4.18 (m, 1H, H4’), 4.45-4.48 (m, 2H, H5’ and H5”), 4.50-4.53 (m, 2H, 2 x 
H3’), 4.69-4.71 (d, J = 6.0 Hz, 2H, OCH2 of Alloc), 5.52-5.55 (dd, J = 10.5, 1.0 Hz, 1H, 
CH of Alloc), 5.58-5.62 (dd, J = 17.0, 1.0 Hz, 1H, CH of Alloc), 5.94-6.01 (ddt, J = 17.0, 
10.5, 6.0 Hz, 1H, CH of Alloc). 6.39-6.42 (m, 2H, 2 x H1’), 6.87-6.89 (m, 4H, Ph of 
DMT), 7.29-7.44 (m, 9H, Ph of DMT), 7.46 (s, 1H, H6), 7.68 (s, 1H, H6).  
13
C NMR (CDCl3, ppm): -4.89, -4.65, 12.68, 13.29, 15.27, 17.93, 25.31, 25.71, 40.61, 
41.05, 41.08, 41.65, 55.27, 62.84, 66.72, 69.02, 71.22, 83.79, 85.32, 85.42, 86.61, 86.77, 
110.19, 110.38, 113.24, 113.27, 119.66, 127.10, 127.98, 128.15, 130.04, 130.08, 131.08, 











Compound 3-15 (0.317 g, 0.305 mmol, 1.0 eq.) was dissolved in anhydrous THF (1.25 
mL). Then, DIPEA (0.059 g, 0.458 mmol, 1.5 eq.) followed by N,N-diisopropylamino 
cyanoethyl phosphonamidic chloride (0.087 g, 0.366 mmol, 1.2 eq.) were added. After 30 
min, the reaction was diluted with EtOAc (50 mL). The organic layer was washed with 
aqueous NaHCO3 (3%, 100 mL ×2) followed by aqueous NaCl (sat., 100 mL), then dried 
over sodium sulfate. After concentration in vacuo, the gum was precipitated from hexane 
to yield 0.269 g (71%) of product as a colorless foam.  




P NMR (Acetone-d6, ppm): 146.71, 146.97.  
ESI-MS (M+Na
+
): 1261.5638 (calcd. 1261.5634). 
 
6.2 Experimental procedure for the development of the cyclization 
strategies to synthesize 7-deazapurine and related analogs 
6.2.1 Materials and General Methods 
All chemicals and solvents for synthesis were purchased from the Aldrich Chemical 
Company. 2-Chloroacetaldehyde (50% in H2O) was distilled to remove the water present 
prior to the Knoevenagel condensation. 
6.2.2 Experimental procedures for syntheses of 7-deazapurines and related 
analogs 
Compound 4-1. Ethyl 2-cyano-4,4-dimethoxybutanoate 
 
To a solution of ethyl 2-cyanoacetate (11.3110 g, 100 mmol, 1.00 eq.) in anhydrous DMF 
(50 mL) was added sodium hydride (2.6400 g, 110 mmol, 1.10 eq.) in portions. The 
solution was stirred at RT for 4 h under a drying tube. 2-Chloro-1,1-dimethoxyethane 
(13.7027 g, 110 mmol, 1.10 eq.) and a crystal of potassium iodide were added to the 
solution, and stirred at 100 
o
C for 20 h under a drying tube. The solution was cooled, and 
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diluted with distilled H2O (200 mL). The crude product was extracted with EtOAc (100 
mL × 5). The organic phase was washed with brine (50 ml), dried over sodium sulfate, 
and filtered. The filtrate was concentrated in vacuo for the further purification by silica 
gel column chromatography using a gradient of hexane/EtOAc (9:1 to 7:3) as eluent to 
afford the product as amber liquid (11.0710 g, 51%). 
Rf (SiO2 TLC): 0.15 in hexane/EtOAc (7:3). 
1
H NMR (CDCl3, ppm): δ 1.34-1.37 (t, J = 7.0 Hz, 3H, CH3 of OEt), 2.26-2.30, 2.32-2.36 
(m, 2H, CH2 of CH2CH(OCH3)2), 3.36 and 3.38 (2s, 6H, CH3 of CH(OCH3)2), 4.24-4.26 
(q, J = 7.0 Hz, 2H, CH2 of OEt), 4.28-4.32 (dd, J = 7.5, 7.0 Hz, 1H, CH of 
CH(CO2Et)(CN)), 4.56-4.58 (dd, J = 6.5, 5.0 Hz, 1H, CH of CH(OCH3)2). 
13




): 224.0903 (calc. 224.0899) 
 
Compound 4-2. 2-(2,2-dimethoxyethyl)malononitrile 
 
 
To a solution of malononitrile (3.3030 g, 50 mmol, 1.00 eq.) in anhydrous DMF (20 mL) 
was added sodium hydride (1.3200 g, 55 mmol, 1.10 eq.) in portions. The solution was 
stirred at RT for 1 h under a drying tube. 2-Chloro-1,1-dimethoxyethane (6.8514 g, 55 
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mmol, 1.10 eq.) and a crystal of potassium iodide were added to the solution, and stirred 
at 100 
o
C for 24 h under a drying tube. The solution was cooled, and diluted with distilled 
H2O (50 mL). The crude product was extracted with EtOAc (50 mL × 5). The organic 
phase was washed with brine (50 ml), dried with sodium sulfate, and filtered. The filtrate 
was concentrated in vacuo for further purification by silica gel column chromatography 
using a gradient of hexane/EtOAc (7:3 to 5:5) as eluent to afford the product as an amber 
liquid (3.315 g, 43%). 
Rf (SiO2 TLC): 0.36 in DCM/MeOH (19:1). 
1
H NMR (CDCl3, ppm): δ 2.25-2.29, 2.37-2.41 (m, 2H, CH2 of CH2CH(OCH3)2), 3.42 
and 3.44 (2s, 6H, CH3 of CH(OCH3)2), 4.14-4.16 (dd, J = 6.0, 6.0 Hz, 1H, CH of 
CH(CN)2), 4.56-4.58 (dd, J = 6.0, 5.0 Hz, 1H, CH of CH(OCH3)2). 
13
C NMR (CDCl3, ppm): δ 31.09, 34.40, 53.55, 54.78, 101.30, 115.48. 
ESI-MS (M+Na
+
): 177.0644 (calc. 177.0640) 
 
Compound 4-3. Ethyl 4-chloro-2-cyanobut-2-enoate 
 
To a solution of 2-chloroacetaldehyde (9.03 g, 115 mmol, 1.15 eq.) and ethyl 2-
cyanoacetate (11.3 g, 100 mmol, 1.00 eq.) in anhydrous DCM (50 mL) were added a 
mixture of piperidine (0.8515 g, 10.0 mmol, 0.1 eq.) and acetic acid (0.6005 g, 10.0 
mmol, 0.1 eq.). After being stirred at RT for 15 min., the reaction mixture was heated 
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under reflux for 12 h. After being cooled down to RT, the solution was concentrated in 
vacuo, and then diluted with diethyl ether (200 mL), and washed twice with water (100 
mL). The aqueous phases were extracted with diethyl ether (100 mL) three times. The 
combined diethyl ether phase was dried over sodium sulfate, and filtered through a short 
silica gel column. After removing the solvent, the crude products were pure enough to be 
used in further reactions. Analytically pure samples were obtained by silica gel column 
chromatography using hexane/EtOAc (19:1 to 9:1) as eluent. 
Rf (SiO2 TLC): 0.66 in hexane/EtOAc (9:1). 
1
H NMR (CDCl3, ppm): δ 1.33-1.36 (t, J = 7.5 Hz, 3H, CH3 of OEt), 4.32-4.40 (m, 4H, 
CH2 of OEt and CH2 of CH2Cl), 7.58-7.59 (t, 7.0 Hz, 1H, CH adjacent to CH2Cl). 
13
C NMR (CDCl3, ppm): δ 14.01, 39.38, 63.25, 111.71, 113.47, 154.15, 164.32. 
EI-MS (M-1): 172.03 (calc.172.02) 
 
Compound 4-4. 2-(2-Chloroethylidene)malononitrile 
 
To a solution of 2-chloroacetaldehyde (9.03 g, 115 mmol, 1.15 eq.) and malononitrile 
(6.61 g, 100 mmol, 1.00 eq.) in anhydrous DCM (50 mL) were added a mixture of 
piperidine (0.8515 g, 10.0 mmol, 0.1 eq.) and acetic acid (0.6005 g, 10.0 mmol, 0.1 eq.). 
After being stirred at RT for 15 min, the reaction mixture was heated under reflux for 12 
h. After being cooled down to RT, the solution was diluted with 150 mL DCM, and 
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washed with water (100 mL) twice. The aqueous phases were extracted with DCM (100 
mL) twice. The combined organic phase was dried over sodium sulfate, and filtered 
through a short silica gel column. After removing the solvent, the crude products were 
pure enough to be used in further reactions. Analytically pure samples were obtained by 
silica gel column chromatography using hexane/EtOAc (9:1 to 7:3) as eluent. 
Rf (SiO2 TLC): 0.61 in hexane/EtOAc (7:3). 
1
H NMR (d6-DMSO, ppm): δ 4.18-4.20 (dd, J = 11.0, 5.5 Hz, 1H, CH2 of CH2Cl), 4.21-
4.23 (dd, J = 11.0, 5.5 Hz, 1H, CH2 of CH2Cl), 7.46-7.49 (dd, J = 5.5, 5.5 Hz, 1H, CH 
adjacent to CH2Cl). 
13
C NMR (d6-DMSO, ppm): δ 36.25, 59.97, 113.00, 113.62, 168.05 
EI-MS (M-1): 125.00 (calc. 124.99) 
 
Compound 4-5. 2-Amino-1H-pyrrole-3-carboxamide 
 
To the prepared ethyl 4-chloro-2-cyanobut-2-enoate (4-3) was added a solution of 
hydrogen chloride in ethanol (2 N, 50 mL). The solution was stirred at RT for 10 h, and 
then dried in vacuo. Ice-cold saturated ammonia in MeOH (100 mL) was added. The 
solution was stirred at RT for 16 h, and then refluxed for another 24 h. The crude product 
was filtered through a short silica gel column and concentrated in vacuo. The residue was 
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purified by silica gel column chromatography using a gradient of hexane/EtOAc (7:3 to 
5:5) then DCM/MeOH (9:1) as eluent to afford the product (8.44 g, 67%). 
Rf (SiO2 TLC): 0.19 in DCM/MeOH (17:3). 
1
H NMR (d6-DMSO, ppm): δ 3.56, 3.59 (s, 5H, NH2 and NH), 7.31 (dd, J = 2.5, 2.0 Hz, 
1H, CH of pyrrole), 7.62 (dd, J = 2.5, 2.0 Hz, 1H, CH adjacent to NH of pyrrole).  
13
C NMR (d6-DMSO, ppm): δ 93.38, 116.74, 117.67, 134.11, 166.75. 
ESI-MS (M+Na
+
): 148.0491 (calc. 148.0487) 
 
Compound 4-6. 2-Amino-1H-pyrrole-3-carbonitrile 
 
To the prepared 2-(2-chloroethylidene)malononitrile (4-4) was added a solution of 
hydrogen chloride in ethanol (2 N, 50 mL). The solution was stirred at RT for 10 h, and 
then dried in vacuo. Ice-cold saturated ammonia in MeOH (100 mL) was added. The 
solution was stirred at RT for 16 h, and then refluxed for another 24 hours. The crude 
product was filtered through a short silica gel column and concentrated in vacuo. The 
residue was obtained by silica gel column chromatography using gradient hexane/EtOAc 
(7:3 to 5:5) then DCM/MeOH (9:1) as eluent to afford the product (7.32 g, 59%). 
Rf  (SiO2 TLC): 0.17 in DCM/MeOH (17:3). 
1
H NMR (d6-DMSO, ppm): δ 6.93 (dd, J = 2.5, 2.0 Hz, 1H, CH of pyrrole), 7.27 (dd, J = 




C NMR (d6-DMSO, ppm): δ 60.20, 115.51, 118.76, 124.35, 136.58. 
ESI-MS (M+Na
+
): 130.0386 (calc. 130.0381) 
 
 
General procedure for the preparation of 7-deazapurines (4-7 to 4-12) by Approach 
A (Scheme 4-2) 
To a solution of ethyl 2-cyano-4,4-dimethoxybutanoate (4-1) or 2-(2,2-
dimethoxyethyl)malononitrile (4-2) (1.0 eq.) was added guanidine hydrochloride, urea or 
thiourea (1.0 eq.) in anhydrous MeOH (100 mL) followed by sodium methoxide (1.0 
excess eq.). The solution was refluxed for 24 h, and cooled down to RT. The solution was 
concentrated and filtered through a short silica gel column. After removing the solvent, 
the residue was treated with hydrogen chloride (2 N, 100 mL) at RT for 10 min, and 
refluxed for 24 h. The solution was concentrated in vacuo, and the residue was loaded on 
a silica gel column for further purification using a gradient of DCM to DCM/MeOH (9:1) 
as eluent. The corresponding yields are shown in Table 4-1. 
 
General procedure for the preparation of 7-deazapurines (4-7 to 4-12) by Approach 
B (Scheme 4-3) 
To a solution of 2-amino-1H-pyrrole-3-carboxamide (4-5) or 2-amino-1H-pyrrole-3-
carboximidamide (4-6) (1.0 eq.) was added guanidine hydrochloride, urea or thiourea 
(1.0 eq.) in anhydrous MeOH (100 mL) followed by sodium methoxide (1.0 excess eq.). 
200 
 
The solution was refluxed for 24 h, and cooled down to RT. The solution was 
concentrated in vacuo, and the residue was loaded on a silica gel column using a gradient 
of DCM to DCM/MeOH (9:1). The corresponding yields are shown in Table 4-2. 
 
Compound 4-7. 2-Amino-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one 
 
Rf  (SiO2 TLC): 0.23 in DCM/MeOH (17:3). 
1
H NMR (d6-DMSO, ppm): δ 6.19 (dd, J = 3.0, 2.5 Hz, 1H, CH of pyrrole), 6.61 (dd, J = 
3.0, 2.5 Hz, 1H, CH adjacent to NH of pyrrole), 4.04, .8.19, 12.66 (3s, 4H, H of NH). 
13
C NMR (d6-DMSO, ppm): δ 99.88, 101.61, 116.61, 151.80, 152.21, 159.00. 
ESI-MS (M+Na
+
): 173.0443 (calc. 173.0439) 
 
Compound 4-8. 1H-pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione 
 
Rf (SiO2 TLC): 0.23 in DCM/MeOH (17:3). 
1
H NMR (d6-DMSO, ppm): δ 6.20 (dd, J = 2.5, 2.0 Hz, 1H, CH of pyrrole), 6.61 (dd, J = 




C NMR (d6-DMSO, ppm): δ 100.18, 108.70, 126.33, 139.84, 151.60, 167.82. 
ESI-MS (M+Na
+
): 174.0283 (calc. 174.0279) 
 
Compound 4-9. 2-Thioxo-2,3-dihydro-1H-pyrrolo[2,3-d]pyrimidin-4(7H)-one 
 
Rf  (SiO2 TLC): 0.32 in DCM/MeOH (17:3). 
1
H NMR (d6-DMSO, ppm): δ 6.19 (dd, J = 2.5, 2.0 Hz, 1H, CH of pyrrole), 6.60 (dd, J = 
2.5, 2.0 Hz, 1H, CH adjacent to NH of pyrrole). 8.85, 9.05, 11.33 (3s, 3H, H of NH). 
13
C NMR (d6-DMSO, ppm): δ 98.46, 108.45, 116.03, 126.60, 167.83, 168.81. 
ESI-MS (M+Na
+
): 190.0055 (calc. 190.0051) 
 
Compound 4-10. 7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
 
Rf  (SiO2 TLC): 0.27 in DCM/MeOH (17:3). 
1
H NMR (d6-DMSO, ppm): δ 6.18 (dd, J = 3.0, 2.5 Hz, 1H, CH of pyrrole), 6.59 (dd, J = 
3.0, 2.5 Hz, 1H, CH adjacent to NH of pyrrole), 7.80, 8.94, 9.89 (3s, 5H, H of NH). 
13
CNMR (d6-DMSO, ppm): δ 89.14, 101.90, 126.28, 151.46, 155.24, 165.10. 
ESI-MS (M+Na
+




Compound 4-11. 4-Amino-1H-pyrrolo[2,3-d]pyrimidin-2(7H)-one 
 
Rf  (SiO2 TLC): 0.25 in DCM/MeOH (17:3). 
1
H NMR (d6-DMSO, ppm): δ 6.18 (dd, J = 3.0, 2.5 Hz, 1H, CH of pyrrole), 6.58 (dd, J = 
3.0, 2.5 Hz, 1H, CH adjacent to N of pyrrole), 10.61, 13.47 (2s, 3H, NH2). 
13
C NMR (d6-DMSO, ppm): δ 97.98, 107.44, 116.89, 135.18, 159.04, 162.80. 
ESI-MS (M+Na
+
): 173.0443 (calc. 173.0439) 
 
Compound 4-12. 4-Amino-1H-pyrrolo[2,3-d]pyrimidine-2(7H)-thione 
 
Rf  (SiO2 TLC): 0.37 in DCM/MeOH (17:3). 
1
H NMR (d6-DMSO, ppm): δ 6.18 (dd, J = 2.5, 2.0 Hz, 1H, CH of pyrrole), 6.59 (dd, J = 
2.5, 2.0 Hz, 1H, CH adjacent to NH of pyrrole), 8.74, 8.89, 12.87 (3s, 4H, H of NH) 
13
C NMR (d6-DMSO, ppm): δ 98.00, 107.89, 116.90, 134.40, 159.04, 178.25. 
ESI-MS (M+Na
+




6.3 Experimental procedure for synthesis of cross-linked nucleosides 
containing 7-deaza-2’-deoxyguanosine 
6.3.1 Materials and General Methods 
Trimethylsilyl chloride (TMSCl), phenoxyacetyl chloride (Pac-Cl), sodium hydride, tert-
butyldimethylsilyl chloride (TBS-Cl),  isobutyryl chloride (iBuCl), 4-
dimethylaminopyridine (DMAP), triphenylphosphine, sodium N,N-
diethydithiocarmbamate, bis(triphenylphosphine)palladium(II) dichloride, copper iodide, 
1,6-heptadiyne, diisopropylethylamine (DIPEA) and all other chemicals and solvents for 
synthesis were purchased from the Aldrich Chemical Company (Milwaukee, WI). 
1-Chloro-3,5-di-O-toluoyl-2-deoxy-α-D-ribofuranose was purchased from Berry & 
Associates, Inc. (Dexter, MI). 4,4’-dimethoxytrityl chloride and N,N-diisopropylamino 
cyanoethyl phosphonamidic chloride were purchased from ChemGenes Inc. 
(Wilmington, MA). 
Flash column chromatography was performed using silica gel 60 (230–400 mesh) 
obtained from Silicycle (Quebec City, QC). Thin layer chromatography (TLC) was 
performed using precoated TLC plates (Merck, Kieselgel 60 F254, 0.25 mm) purchased 
from EMD Chemicals Inc. from (Gibbstown, NJ). All solvents for column 




C NMR spectra were recorded on a Varian 500 MHz NMR spectrometer at RT at 




C, respectively. Chemical shifts were 
reported in parts per million downfield from tetramethylsilane. 
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decoupled) were recorded at a frequency of 202.4 MHz with H3PO4 used as an external 
standard. 
 





To the solution of 7-deazaguanine (3.0 g, 20 mmol, 1.0 eq.) in anhydrous pyridine (20 
mL) was added TMSCl (4.35 g, 40 mmol, 3.0 eq.) in portions. The solution was stirred in 
an ice-bath and allowed to warm to RT for 1.5 h. Phenoxyacetyl chloride (5.1 g, 30 
mmol, 1.5 eq.) was added in portion, and the solution stirred at RT for overnight. The 
solution was concentrated in vacuo, and the residue was washed with ice-cold water. 
Then the residue was run through a silica gel columnn to remove most of the pyridine 
solvent with hexane/EtOAc (v/v, 9:1 to 5:5) as eluent. The crude product was eluted off 
the column with DCM/MeOH (v/v, 19:1). 
The TMS protective group at the 6-oxo position was labile at higher temperature, and 
cleavage of TMS at this site occurred during removal of pyridine from the product. The 







To the solution of compound 5-1 in DMF (20 mL) was added iodine (6.6 g, 26 mmol, 1.3 
eq.) in portions. The brown solution was stirred at RT overnight. The solution was 
concentrated in vacuo (water bath at 65 
o
C), and the residue was purified by silica gel 
column chromatography (twice) using a gradient of hexane/EtOAc (v/v, 8:2 to 2:8) to 
DCM/CH3OH (v/v, 10:0 to 9:1) as eluent. The product, a brown solid was obtained with 
a yield of 5.8 g (71%) over two steps. 
1
H NMR (d6-DMSO, ppm): δ 4.84 (s, 2H, CH2 of Pac), 6.89-6.97 (m, 4H, Ph of Pac and 
H of C8), 7.26-7.31 (m, 2H, Ph of Pac).  
13
C NMR (d6-DMSO, ppm): δ 68.93, 113.11, 113.14, 114.67, 114.76, 118.89, 121.10, 
129.68, 129.73, 143.98, 149.77, 158.11, 166.40, 175.89. 








To the solution of compound 5-2 (5.0600 g, 12.33 mmol, 2.4 eq.) in anhydrous 
acetonitrile (50 mL) was added sodium hydride (0.3084 g, 12.85 mmol, 2.5 eq.) in 
portions.  The solution was stirred at RT for 45 min. 1-Chloro-3,5-di-O-toluoyl-2-deoxy-
α-D-ribofuranose (2.000 g, 5.14 mmol, 1.0 eq.) was added, and the solution was stirred at 
RT for another 12 h. The solution was concentrated, and the residue was purified by 
silica gel column chromatography using a gradient of hexane/EtOAc (v/v, 8:2 to 3:7) as 
eluent to afford the product as a yellow solid (2.0310 g, 66%) 
Rf  (SiO2 TLC): 0.61 in hexane/EtOAc (3:7).  
1
H NMR (CDCl3, ppm): δ 2.67, 2.68 (2s, 6H, CH3 of Tol), 2.87-2.90 (m, 1H, H2’), 3.14-
3.17 (m, 1H, H2”), 4.52-4.54 (m, 1H, H5’), 4.63-4.69 (m, 4H, CH2 of Pac, H4’ and H5”), 
5.15-5.18 (m, 1H, H3’), 6.35-6.38 (dd, J = 6.0, 6.0 Hz, 1H, H1’), 7.13-7.33 (m, 9H, Phs 




C NMR (CDCl3, ppm): δ 21.70, 21.75, 34.55, 63.42, 69.20, 74.27, 87.90, 97.97, 105.06, 
125.41, 126.14, 127.04, 128.29, 129.07, 129.11, 129.21, 129.37, 129.39, 129.48, 129.62, 
129.69, 129.71, 129.81, 129.89, 130.19, 130.23, 140.61, 144.58, 145.10, 146.16, 165.10, 
166.14. 






Compound 5-3 (2.000 g, 2.62 mmol, 1.0 eq.) was dissolved in a saturated solution of 
ammonia in MeOH. The solution was stirred with an ice-bath and allowed to warm to RT 
for 6 h, then concentrated in vacuo. The residue was loaded onto silica gel, and purified 
by silica gel column chromatography using a gradient of DCM to DCM/MeOH (v/v, 9:1) 
as eluent. A yellowish solid was obtained, and this precursor was employed directly for 
following reaction. 








To a solution of compound 5-4 (0.7012 g, 1.79 mmol, 1.0 eq.) in anhydrous pyridine (15 
mL) was added TMSCl (1.1668 g, 10.74 mmol, 6.0 eq.). The solution was stirred at RT 
for 2 h followed the addition of isobutyryl chloride (0.2861 g, 2.69 mmol, 1.5 eq.). The 
solution was stirred at RT overnight, and then concentrated in vacuo.  The residue was 
purified by silica gel column chromatography, and then treated with saturated ammonia 
in MeOH with an ice-bath for 30 min. The solution was again concentrated in vacuo, and 
was purified by silica gel column chromatography to obtain a polar residue. TLC analysis 
indicated that pyridine was also present, and no further purification was performed for the 
following step.  
 




Compound 5-5 (containing pyridine) was dried on a high vacuum for 2 days, and then 
dissolved in anhydrous pyridine (3.5 mL). 4,4’-Dimethoxytrityl chloride (0.7280 g, 2.15 
mmol, 1.2 eq.) was added in two portions. The reaction was allowed to stir at RT 
overnight, and then concentrated in vacuo. The residue was diluted with aqueous sodium 
bicarbonate (sat., 50 mL), and then extracted with EtOAc (50 mL) three times. The 
organic phase was dried over sodium sulfate, and concentrated for silica gel column 
chromatography using a gradient of DCM to DCM/MeOH (v/v, 19:1) as eluent. An 
amber gum was obtained with a yield of 0.7520 g (42% for two steps from compound 5-3 
to 5-6). 
Rf  (SiO2 TLC): 0.29 in DCM/MeOH (19:1).  
1
H NMR (CDCl3, ppm): δ 1.06-1.08 (d, J = 7.0 Hz, 3H, CH3 of iBu), 1.10-1.11 (d, J = 
6.5 Hz, 3H, CH3 of iBu), 2.45-2.50 (m, 2H, H2’ and H2”), 2.67-2.70 (dd, J = 7.0, 6.5 Hz, 
1H, CH of iBu), 3.27-3.33 (m, 2H, H5’ and H5”), 3.70, 3.71 (2s, 6H, OCH3 of DMT), 
4.16-4.17 (m, 1H, H4’), 4.72-4.73 (m, 1H, H3’), 6.16-6.19 (dd, J = 7.0, 6.5 Hz, 1H, H1’), 
6.71-6.74 (m, 4H, Phs of DMT), 7.12-7.70 (m, 10H, H8 and Phs of DMT). 
13
C NMR (CDCl3, ppm): δ 17.94, 18.72, 36.24, 40.71, 51.45, 55.23, 55.26, 63.31, 72.46, 
84.26, 86.32, 87.03, 113.21, 122.04, 127.01, 127.94, 128.04, 129.93, 129.94, 135.69, 
135.87, 137.33, 144.68, 147.26, 148.10, 158.63, 158.64, 162.62, 178.38. 
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ESI (M+Na): 787.1609 (calc. 787.1605). 
 
Compound 5-7. 7-(1,6-Heptadiynyl)-7-deaza-5’-O-dimethoxytrityl-2’-deoxyguanosine 
(NiBu) 
 
Compound 5-6 (0.1210 g, 0.16 mmol, 1.0 eq.), bis(triphenylphosphine)palladium(II) 
dichloride (0.0023 g, 0.0032 mmol, 0.02 eq.), copper(I) iodide (0.0030 g, 0.016 mmol, 
0.1 eq.) and triphenylphosphine (0.0042 g, 0.016 mmol, 0.1 eq.) were dissolved in 
anhydrous DMF (2 mL). The solution was purged with argon three times, and 1,6-
heptadiyne (0.0583 g, 0.63 mmol, 4.0 eq.) and triethylamine (0.1 mL) were injected into 
the solution. The reaction was conducted under argon atmosphere at 40 
o
C for 60 h. The 
reaction was quenched with aqueous sodium bicarbonate (sat. 50 mL). The crude product 
was extracted with EtOAc (50 mL) three times, and the organic phase dried over sodium 
sulfate. The concentrated residue was purified by silica gel column chromatography using 
a gradient of hexane/EtOAc (v/v, 9:1 to 3:7) as eluent to afford the product as a yellowish 
solid (0.1002 g, 86%). 




H NMR (CDCl3, ppm): δ 0.96-0.98 (d, J = 6.5 Hz, 3H, CH3 of iBu), 1.18-1.20 (d, J = 
6.5 Hz, 3H, CH3 of iBu), 1.59-1.61 (m, 2H, CH2 of heptadiynyl), 2.22-2.25 (m, 1H, H2’), 
2.55-2.58 (m, 4H, CH2 of heptadiynyl), 2.61-2.66 (m, 3H, H2”, CH of iBu, CH of of 
heptadiynyl), 3.15-3.17, 3.36-3.38 (m, 2H, H5’ and H5”), 3.78, 3.79 (2s, 6H, OCH3 of 
DMT), 4.06-4.08 (m, 1H, H4’), 4.57-4.59 (m, 1H, H3’), 6.18-6.21 (dd, J = 8.5, 5.0 Hz, 
1H, H1’), 6.80-6.85 (m, 4H, Phs of DMT), 7.07-7.70 (m, 10H, H8 and Phs of DMT). 
13
C NMR (CDCl3, ppm): δ 18.96, 21.62, 21.64, 25.80, 31,38, 36.42, 40.95, 55.22. 55.26, 
64.32, 65.31, 71.11, 83.87, 84.65, 87.09, 93.87, 94.00, 98.89, 105.42, 113.11, 113.46, 
113.48, 126.44, 127.75, 127.82, 127.89, 127.98, 128.20, 128.56, 130.07, 130.11, 132.01, 
133.95, 134.05, 141.05, 149.11, 150.13, 158.09, 162.50, 175.69. 
ESI (M+Na): 751.3114 (calc. 751.3108). 
 







Compound 5-6 (0.2010 g, 0.28 mmol, 1.0 eq.), compound 5-7 (0.2000 g, 0.28 mmol, 1.0 
eq.), bis(triphenylphosphine)palladium(II) dichloride (0.0040 g, 0.0056 mmol, 0.02 eq.), 
copper(I) iodide (0.0054 g, 0.028 mmol, 0.1 eq.) and triphenylphosphine (0.0074 g, 0.028 
mmol, 0.1 eq.) were mixed in anhydrous DMF (3 mL). The solution was purged with 
argon three times, and triethylamine (0.1 mL) was injected into the solution. The reaction 
was conducted under argon atmosphere at 40 
o
C for 60 h. The reaction was then 
quenched with aqueous sodium bicarbonate (sat. 50 mL). The crude product was 
extracted with EtOAc (50 mL) three times. The organic phase was treated with aqueous 
N,N-diethydithiocarmbamate (0.5 g in 50 mL distilled H2O) and then dried over sodium 
sulfate. The concentrated residue was purified by silica gel column chromatography using 
a gradient of hexane/EtOAc (v/v, 9:1 to 3:7) as eluent to afford the yellowish solid 









To the solution of compound 5-8 (0.1900 g) in MeOH (30 mL) was added 0.1000 g  of 
palladium on activated carbon (Pd/C, 10%). Hydrogenation was performed with a Parr 
hydrogenator. The solution was purged with hydrogen (20 psi) three times, and then the 
hydrogen pressure was increased to 60 psi. The solution was shaken at RT for 60 h. The 
hydrogen was released, and the solution was run though a short silica gel column to 
remove the Pd/C. The solution was concentrated in vacuo, and aqueous sodium 
bicarbonate (sat. 50 mL) was added. The crude product was extracted with EtOAc (50 
mL) three times. The organic phase was treated with aqueous N,N-diethydithiocarbamate 
(0.5 g in 50 mL distilled H2O) and then dried over sodium sulfate. The concentrated 
residue was purified by silica gel column chromatography using a gradient of 




Rf  (SiO2 TLC): 0.26 in DCM/MeOH (19:1). 
1
H NMR (CDCl3, ppm): δ 1.11-1.27 (m, 18H, 4 CH3 of iBu, 3 CH2 of (CH2)7), 1.57-1.59 
(m, 4H, 2 CH2 of (CH2)7), 2.10-2.12 (m, 2H, H2’ and H2’’), 2.40-2.60 (m, 6H, H2’ and 
H2’’, 2 CH2 of (CH2)7), 2.64-2.68 (m, 2H, CH of iBu), 3.37-3.47 (m, 4H, H5’ and H5’’), 
3.78-3.80 (4s, 12H, OCH3 of DMT), 4.35-4.39 (m, 2H, H4’ and H4’’), 4.40-4.44 (m, 2H, 
H3’ and H3’’), 6.08-6.10 (dd, J = 7.0, 6.5 Hz, 1H, H1’), 6.12-6.15 (J = 8.0, 6.0 Hz, 1H, 
H1’’), 6.76-6.82 (m, 10H, Phs of DMT, H of C8), 7.14-7.38 (m, 18H, Phs of DMT). 
13






Chapter 7. Conclusions and Future Work 
7.1 Conclusions 
A synthetic strategy to produce ICL duplexes containing completely asymmetric 
nucleotide sequences around the cross-linked site has been developed. Dimethoxytrityl 
(DMT), tert-butyldimethylsilyl (TBS), levulinoyl (Lev), phenoxyacetyl (Pac) and 
allyloxycarbonyl (alloc) were screened for the compatibility of these protective groups in 
solution and solid-phase synthesis. By comparison of the solid-phase synthesis process 
with the two novel cross-linked dimer phosphoramidites, phosphoramidite 3-16 with 
DMT and Alloc protective groups for two 5’-O and one TBS for 3’-O enabled 
preparation of H-shaped ICL duplexes of completely asymmetric nucleotide composition 
around the cross-linked sites in satisfactory yields. 
Four duplexes containing a N3T-butylene-N3T ICL, two partially asymmetrical and two 
completely asymmetrical sequences, were synthesized and characterized by circular 
dichroism which suggested that they formed a B-form DNA duplex. The composition of 
the expected ICL duplexes was confirmed by enzymatic digestion and mass 
spectrometry. This approach is now being explored for the synthesis of other ICL DNA 
systems to produce substrates for various DNA repair experiments. 
For the preparation of ICL oligonucleotides containing 7-deazaguanine, a synthetic 
procedure for important precursor 7-deazaguanine was optimized. Two synthetic routes 
for the preparation of a series of 7-deazapurines have been developed. These heterocyclic 
molecules were synthesized based on two cyclization strategies, either from pyrimidine to 
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purine or from pyrrole to purine. The merits and shortcomings of these two methods were 
compared, which provided an efficient and convergent synthetic strategy to generate 7-
deazapurines. The compound 7-deazaguanine, prepared by these approaches, was 
employed in a synthesis to attempt to prepare a cross-linked dimer containing two 7-
deaza-2’-deoxyguanosines linked at the C7 atoms by an alkylene linker. 
The precursor, N-(5-iodo-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-2-
phenoxyacetamide was prepared and coupled with 1-chloro-3,5-di-O-toluoyl-2-deoxy--
D-ribofuranose.  Numerous obstacles were encountered in the optimization of various 
steps after the removal of toluolyl protective group at both 3’-O and 5’-O positions which 
generated 7-iodo-7-deaza-2’-deoxyguanosine which was converted into the 5’-O-DMT 
protected nucleoside.  A C7 alkynyl linker was introduced to the protected nucleoside by 
the Sonogashira reaction. Attempts to form a cross-linked dimer with a second 
Sonogashira coupling reaction were not successful. This Sonogashira coupling reaction 
was attempted between the two monomers: 7-iodo-7-deaza-5’-O-DMT-2’-
deoxyguanosine (NiBu) (5-6) and 7-(1,6-heptadiynyl)-7-deaza-5’-O-DMT-2’-
deoxyguanosine (NiBu) (5-7).  It is believed that this coupling was not successful due to 
steric hinderance of the two bulky DMT moieties at the 5’-O position. Nuclear magnetic 
resonance analysis of what was isolated from the coupling reactions indicated that 
monomer(s) and dimer co-existed in the final product. 
An attempt to proceed forward to prepare the phosphoramidite(s) following 
hydrogenation revealed 5 major signals by 
31
P NMR data which is assumed to be a 
mixture of inseparable monomer and dimer products. 
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7.2 Future Work 
To optimize the preparation of the cross-linked dimer, it is proposed that a C8-
halogenated derivative of 2’-deoxyguanosine rather than 7-deaza-2’-deoxyguanosine be 
explored. For example, 8-bromo-2’-deoxyguanosine could be employed as substrate. By 
attaching a halogen atom to the C8 position, coupling reactions to introduce a linker 
between two 2’-deoxyguanosines may be studied. In Chapter 5, obstacles were 
encountered with the second Sonogashira reaction to prepare the dimer. Preliminary 
reactions can be conducted with 8-bromo-2’-deoxyguanosine to optimize this crucial 
coupling step. A proposed synthesis is shown in Scheme 7-1. 
 
 
Scheme 7-1. Synthesis of crosslinked dimer phosphoramidite containing C8-heptylene-
C8 guanosine 
a) N-bromosuccinimide, acetonitrile/water 4:1, 1 h, RT. b) TMSCl, pyridine, RT, 1h; c) isobutyryl chloride, 
pyridine, RT, overnight; d) DMTCl, pyridine, RT, overnight; e) 1,6-heptadiyne, PdCl2(PPh3)2, CuI, Et3N, in 
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DMF, argon; f) 8-bromo-2’-deoxyguanosine, PdCl2(PPh3)2, CuI, Et3N, in DMF, argon; g) hydrogen, Pd/C 
in MeOH, rt; h) ClP(OCH2CH2CN)(NiPr2). 
 
To convert 2’-deoxyguanosine into the 8-bromo adduct, 2’-deoxyguanosine can be used  
as starting material rather than 5’-O-DMT-2’-deoxyguanosine.[591-595] After the 
attachment of DMT protective group at the 5’-O position, the first Sonogashira reaction 
can be performed following the published procedures outlined in Chapter 5. The key 
step, the second Sonogashira reaction, must be optimized to get better conversion and 
improved isolation of cross-linked dimers from unreacted monomer(s). Afterwards, 
hydrogenation will produce the precursor that can ultimately be converted into the 
phosphoramidites required for solid-phase synthesis of ICL DNA. 
Once optimized, these conditions may be extended towards the formation of the 7-deaza-
2’-deoxyguanosine crosslinked dimer which may ultimately be used for DNA repair 
studies.  
 
The chemical instability of N7-alkyl-2’-deoxyguanosine is caused by the positive charge 
on the guanine ring system.[336] To mimic the main adduct formed by the introduction 
of alkylating agents (including bifunctional alkylating agents), another synthetic approach 
involving modified nucleosides is proposed. This would involve the modification of 7-
alkyl-2’-deoxyguanosines to generate chemically stable substrates. After the alkylation of 
N7 of 2’-deoxyguanosine, the product formed is structurally similar to a guaninium salt. 
This may react as a NHC carbene, coordinating to a transition metal complex such as 
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xanthinium.[596] When treated with reducing agents, i.e. sodium borohydride, more 
stable structures containing 8-H-guanine may be generated.[597-601] This may produce 
molecules that are more stable substrates for various repair and structural studies. 
Addition of alkyl or aromatic groups on C8 of N7-alkyl-guanosine could produce an 
interesting class of modified nucleosides that may find use in a wide range of applications 
(see Scheme 7-2). 
 
 
R = H or other protective groups (PG) 
R’ = alkyl or aromatic 
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